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Abstract
Development of Diverse Bifunctional Molecules for Interrogating DcpS, HER3, Brachyury, and
Phosphorylation-Driven Diseases Towards Therapeutic Applications
Jake C. Swartzel
2021
Technologies that hijack cellular pathways using bifunctional small molecules have recently risen
to the forefront of the drug discovery world. The first targeted protein degradation (TPD)
technology to be developed, PROteolysis Targeting Chimeras (PROTACs), were disclosed two
decades ago. The recent successes of AR and ER-degrading PROTACs in pioneering clinical trials
has propelled interest in developing novel platforms to further expand the druggable proteome and
the arsenal of strategies that are available for therapeutic intervention. This thesis is focused on the
development of novel bifunctional molecules that enable interrogation of diseases driven by
traditionally challenging protein targets. The first chapter begins with a review of the important
discoveries that built the foundation for modern PROTAC campaigns. I then discuss other novel
bifunctional molecule technologies that have been recently developed. In chapter two I describe
our development of potent DcpS targeting PROTACs. DcpS is a driver of SMA and AML, and
efforts toward therapeutic intervention have been largely unsuccessful. In chapter three I describe
HER3 targeting molecules. HER3 is a challenging drug target, and I will outline our dutiful efforts
towards developing novel degraders to investigate HER3 driven disease. In chapter 4 I disclose
PROTACs targeting Brachyury, a transcription factor that untreatable chordomas are addicted to.
In chapter 5 I present efforts towards developing a novel class of bifunctional molecules that enable
interrogation of disease states driven by aberrant phosphorylation. Finally, in chapter 6 I present a
synthetic project where we developed a novel method for generating isoquinolones.
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Chapter 1: Introduction to Bifunctional Molecules and Targeted Degradation Strategies:
1.1 Introduction
Cells have evolved regulatory machinery such as the ubiquitin proteasome system (UPS) and the
lysosome to target proteins for degradation.1 Other systems such as the neonatal Fc-receptor
(FcRn) and recycling vesicles compliment these degradation strategies by increasing the half-lives
of other proteins.2 Cells masterfully balance these protein expression, degradation, and
stabilization strategies to establish their overall state of proteostasis. As a result, some proteins
have half-lives on the order of minutes, while others can last hours to days.3
In some disease states this delicately balanced proteostatic flux is disrupted. In most of these cases,
such as in many cancers, a specific protein or group of proteins homeostasis is unbalanced, leading
to the disease phenotype. Strategies which hijack the proteostatic machinery, especially to induce
degradation of a specific target protein (i.e. Targeted Protein Degradation strategies, TPD) are
desirable as potential therapeutics. The first TPD strategy to be discovered was Proteolysis
Targeting Chimeras (PROTACs), which were disclosed by our lab along with the Deshaies lab
two decades ago. PROTACs are bifunctional small molecules that hijack the UPS and induce
degradation of a target protein. Since our seminal PROTAC publication in 2001,4 several more
distinct novel technologies for targeted protein degradation have been developed.
In this introductory chapter, I will discuss PROTAC technology and the important discoveries that
informed the development of the novel PROTACs presented in this thesis. I will follow this by
briefly reviewing other targeted degradation strategies, one of which (MoDE-As) I helped develop
during the first three years of my PhD in David Spiegel’s lab. In the subsequent chapters I will
describe my work on the development of PROTACs for three novel and therapeutically relevant
protein targets DcpS, HER3, and Brachyury. In the later chapters I will discuss my preliminary
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work towards the development of a new bifunctional molecule (PhosTAC) technology, and finally
end with a brief synthetic side project on a new methodology for isoquinolone synthesis.
1.2 Proteolysis Targeting Chimeras (PROTACs) Hijack the Ubiquitin Proteasome System (UPS)
1.2.0 Pathways of Protein Degradation in the Cell
Until the 1980s scientists were largely focused on understanding the processes of transcription and
translation, with less effort being directed towards understanding how proteins are regulated after
synthesis. Upon the discovery of the lysosome,5 it was proposed that all proteins in the cell are
degraded by this new destructive organelle. However, several independent inquiries demonstrated
that intracellular protein degradation cannot be entirely lysosomal because different proteins
respond differently when cells are treated with lysosomal inhibitors.3,6 The discovery of the UPS
finally revealed the other main mechanism by which many proteins are destroyed.6 More recently,
it has been demonstrated that these degradation pathways participate in “cross-talk” that can
influence their substrate selectivity and rate of efficiency.7 In this section we will form an
understanding of these independent protein degradation pathways and the molecular technologies
that have been developed to harness them.
The lysosome is a vacuolar organelle in the cell containing hydrolytic enzymes which are active
in the acidified environment provided by membrane-associated ATP-driven proton pumps.
Proteins subjected to this environment are invariably hydrolyzed and destroyed. The membrane of
the lysosome protects the general cellular milieu from these active hydrolases. Proteins to be
degraded are directed to the lysosome by numerous related processes including ubiquitination,
autophagy, pinocytosis, receptor-mediated endocytosis, and phagocytosis (Fig 1.1).3
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Figure 1.1: Digestive Processes Mediated by the Lysosome (Figure Adapted from Cell Death Differ. 12, 11781190 (2005))

Degradation of intracellular proteins entirely by the lysosome was not substantiated by the
experimental evidence because classes of proteins have different half-lives and respond differently
to lysosomal inhibitors.8,9 Years of further research led to the discovery of the UPS, which can
regulate the lifetime of specific proteins with unmatched precision. The UPS functions by marking
proteins destined for degradation with a poly-ubiquitin chain, which causes them to be recognized
by the 20S proteasome and subsequently degraded.6
The UPS cascade leading to substrate degradation is initiated by the ATP-dependent formation of
a thioester bond between Ubiquitin, a small 8 kDa protein, and a ubiquitin-activating E1 ligase.
The ubiquitin monomer is then relocated to an E2 conjugation enzyme by a trans-thioesterification
reaction. At this stage an E3 adaptor enables substrate recognition and the ubiquitin is terminally
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transferred to the amine of a lysine residue on the substrate. Because ubiquitin has 7 lysines of its
own, this process can be repeated to create a poly-ubiquitin chain attached to the substrate protein.
The variation in this chain (i.e. which lysine(s) the chain is linked to) creates a code that determines
the fate of the ubiquitinated substrate. For example, K48 linkage promotes proteasomal
degradation and K63 linkage promotes lysosomal degradation. The poly-ubiquitinated protein is
then recognized by the appropriate proteolytic machinery and destroyed.10
1.2.1 PROTAC Mechanism of Action and Advantages
In 2001 our lab along with Ray Deshaies group demonstrated that the UPS can be hijacked by
PROTACS to induce degradation of a desired substrate.4 PROTACs are bifunctional molecules
which mediate ternary complex formation between a substrate protein and an E3 complex (Fig
1.2). This ternary complex enables the poly-ubiquitination and subsequent destruction of the
PROTAC-specified substrate. The first PROTACs were not very drug-like, and required peptide
ligands and microinjections to induce a cellular consequence. Nonetheless, they established the
potential of PROTAC technology and demonstrated that we have the ability to robustly and
specifically control the E3 machinery using bifunctional molecules..11

Figure 1.2: PROTACs are Bifunctional Molecules that Hijack the UPS (figure adapted from Cell Chem. Biol.
27, 998-1014 (2020))

xv

This seminal work was followed quickly by the development of a more drug-like, entirely small
molecule PROTAC, which helped boost the technology into the spotlight of the drug discovery
world. This PROTAC featured nutlin as a ligand to recruit the E3 ligase MDM2 to the androgen
receptor (AR) to induce its degradation.12 In subsequent years, PROTACs have been developed to
degrade a plethora of protein targets, which have been reviewed extensively and will not be the
focus of this thesis.13,14,10,15,16 Of note, PROTACs have found success targeting proteins that were
considered undruggable by traditional inhibition strategies, such as KRAS17 and pathogenic tau.18
PROTACs have also been developed to target proteins in specific cellular compartments.16
Overall, PROTACs benefit from several unique advantages not available to traditional small
molecule inhibition strategies. For example, PROTACs can inhibit the scaffolding roles as well as
enzymatic roles of proteins since the protein is destroyed.16 PROTACs can induce isoform
selective degradation,19 can induce degradation of multi-domain proteins,20 can convert
promiscuous ligands into selective degraders,21 and can act catalytically.22,23 In the following
sections, I will review the landmark advancements in the development of PROTAC technology
that revealed these advantages and discuss the principles we learned from these studies for guiding
the development of successful PROTAC campaigns.
1.2.2 Discovery of E3 Recruiting Elements
When considering the structure of a PROTAC there are three crucial elements: the substrate
recruiting ligand, the E3 recruiting ligand, and the linker. At the advent of PROTAC technology
the substrate recruiting ligand was the most accessible element, since any direct binding inhibitor
could be used and inhibitor design was (and remains) a very active field. However, the choice of
E3 recruiting elements was more limited. Until the proof-of-principle PROTAC was disclosed
there was little reason for anyone to pursue E3 ligands or inhibitors. In fact, the E3 machinery was
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long considered un-druggable by the pharmaceutical community. Here, I will briefly review the
discovery of important E3 ligands and outline the most promising strategies by which ligands for
new E3 proteins are being discovered today.
The E3 ligands used in the first PROTACs were peptidic in nature, derived from interrogating the
interaction between the E3 von-Hippel-Lindau (VHL) and hypoxia-inducible factor-1a (HIF1a).
These peptides bound the E3 von-Hippel-Lindau VHL to induce ternary complex formation.
Peptide ligand suffer from limited cell permeability, poor synthetic tractability on scale, and poor
pharmacokinetics (PK) and pharmacodynamics (PD) in many cases. This motivated efforts to
design fully small molecule E3 ligands. The most notable discoveries in this vein have been
improved small molecule ligands for the E3 ligases VHL,24,25 cereblon (CRBN),26,27 and inhibitors
of apoptosis protein (IAPs).28
In the 1990s it was found that HIF1a regulates a variety of biological responses such as
suppression of reactive oxygen species and cancer metastasis.29 It was later demonstrated that in
healthy cells HIF1a levels are kept low by the tumor suppressor VHL, which is responsible for its
proteasomal degradation. VHL is a subunit of the E3 ligase complex CUL2–RBX1–ElonginB–
ElonginC–VHL. The solved crystal structure of this VHL complex in coordination with HIF1a
revealed that VHL is the crucial recognition element in the process of HIF1a ubiquitination and
degradation.30 The E3 binding peptides employed in the first PROTACs were based on the epitope
of HIF1a that engages VHL (ALAPYIP).31 These peptides were appended with a positively
charged poly-D or poly-K tag to allow cell penetration without a microinjection.11,32 These peptidic
PROTACs were the first to demonstrate degradation of FKBP12X and androgen receptor (AR) in
the cell without requiring microinjections, further driving efforts to discover a small molecule
ligand of VHL and ligands for other E3 ligases.
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In 2012 our lab along with the Ciulli lab, ever at the forefront of PROTAC development, disclosed
a novel peptidomimetic fully small molecule VHL ligand.25 This ligand was developed by a
combination of computational structure-activity-relationship (SAR) analysis and chemical
synthesis to generate molecules mimicking the crucial hydroxyproline region in the VHL-binding
epitope of HIF1a. This first-generation ligand inhibited the interaction of VHL-HIF1a with low
micromolar dissociation constant (KD). Second generation ligands were developed by iterative
structure-based design to improve the interactions with VHL, culminating in the development of
sub-100 nanomolar (nM) small molecule VHL ligand VH032. This development was accompanied
by the discovery of a suitable vector for modification with a linker for PROTAC development
using this ligand. Today, VH032 remains the VHL ligand mainly employed in design of PROTACs
targeting VHL.
Alongside VHL, CRBN is the most common E3 ligase recruited for use in PROTACs.
Thalidomide is most well-known for its teratogenicity which led to the birth of nearly 10,000
deformed children in the late 1950s Thalidomide was withdrawn from the market following these
births. Nearly 50 years later, thalidomide was shown to be effective in treatment of multiple
myeloma, but the mechanism of therapeutic action remained elusive.33 Finally, in 2010 it was
demonstrated by Ito that thalidomide, like HIF1a, binds to an E3 ligase complex.26 In this case the
E3 complex is CUL4–RBX1–DDB1–CRBN and thalidomide binds to the CRBN subunit. This
engagement was shown to contribute to teratogenicity in animal models. Later in 2014 the binding
mode was demonstrated by two independent cocrystal structures.27 These structures also identified
the availability of the phthalimide ring of thalidomide for linker substitution. Quickly several
PROTACs using thalidomide as an E3 recruiting element were developed, and CRBN has been an
important player in the PROTAC field ever since.
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These ligands for VHL and CRBN that remain the most popular in the PROTAC field. They are
also the ligands that are used in the development of the PROTACs described in this thesis. They
are ideal ligands because of their well-characterized binding interactions, suitability for
modification with a linker, and drug-like properties.16 Additionally, degradation of diverse protein
families using these ligands has been achieved, which makes them a good starting point for any
new PROTAC campaign.
Despite the success of VHL and CRBN recruiting PROTACs, there is a desire to further expand
the E3 ligase toolbox. Small molecule ligands have been recently developed to recruit other E3
ligases including ligands for IAPs34, KEAP1,35 DCAF15,36 RNF4,37 RNF114,38 DCAF16,39 and
AhR.40 While these E3s have found less application in PROTACs so far, we often need multiple
options for E3 recruitment when targeting a stubborn substrate. It has been demonstrated by several
groups that the substrate ubiquitination pattern will vary significantly between different recruited
E3 ligases.7 Further, sometimes a particular protein target will only be degraded when recruiting
one E3 ligase but not another, as demonstrated by the DcpS study presented later in this thesis.
These new E3 ligands were developed by a variety of target-based screening as well as phenotypic
screening approaches. While I will not describe these strategies in detail, successful efforts for
identification of these ligands include fragment-based drug design, structure-guided drug design,
high-throughput screening with DNA-encoded libraries, scalable chemical profiling, and phage
display.34-40 While there has been significant progress made towards the development of E3
ligands, there are still over 20 additional E3 ligases that have not been targeted with PROTACs
but that have cocrystal structures with bound ligands solved, demonstrating that the field of E3
ligand design remains ripe with potential.
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1.2.3 The Importance of Linkerology in PROTAC Design
After considering the substrate and E3 binding ligands, the final piece of the PROTAC puzzle is
choosing the linker to connect them. This may seem simple at surface level, but it can actually be
one of the most challenging and rigorous aspects of PROTAC design. PROTAC linkers must be
long enough to bridge the gap between the substrate and recruited E3 complex, but that alone is
not enough. There must also be enough conformational flexibility that the E3 is able to adopt the
appropriate orientation to enzymatically act on the substrates lysines and induce ubiquitination.
Therefore, the window of linker lengths that will induce target degradation for a particular
PROTAC target can be very small. Furthermore, the linker composition is important as it will
strongly influence cell permeability and can impact the conformation of the PROTAC and the
chemical interactions that make up the ternary complex.41 The importance of linkerology is well
illustrated by the work on DcpS targeting PROTACs that follows in this thesis, where only a 17atom linker was found to induce potent degradation of DcpS, with modest degradation observed
for the 16-atom and 18-atom PROTACs. In the past our lab has further demonstrated how linker
choice can impact PROTAC efficacy. The first example is from the development of
HaloPROTACs.42 HaloTag protein is a bacterial dehalogenase that covalently binds chloroalkanes.
To create HaloTag-degrading PROTACs, we linked a chloroalkane to a VHL-recruiting ligand
with polyethylene glycol (PEG) linkers of increasing length. After discovering a successful
candidate, it was uncovered that PROTACs with an ethylene glycol unit removed or added were
no longer able to induce degradation, confirming the tight linker requirements for HaloTag
degradation. Another example comes from our development of BCR-ABL PROTACs, we found
that replacing an amide bond with an ether linkage improved cell penetration and PROTAC
potency.43 Furthermore, we found Lapatinib-based PROTACs with different linker lengths to be
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selective EGFR degraders or EGFR/HER2 dual degraders based only on differences in their linker
length, further illustrating the critical importance of linker SAR in PROTAC development.44 More
recently we disclosed isoform-specific p38a and p38d PROTACs, which gain their specificity
through linker selection and the attachment vector from the VHL ligand.45 Other groups have also
demonstrated the importance of linkers to inform specificity and PROTAC efficacy by developing
CDK2 and BTK selective PROTACs.19,22 More creative uses of linkers have also been recently
developed, well-illustrated by PHOTACs (Photo-inducible PROTACs) where the linker is lightsensitive and can be activated as a photo switch to enable additional spatiotemporal control of
PROTAC action.46 Overall, linkerology is one of the most important parts of PROTAC
development, but it is challenging to predict what will work. Therefore, numerous PROTACs with
diverse linker lengths and E3 ligands must be generated before degradation can be ruled out for
that substrate. While new computational methods can aid in choosing a starting point for linker
design, the synthesis of PROTACs with many linker lengths is often necessary to establish a strong
tool compound degrader which is able to induce the appropriate conformations within the ternary
complex.
1.2.4 Cooperativity, Ternary Complex Formation and Catalytic PROTAC Action
In addition to simply forming the active ternary complex, linker choice in PROTAC design is
important for establishing binding cooperativity. Cooperativity is the impact that binary binding
(i.e. A:B or B:C) has on the ability of the ternary complex (A:B:C) to form. Cooperativity in ternary
complex formation has been mathematically defined, but is beyond the scope of this thesis.47
Positive cooperativity occurs when the ternary complex benefits from additional stabilizing
interactions between the substrate and E3. Negative cooperativity occurs when there are steric or
chemical clashes between the members of the ternary complex which can disrupt formation. The
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“hook effect” occurs when we observe a disproportionate formation of binary species A:B and
B:C when the concentration of bifunctional molecule B is too high.48 Where along the
concentration gradient the hook effect is observed is directly impacted by the cooperativity of the
complex in question. The hook effect should be observed at some relatively high concentration in
all systems where a ternary complex is implicated.
Today there are several methods of monitoring ternary complex formation including FRET-based,
Nano-BRET based, and HiBIT-based assays.49,50 Cocrystal structures of several PROTAC ternary
complexes have been elucidated, providing further insight into the formation and cooperativity of
PROTAC ternary complexes. These x-ray structures have propelled computational efforts to
predict ternary complex formation and inform linker design.51 However, as I mentioned
previously, PROTAC development campaigns today remain largely empirical. Often confirmation
of ternary complex formation or computational analysis will be undertaken once a degradation
signal has been obtained. Observation of a hook effect is also very good evidence that a ternary
complex is at play in the mechanism of action of a candidate PROTAC.
Non-covalent PROTACs are also known to act catalytically.22 After successful ternary complex
formation and ubiquitination the substrate protein of the ternary complex is destined for
degradation in the proteasome. If the substrate ligand employed in the PROTAC is non-covalent,
the PROTAC may act catalytically and dissociate from the ubiquitinated substrate before or during
proteasomal degradation, along with the E3 complex. Therefore PROTACs are often observed to
be sub-stoichiometric, able to induce degradation at concentrations far lower than those predicted
by ternary complex modeling alone. However, catalytic turnover can sometimes be disrupted by
poor permeability and negative cooperativity. PROTACs are less likely to be catalytic if they
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engage the substrate protein covalently because the covalent attachment will prevent them from
disengaging the substrate before or during proteasomal degradation.23
1.2.5 PROTACs Can Increase Selectivity and Decrease Toxicity of Inhibitors
Selectivity in drug discovery is a particular challenge because so many disease relevant proteins
belong to protein families that share significant sequence and structural similarities. Our lab
demonstrated that PROTACs can enhance the selectivity of a poorly selective inhibitor by
generating Foretinib-based PROTACs.45 Foretinib is a highly promiscuous kinase inhibitor that
binds to 133 kinases at 10 µM concentration. When we conjugated Foretinib to a VHL ligand we
observed degradation of only nine kinases using these PROTACs, while CRBN based PROTACs
degraded fourteen kinases. Increased selectivity is achieved by the combination of several
mechanisms. Addition of the linker and E3 ligand provides steric bulk that precludes binding to
many of the kinases. Further selectivity is achieved because PROTACs require the formation of
an active ternary complex. Not only must the PROTAC be able to engage both the substrate and
E3, there must be an accessible surface lysine in the appropriate orientation for poly-ubiquitination
to occur. Therefore, some kinases that are been engaged by the PROTAC will not be degraded.
These results also demonstrate that ternary complex formation is not sufficient for degradation, a
theory which has been corroborated by several other groups. To be sufficient the conformation of
the formed complex must also enable productive poly-ubiquitination of the substrate.
PROTACs can also exhibit decreased general toxicity when compared to their parent substrate
ligand. This is influenced by the same mechanisms that increase selectivity, as increasing
selectivity will often also decrease general toxicity if the substrate protein of interest is aberrantly
expressed in the disease state. Decreasing general toxicity and increasing selectivity combine to
improve the therapeutic index of a drug candidate. This was demonstrated in our lab by generation
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of FLT-3 degrading PROTACs based on the FMS-Like Tyrosine Kinase 3 (FLT-3) internal tandem
duplication (ITD) variant inhibitor Quizartinib.21 Quizartinib had limited efficacy in the clinic, and
was observed to be promiscuous, like many other kinase inhibitors. We demonstrated that
PROTACs based on Quizartinib inhibited fewer off-target kinases and inhibited the growth of
FLT-3 ITD dependent cancer cells more potently than the inhibitor alone. PROTACs benefitting
from improved selectivity and decreased toxicity compared to their parent substrate inhibitor have
also been reported by other groups.19,52
1.2.6 Differential Biology of Degradation vs. Inhibition
PROTACs often exert differential biological effects when compared to their parent substrate
ligands, partially as a result of the increased selectivity and decreased toxicity of PROTACs I have
just described. The main reason for the differential biology of PROTACs is that they completely
remove the protein of interest from the system. Small molecule inhibitors usually only inhibit
enzymatic activity, leaving the inhibited substrate available to participate in scaffolding and other
non-enzymatic roles.16 The complete removal of the substrate from the system can have more
profound biological outcomes compared to inhibition alone.
We demonstrated the differential biology of PROTACs during our campaign to generate Focal
Adhesion Kinase (FAK) targeted degraders. The FAK ligand employed in the design of these
PROTACs is Defactinib. On its own Defactinib is an inhibitor of cell division, while PROTACs
generated from Defactinib were found to inhibit both cellular proliferation and motility.53
Therefore we demonstrated that degradation of FAK can inhibit cellular processes that inhibition
of FAK alone cannot. Additional studies have confirmed that degradation can lead to a more
profound cellular consequence than inhibition alone. We elucidated FLT-3 and epidermal growth
factor receptor (EGFR) PROTACs that were demonstrated to induce more sustained and potent
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inhibition of proliferation in relevant cancer cell models than their parent inhibitors.21,44 Other
groups have also recognized the differential biology of PROTAC induced degradation. For
example, degradation of bromodomain containing 4 (BRD4) caused c-MYC to be more strongly
suppressed than when BRD4 was merely inhibited.54 Overall, generation of PROTACs based on
substrate inhibitors can improve their therapeutic potential and lead to the discovery of additional
substrate functions when differential biology suggests non-enzymatic roles in the context of the
relevant disease.
1.2.7 Limitations of PROTACs
While PROTACs are incredibly powerful molecules, they do suffer some limitations and
drawbacks that must be overcome during the design of a successful candidate, especially as they
move towards the clinic. For example, many bivalent molecules exhibit poor drug-like properties
as a result of their relatively high molecular weight, polar surfaces, large number of H-bond donors
and acceptors, and high number of rotatable bonds.13 These attributes can lead to poor
permeability, solubility, metabolic stability, tissue distribution, and bioavailability. Furthermore,
it is possible for cells to gain resistance to PROTACs just as they do to small molecule inhibitors.
One mechanism of resistance to PROTACs is genomic alteration of the core components of the
E3 machinery that render the PROTAC unable to form a cooperative ternary complex. This was
demonstrated in a striking study where acquired resistance to BET-PROTACs was investigated.55
Interestingly, the resistance did not result from mutations that rendered the PROTAC unable to
bind, rather the E3 machinery in the cancer lines studied mutated to compromise the degradatory
efficiency of the recruited E3 complex. This study illustrates that cells will certainly develop
resistance to PROTACs by diverse mechanisms after chronic treatment. This is very important for
researchers to remember when advancing PROTACs towards the clinic. Overall, it is important to
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carefully analyze all of the described properties of any proposed PROTACs and consider the use
of target validation techniques (such as the dTAG system described later in this chapter) before
engaging in the time-consuming and costly process of developing a TPD candidate.
In summary, PROTACs offer many distinct and unique opportunities for therapeutic discovery
when compared to simple inhibitors. Since their inception two decades ago the field has blossomed
into one of the most promising avenues for drug discovery. Today Arvinas, Dr. Crews’ company
founded to develop PROTAC technology, has begun human phase trials of AR and ER degrading
PROTACs, finally demonstrating the therapeutic viability of PROTACs in the clinic. Due to
promising clinical data, Pfizer recently acquired Arvinas leading ER-degrading PROTAC
candidates for $1B. It is fair to say that the excitement around bifunctional molecule technology
in the pharmaceutical world has reached a fever pitch. Now that we understand the essential
principles of PROTAC development and important discoveries that have informed the design of
the novel PROTACs in this thesis, I will move on to review non-PROTAC targeted degradation
strategies that have been pioneered in recent years and are advancing towards the clinic.
1.3 Non-PROTAC Targeted Degradation Strategies
1.3.1 MoDE-As Recruit Extracellular Proteins to the Lysosome in Hepatocytes
During the first half of my PhD I worked in David Spiegel’s laboratory towards the development
of several bifunctional molecule technologies. The most successful of these were Molecular
Degraders of Extracellular proteins through the Asialoglycoprotein receptor (ASGPR)
(MoDE-As).56 Since PROTACs are limited to the degradation of intracellular proteins and
extracellular proteins make up about forty percent of the proteome, we were interested in
generating bifunctional molecules that could recruit extracellular proteins to bring them into cells
to be degraded. One pathway of extracellular protein degradation in our bodies is through ASGPR.
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ASGPR is primarily expressed in hepatocytes and has been targeted for the specific delivery of
therapeutic agents to the liver.57 Many proteins carried in the bloodstream have complex
carbohydrate chains decorating their surfaces and it has been demonstrated that proteins with
exposed N-acetylgalactosamine (GalNAc) residues are recruited to ASGPR for endocytosis and
lysosomal degradation. The ASGPR receptor is recycled after substrate disengagement in the late
endosome, so we expect our MoDE-As to act catalytically if they are able to disengage ASGPR
while releasing the substrate in the late endosome. To harness this tissue-specific degradation
pathway using bifunctional molecules we generated compounds combining an ASGPR binding
domain based on a tri-GalNAc motif, a PEG spacer, and a protein-binding ligand (Fig 1.3).

Figure 1.3: MoDE-As Mediate Degradation of Extracellular Proteins: A) Mechanism of internalization and
degradation. B) General Structure of MoDE-As targeting anti-DNP (D) or MIF (M) (Figure adapted from ref 56)

As a proof of principle we generated D-MoDE-As that successfully degraded anti-dinitrophenyl
(DNP) antibodies in hepatocytes. We moved on to generate M-MoDE-As that degrade migratory
inhibitory factor (MIF), a cytokine contributing to several inflammatory diseases. Finally, we
demonstrated that MoDE-As mediated depletion of anti-DNP antibodies and MIF from serum
through ASGPR-mediated endocytosis in a mouse model. Along the way we validated that these
xxvii

molecules act through a bifunctional mechanism, experimentally demonstrating all steps of the
process from ternary complex formation on the surface of hepatocytes to endocytic internalization
and colocalization and finally lysosomal degradation. This study was the first demonstration that
extracellular protein degradation by a bifunctional small molecule in vivo is viable. Briefly after
our disclosure of MoDE-As the Bertozzi group published on ASGPR-targeting LYTACs, which
harness the same cellular mechanism to induce extracellular protein degradation.58
1.3.2 dTAG
Nathaniel Gray and Jay Bradner’s groups pioneered the development of the degradation tag
(dTAG) system. Many proteins in the proteome lack sufficiently selective and tight-binding
ligands for PROTAC development. dTAG was developed as a complementary chemical-genetic
strategy to quickly evaluate the functional impact of target protein loss to enable target validation
before devoting effort to the time and material intensive generation of a PROTAC library or
substrate ligand development.59 The strategy requires the fusion of the target protein with a degron
tag that is responsive to its accompanying ligand. Ligand binding to the degron tag induces rapid
and irreversible degradation of the entire fusion construct. (Fig. 1.4)
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Figure 1.4: The dTAG system uses fusion protein technology to probe the biological outcomes of targeted
degradation of a novel target (Figure adapted from Ref 59)

In the dTAG system the fusion substrate protein is based on FKBP12F36V and the dTAG molecule
mediates the formation of a ternary complex with an E3 complex. Because FKBP12F36V is
employed FKBP12WT containing proteins are not destroyed. A key example of the utility of the
dTAG platform was the development of dTAG degraders of eleven-nineteen leukemia protein
(ENL), an important part of the super elongation complex. ENL was identified as a dependency in
acute myeloid leukemia (AML). A cellular dTAG system containing ENL-FKBP12F36V was
developed and rapid degradation of the fusion protein was observed using a dTAG molecule. The
degradation led to suppression of RNA polymerase II and loss of viability which confirmed that
ENL is a targetable AML dependency.
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While dTAG was used to validate ENL as a TPD target, the system has also invalidated other
protein targets to discourage wasting resources on “doomed-to-fail” targeted degradation
campaigns. For example, serine/threonine kinase MELK was proposed by several small molecule
inhibition and genetic knockdown studies to be a dependency in basal-like breast cancer lines.
However, a dTAG system targeting MELK demonstrated that MELK degradation was not a crucial
dependency as was previously hypothesized.60 Therefore, the small molecule inhibitors and
genetic knockdowns of MELK in these earlier studies likely exhibited from some unknown offtarget effects. These examples demonstrate the versatility of the dTAG system for validating
protein targets before undertaking targeted degradation campaigns. The dTAG system has also
been used to interrogate the biological consequences of degrading MYC, BRD4, EZH2, and
KRASG12V, among others. It is important to remember that the dTAG construct insertion will not
stop the activity of the natural protein that already exists in the cell. Therefore dTAG is not able to
determine the downstream effect of degrading the target unless the native population is suppressed.
1.3.3 Molecular Glues
While molecular glues (MGs) have been around for decades, their focused development is a recent
offshoot of targeted protein degradation. MGs employs small molecules binding E3 ligases to
reprogram their substrate recognition site and enable degradation of a neo-substrate.61 PROTACs
are technically large bifunctional molecular glues, but the term is usually used to refer to
monovalent small molecules that bind at already existing protein-protein interaction (PPI) sites
(and these are the only types of molecular glues that have been FDA approved at the time of the
preparation of this thesis). These include drugs like thalidomide and rapamycin that prime their E3
host for the recognition of a particular substrate set rather than directly inducing the ternary
complex by binding both the substrate and E3. The first molecular glue to be studied was
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Cyclosporin, which was used in the early 1990s to treat transplant rejection.61 Nearly a decade
after its medical introduction, Cyclosporin’s mechanism of action as a molecular glue mediating
the interaction between Cyclophilin and Calcineurin A/B was revealed. Since then, many other
important molecular glues (including FK-CsA, Rapamycin, Synstab A, Discodermolide, Taxol,
Rimiducid, Indisulam, and Lenalidomide/Thalidomide) have been discovered, developed, and
introduced in the clinic. MGs can be more pharmaceutically favorable than PROTACs because
these monovalent degraders are usually much smaller and more drug-like.62 Unfortunately,
designing MGs empirically has been very challenging within the limitations of current
technologies, and most that have been discovered have been revealed in retrospect or
serendipitously. However, recent technological advancements such as scalable chemical profiling
approaches have provided new methods to enable the discovery of MGs.62 Looking towards the
future, the discovery of novel MGs using these modern strategies will further expand the chemical
biologist’s toolbox for rewiring the cellular circuitry at the protein level and enable the design of
completely new therapeutics.
1.3.4 Deubiquitinase Inhibitors
Like most post-translational protein modifications, ubiquitylation is reversible. The removal of
ubiquitin from a substrate protein is carried out by a diverse family of deubiquitylating enzyme
(DUBs). DUBs are able to cleave, edit, and further process ubiquitin chains in myriad ways. DUB
misregulation contributes to the pathogenesis of many diseases including melanoma,
mesothelioma, and renal cell carcinoma.63 DUBs offer another potential platform for therapeutic
intervention in the field of TPD, and they are attractive as drug targets because they have welldefined catalytic clefts which enable inhibitor design. DUB inhibitors of the past have suffered
from poor selectivity and poor mechanistic understanding. Recent advancements in the
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understanding of DUB function, mechanism of action, regulation, and disease pathology along
with technological screening improvements have enabled the generation of more selective and
therapeutically relevant DUB inhibitors, some with solved binding structures that enable further
elaboration and refinement.64 Selective DUB inhibitors are an interesting recent addition to the
TPD toolkit and are entering their first clinical trials.
1.3.5 Targeting to the Lysosome: LYTACs and AUTACs/ATTECs
Carolyn Bertozzi’s group recently developed the lysosome targeting chimera (LYTAC)
technology to target specific extracellular proteins for degradation in the lysosome.65 Within days
of our pre-print disclosure of MoDE-As during my time in Spiegel’s lab, Bertozzi also published
in pre-print on ASGPR-targeting LYTACs that mediate EGFR degradation by the same
mechanism as the MoDE-As I helped develop.58 It is clear that TPD technology development (in
this case expanding the toolkit to extracellular and membrane proteins) is a highly competitive
field today. However, the Bertozzi ASGPR-LYTACs were based on a large antibody fragment
(3.4 kDa) as a substrate ligand, while our MoDE-As were completely small molecule based and
much more drug-like. Further, they did not demonstrate in vivo depletion of a blood-borne protein
using LYTACs like we did for MoDE-As. A year before this disclosure Bertozzi published the
first LYTACs which were bifunctional molecules that hijack the universally expressed endocytic
cation-independent mannose-6-phosphate (M6P) receptor to induce cellular uptake and eventual
lysosomal degradation of the target protein (Fig. 1.5). M6P functions similarly to ASGPR, but
instead of GalNAc it recognizes exposed M6P residues. M6P is also expressed in most tissues
while ASGPR is liver-specific. Like ASGPR, M6P mediates internalization of its cargo and in the
slightly acidified endosome it releases the bound protein which is destined for the lysosome, and
the receptor is then recycled to the surface by recycling endosomes.
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Figure 1.5: LYTAC mechanism of targeted degradation (Figure adapted from ref 58)

In these proof-of-principle LYTACs the M6P recruiting element is a glycopeptide ligand based on
poly-mannose. This ligand is conjugated through a linker to an antibody or small molecule ligand
for a secreted or membrane-associated protein. These constructs are very large and not drug-like,
but they were able to induce the internalization and lysosomal degradation of disease relevant
proteins in vitro including EGFR, apolipoprotein E4, CD7a, and PDL-1. LYTAC technology will
advance towards therapeutic relevance as new tissue-specific receptors are co-opted to induce
lysosomal degradation, and as the molecules employed become small-molecule focused.
Other bifunctional molecule technologies that mediate degradation in the lysosome include
autophagy-targeting chimeras (AUTACs/ATTECs). While LYTACs hijack surface receptors to
induce internalization and degradation, AUTACs commandeer the macroautophagic machinery by
binding LC3 or mimicking s-guanylation (Fig 1.6).66,67
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Figure 1.6: AUTAC/ATTEC mechanism of targeted degradation (Figure created by S. Alabi in Biorender)

Macroautophagy is a distinct cellular degradation mechanism that enables the cells to digest large
portions of their own cytosol containing proteins and damaged organelles. The process is initiated
by the formation of a phagophore, a dual-membrane structure that is nucleated by a protein
complex that includes microtubule-associated protein light chain 3 (LC3) among other proteins.
After nucleation the autophagic machinery continues to elongate the phagophore until it becomes
an enclosed vesicle, the autophagosome. The autophagosome then merges with a lysosome to
become the autolysosome, where the contents of the autophagosome are degraded by the active
proteases and hydrolases in the acidic environment. It has been demonstrated by several studies
that macroautophagy can be non-selective, digesting cytosolic contents at random, or selective.66
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The unraveling of selective autophagy by the Arimoto group fueled their work towards developing
the first functional AUTACs. They discovered that s-guanylation of proteins could bias them
towards autophagic degradation.67 They moved

on

to develop

a GMP

analogue

fluorobenzylguanine (FBnG) that could induce selective autophagy without activating other
cellular pathways that utilize cGMP. Using FBnG they generated the first AUTACs targeting
MetAP2, which were able to induce MetAP2 degradation with low micromolar potency. They also
generated AUTACs capable of degrading entire mitochondria, a pioneering demonstration of
selective organelle degradation in the cell. Other groups generated compounds to recruit the
substrate protein directly to LC3, such as in the elegant study where the Lu group were able to
identify molecular glue-like compound AN1 that dually bound LC3 and mutant huntingtin
(mHTT) protein to induce the degradation of the pathogenic mHTT protein.68 Moving forward,
the field of macroautophagy-recruiting degraders will expand as more selective ligands for the
autophagic machinery are developed and our understanding of selective autophagy becomes more
well-defined.
1.4 Summary and Outlook
We have learned during this introductory chapter that research over the past two decades has
significantly expanded our ability to manipulate protein function and lifetime by a variety of
mechanisms. PROTACs and other TPD technologies are now at the forefront of drug discovery
both in academia and industry. This fervor for targeted protein degradation is sure to continue to
grow as the first PROTACs from Arvinas are producing promising data in human clinical trials.
While massive improvements and important insights into the technology of targeted protein
degradation have been made, the field remains ripe with potential discovery as we continue to
explore the application of these strategies to treat real human disease.
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In the following chapters of this thesis I will describe my successful efforts towards developing
novel PROTAC degraders of scavenger mRNA-decapping enzyme (DcpS) and receptor tyrosineprotein kinase erbB-3 (HER3), as well as efforts towards developing PROTACs for transcription
factor Brachyury. My work towards the development of PhosTACs to recruit a native phosphatase
to a protein of interest and induce dephosphorylation will be discussed in chapter 5, and a brief
synthetic submarine project will be described in chapter 6.
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Chapter 2: The Development of DcpS PROTACs
Parts of this chapter adapted from resultant manuscript:
Initial efforts on the DcpS project were undertaken by Evan Carder
Mike Bond was instrumental in helping collect the data presented in section 2.3.
2.1 DcpS Background and Disease Relevance
The 5’ mRNA cap structure enhances translational efficiency and protects the mRNA transcript
from premature degradation.1 The scavenger mRNA-decapping enzyme DcpS is a histidine triad
(HIT) pyrophosphatase responsible for the final hydrolysis of this cap structure during the 3’ to 5’
mRNA degradation process in eukaryotes.2 DcpS also participates in micro-RNA turnover, premRNA splicing, and the 5’ to 3’ mRNA decay pathway, demonstrating that it has multiple
functional roles in the regulation of RNA in the cell.3,4,5
Although the interplay of the many functions of DcpS with other RNA processing machinery is
not fully understood, DcpS has been implicated in several diseases. DcpS was first identified as a
driver of spinal muscular atrophy (SMA).6 SMA is caused by deletion or mutation of both copies
of the survival motor neuron 1 (SMN1) gene, which codes for SMN, a protein necessary for proper
motor neuron development and function. The severity of SMA symptoms is dependent on the
variable copy number of the related gene SMN2; patients with high levels of SMN2 expression
have less severe symptoms. C5-substituted quinazolines were found to be potent SMN2 promoter
inducers but the molecular target was not known.7 In subsequent protein microarray array studies
using a radio-labelled C5-substituted analog, this class of compounds was found bind and inhibit
DcpS.8,9 Candidate C5-quinazoline inhibitor RG3039 was advanced as a potential SMA therapy,
where it was shown to improve survival and motor function in SMA mice.10 RG3039 showed
additional promise during a phase 1 clinical trial after being acquired by Repligen and Pfizer, but
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work was later terminated towards development as an SMA therapy due to the inability to increase
SMN1 protein levels in humans. DcpS mutations have also revealed a crucial role of mRNA
processing in intellectual development, as autosomal recessive variants have been identified as
drivers of intellectual disability during development.11
In addition to SMA and developmental intellectual disability, DcpS has been recently identified as
a driver of acute myeloid leukemia (AML).12 This unexpected finding illustrates the knowledge
gap in understanding the role of aberrant mRNA processing in diverse disease states. Genomewide CRISPR-Cas9 screening using AML cell lines revealed that DcpS is an essential gene for
AML cell survival. Inhibition of DcpS with RG3039 lead to potent antileukemic activity in both
cellular and human AML xenograft models. Hematopoietic cells containing bi-allelic DcpS lossof-function mutations were phenotypically normal, indicating DcpS is dispensable in normal blood
cells but necessary in AML, which opens a good therapeutic window for specific intervention.
Further, siRNA silencing of DcpS demonstrated antileukemic activity, corroborating that the
activity of RG3039 in AML cells was due to DcpS inhibition. Therefore, we became interested in
generating a molecular degrader of DcpS to interrogate the impact of sustained DcpS degradation,
rather than inhibition or gene silencing, on AML progression.
We generated PROTACs based on RG3039 as the DcpS binding warhead, resulting in the
discovery of VHL-based DcpS degrader JCS3971. To our knowledge, this is the first example of
a PROTAC that can induce degradation of mRNA processing machinery. We observed rapid and
sustained degradation of DcpS via a PROTAC mechanism in multiple AML cell lines, leading to
decreased proliferation. JCS3971 is a valuable chemical tool to interrogate the impact of DcpS
degradation on mRNA biology in many cellular contexts and may serve as a blueprint for the
development of clinical candidate DcpS degraders. To summarize, the RNA decapping scavenger

45

DcpS has recently been identified as a dependency in acute myeloid leukemia.13 The potent DcpS
inhibitor RG3039 attenuates AML cell viability and siRNA knockdown of DcpS is also
antiproliferative.12 Importantly, DcpS was found to be non-essential in normal human
hematopoietic cells, which opens a therapeutic window for AML treatment by modulation of
DcpS. Considering the strong dependence of AML cell lines on DcpS, we wanted to explore
PROTAC-mediated degradation as an alternative strategy to inhibit DcpS activity. We determined
that the di-chloro motif in RG3039 was not required for DcpS binding by analyzing the docked
structure in MOE. We chose to change this into a simple phenyl ring and use it as the vector
attachment point for linker addition. We generated 28 PROTACs based on this design and
identified our lead compound JCS3971, the first PROTAC capable of degrading an mRNAdecapping enzyme. JCS3971 non-covalently binds DcpS with an RG3039-based warhead and
recruits the E3 ligase VHL, which induces potent, rapid, and sustained DcpS degradation in several
AML cell lines. JCS3971 will serve as a chemical biology tool to interrogate DcpS function in
different cellular contexts and may be an applicable strategy for the treatment of AML and other
DcpS dependent genetic disorders.
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2.2 DcpS-targeted PROTACs Design and Synthesis

Scheme 1: Synthetic strategy for DcpS PROTACs

We determined that the di-chloro motif in RG3039 was not required for DcpS binding by analyzing
the docked structure in MOE. We chose to change this into a simple phenyl ring and use it as the
vector attachment point for linker addition. We generated a library of PROTACs based on this
warhead (Scheme 1). The synthesis commences with pivolate protection of 6a to yield 6b.
Borohydride mediated reduction of the benzaldehyde and subsequent Appel reaction yields
intermediate 6, which will be used later in the scheme. The synthesis of advanced quinazoline
intermediate 8 begins with hydride mediated SNAr between 1 and 2. The product 3 is then
condensed with guanidine carbonate at high temperatures to furnish 4. Deprotection and
subsequent SN2 reaction with 6 prepared earlier furnishes the protected DcpS ligand 7. Hydroxide
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mediated deprotection of 7 provides the DcpS ligand prepared for attachment to the VHL binding
component by either amide coupling (LH-VHL) or carbonate mediated phenol substitution
reactions (RH-VHL, CRBN).
2.3 Biological Characterization of DcpS PROTACs in AML Cell Lines
2.3.1 DcpS PROTAC Degrades DcpS in Multiple AML Cell Lines with Dose-dependence
Considering its positive Phase 1 trial data we chose RG3039 (Figure 2.1A) as the DcpS recruiting
element to design DcpStargeting

PROTACs.

Docking analysis revealed
that the dichlorobenzene
motif

does

significant

not

form

interactions

with DcpS (PDB: 1st0).
We decided to eliminate
the halogens in favor of a
meta-phenol
enable

vector

facile

attachment
Figure 2.1: JCS3971 degrades endogenous DcpS in AML cell lines: A)
Chemical structures of RG3039 (DcpS inhibitor), JCS3971 (active
PROTAC), JCS3979 (inactive epimeric control PROTAC). B) JCS 3971
degrades DcpS in a dose-dependent manner in MOLM-14 cells and C) in
MV411 cells. Cells were treated for 24 hours. Blots show lysates from
independent wells harvested side-by-side on the same day. Quantitation
below for MV411 blot. Quantified data represents the mean ± SD from two
independent biological replicates.

PROTAC
library
targeting

of

to

linker
during
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PROTACs

recruiting either VHL or

CRBN) was synthesized. Either the amide linked or phenol linked VHL ligand developed in our
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laboratory was used to recruit VHL while a 4-hydroxy thalidomide derivative was used to recruit
CRBN. Interestingly, only JCS3971, which linked a des-chloro RG3039 to the phenol VHL ligand
via a 4 PEG (17 atom) linker was able to induce DcpS degradation in multiple AML cell lines.
The observed degradation was potent with maximal degradation (Dmax) of 90% and DC50 (the
concentration at which half the Dmax is reached) value of 81 nM in MOLM-14 AML cells (Figure
2.1B). We tested a small panel of AML cell lines and JCS3971 was able to efficiently induce DcpS
degradation with DMax values from 13 nM to 81 nM and DC50 >90% in all cell lines (Table 1).

To ensure that the 17 atom, 4 PEG linker was the optimal linker length for inducing DcpS
degradation, PROTACs were synthesized with linker lengths of 15, 16, 18, and 19 atoms.
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Remarkably, potent degradation was only observed for the 17-linker atom PROTAC JCS3971,
with minimal degradation observed for the 16 and 18 atom derivatives and no degradation
observed for the PROTACs with 15 or 19 atom linkers (Table 1) These data illustrate the incredibly
stringent requirements for ternary complex formation and subsequent ubiquitination and
degradation in this system.
2.3.2 DcpS PROTAC Degrades DcpS via a Time-sensitive PROTAC Mechanism

Figure 2.2: Characterization of DcpS degradation by JCS3971 in MOLM-14 cells: A) Degradation is via
a protac mechanism: Epimer 3971 does not induce degradation and degradation is rescued by VHL ligand
competition, proteasome inhibition by epoxomicin (Epox), and neddylation inhibition by MLN4924 (MLN).
Blots show lysates from independent wells harvested side-by-side on the same day. Quantitation to the right.
B) 24 hour timecourse for DcpS degradation by 1uM JCS3971 in MOLM-14 cells. C) Extended 72 hour
timecourse with a single treatment of 1uM JCS3971. D) DcpS recovery following washout after 24 hour
initial treatment with 1uM JCS3971 with either plain media (med) or with 10uM VHL-ligand to compete
residual PROTAC action following washout.
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PROTAC targets are marked for degradation via ubiquitination which is dependent on the ternary
complex formation between the target, the PROTAC, and the E3 ligase. The hydroxy proline
moiety of the VHL ligand is crucial for binding to the E3 ligase, and inversion of the
stereochemistry of the 4-hydroxy proline abrogates VHL binding. We generated JCS3979 (Figure
2.1A) as an epimeric control PROTAC that cannot bind VHL and form the necessary ternary
complex needed for ubiquitination. As expected, the inverted hydroxy proline epimeric control
PROTAC JCS3979 did not induce DcpS degradation (Figure 2.1B). Additionally, we disrupted
VHL binding by competition with excess VHL ligand, which inhibited ternary complex formation
and subsequent DcpS degradation (Figure 2.1C). Neddylation of CUL2, a VHL adaptor protein,
and functional proteasomes are also required for degradation via a PROTAC mechanism.
Degradation by JCS3971 was inhibited by the neddylation inhibitor MLN4924 (MLN) and
proteasome inhibitor epoxomicin (epox), providing further evidence that degradation is via a
PROTAC mechanism (Figure 2.2A). Finally, free DcpS inhibitor RG3039 also does not induce
DcpS degradation, nor does a combination of un-linked RG3039 and VHL ligand, the free
components of the PROTAC. (Figure 2.2A). Together, these data clearly demonstrate that
JCS3971 induces the degradation of DcpS via a PROTAC mechanism.
After confirming that DcpS degradation by JCS3971 is via a bona fide PROTAC mechanism, we
moved on to further interrogate the kinetics of degradation in MOLM-14 cells. A 24-hour time
course treating with 1 uM JCS3971 revealed that degradation occurs as early as 4 hours post
treatment, with maximal degradation observed between 12 and 24 hours (Figure 2.2B). We also
carried out an extended time course to determine how quickly DcpS is resynthesized after
PROTAC depletion. Strikingly, degradation of DcpS was maintained out to 72 hours by a single
treatment of 1 µM JCS3971 (Figure 2.2C). Considering this result, we carried out a washout
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experiment to determine if the slow recovery of DcpS levels is due to slow DcpS resynthesis or
residual PROTAC activity (Figure 2.2D). MOLM-14 cells were treated for 24 hours with 1uM
JCS3971 after which media was exchanged for fresh media containing DMSO or excess VHL
ligand to compete away residual PROTAC binding to VHL. Interestingly, the media washout alone
was not sufficient to recover DcpS levels over 72 hours, indicating that the residual PROTAC
remaining after washout is able to degrade newly synthesized DcpS faster than the cell can produce
it. However, when competing the residual PROTAC activity with VHL ligand, DcpS levels were
recovered (Figure 2.2D). These data indicate that DcpS resynthesis is slow and that the PROTAC
may act catalytically as expected for a noncovalent degrader.
2.3.3 DcpS Degradation is Antiproliferative in MOLM-14 Cells
To determine the effect of DcpS degradation on AML cell viability we conducted extended cell
counting and MTS experiments in MOLM14 cells. We treated cells with either the epimer,
JCS3979, or the PROTAC, JCS3971, to understand how AML cell viability is affected when DcpS
is inhibited vs degraded. The epimer was used to interrogate the effect of inhibition rather than
DcpS inhibitor RG3039 because the epimer has similar challenging physiochemical prosperities
(e.g., solubility and permeability) as the PROTAC.
For long term cell counting experiments cells were treated every 3 days with either DMSO, 1 µM
JCS3979, or 1 µM JCS3971 for 12 days. A significant decrease in cell number was observed at 3,
6, 9, and 12 days for the PROTAC treated cells compared to DMSO (Figure 2.3A). Epimer
treatment significantly decreased cell number by day 6, however it was to a lesser extent than the
PROTAC treated cells. Moreover, by 9 days epimer treated cells had similar cell counts to DMSO
treated cells. MTS data monitoring cell viability cooperated the cell counting data. The PROTAC
was ~3x more potent than the epimer with EC50 values of 1.1 ± 0.1 and 3.6 ± 0.6 µM respectively
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after 96 hours of compound treatment (Figure 2.3B). These data demonstrate that degradation of
DcpS is more antiproliferative than inhibition by an equally potent non-degrader in MOLM-14
AML cells.

Figure 2.3: Effects of degradation vs inhibition on MOLM14 cell proliferation and viability. (A) Cells were
seeded at a density of 0.5 x 105 cells/mL and treated with compounds every 3 days for 12 days. Significant
reduction in cell proliferation by the PROTAC observed between days 3 and 12. Proliferation was reduced by
the epimer at day 6, however recovered to DMSO levels by day 9. (B) MTS assay monitoring cell viability over
96 hours. The PROTAC is ~3x more potent than the epimer. Quantitation represents mean ± SEM from two
independent biological replicates performed in technical triplicate. Not significant (N.S.), ** p < 0.01, *** p <
0.005, **** p <0.0001.

2.4 Impact of DcpS Degradation on the mRNA Pool of MOLM-14 Cells
We wanted to further interrogate the downstream impacts of PROTAC-mediated degradation of
DcpS in AML cells. To do this we entered a collaboration with Dr. Matthew Simon’s lab. In
collaboration with the Slavoff lab they had profiled the cellular substrates of Dcp2 by using a novel
RNA-seq based methodology (Figure 2.4).14 Cells are fed 4-thiouridine (S4U) which is recognized
by the RNA processing machinery as uridine. After the cells are given a chance to take up the S4U
they are lysed and the RNA is harvested. A chemospecific oxidation then enables conversion of
the S4U to cytidine. Then in the RNA-seq experiment the percentage of U-to-C conversion can be
quantified and is proportional to the level of incorporation of S4U. This data can be analyzed on a
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transcript-by-transcript basis or by more “birds-eye-view” algorithms which enable us to
determine the overall impact of knockout on mRNA homeostasis. Furthermore, the level of S4U
incorporation in a specific transcript helps determine which effects are decay-driven and which are
synthesis-driven. This experimental design seemed ideal to interrogate the impacts of PROTACmediated degradation of DcpS, as it had worked for a sister system, studying Dcp2. In a subsequent
publication Simon and Slavoff developed a bicyclic stapled peptide inhibitor of Dcp2 and used it
to discover novel cellular substrates of Dcp2 by the same RNA-seq strategy.15

Figure 2.4: S4U-RNA-Seq Enables Direct Quantitation of the Impact of Treatment on the total mRNA
Pool and Specific Transcripts (Figure adapted from Ref. 14)

I generated the appropriate RNA samples to the Simon lab to for analysis. I prepared samples
where MOLM-14 cells were treated for 6 or 24 hours with JCS3971, the epimeric control, or the
free inhibitor RG3039. S4U treatment was included for the last 2 hours of treatment. These samples
along with appropriate controls were sequenced by the Simon lab and the data analyzed using their
proprietary algorithm. We then further analyzed the data set to determine genes of interest. We
decided to focus on genes that were upregulated in the PROTAC treated sample but not in the
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epimer treated sample. We reasoned that these transcripts are normally de-capped by DcpS, and
PROTAC-mediated degradation of DcpS disrupts this homeostasis while epimer treatment does
not. The following heat-map generated by Andreas in Matt Simon’s lab helps visualize the
differential impacts of treatment on important transcripts.

Figure 2.5 – Heat Map visualizing 50 genes differentially expressed under different treatment conditions
(prepared by Andreas U.). 6 or 24 refers to the length of treatment. The most differentially expressed genes are
being clustered based on their read counts. The read count data has been transformed using DESeq2 rlog
function to account for variance that is expected grow with the mean read count value. This enables us to assess
overall similarities between samples and clusters by expression patterns. Relevant signal carrying genes are
clustered (in dendograms) by their expression patterns. The red-blue scale indicates how the gene read count for
that sample has changed relative to the mean. The size factor corrects for library size, and here we do not
observe artifacts of count trends. There are AML relevant genes represented in this clustering data which we
plan to explore further in vitro after Simon lab confirms some downstream hypothesis by GO or GSEA analysis
of the relevant clusters.

At this stage the initial DcpS PROTAC story is being published as Mike and I are graduating.
Promising future studies include investigation of PROTAC mediated cooperativity by SPR and
ITC since the linker window for DcpS degradation is so specific, further phenotypic analysis of
the genes identified as AML/DcpS-relevant and impacted by PROTAC treatment, and generation
of more therapeutically relevant compounds by using an improved RG3039 that does not suffer
from lysosomal accumulation. These studies may be undertaken by future Crews’ lab scientists.
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2.5 Synthetic Schemes and Characterization and Biological Methods
A. General considerations. Chemicals used for synthesis were purchased from commercial
sources and were used without further purification. Flash chromatography was performed using
Biotage flash chromatography system using pre-packed silica gel columns. 1H NMR and 13C NMR
spectra were recorded on an Agilent DD2 600 NMR spectrometer (600 MHz for 1H and 151 MHz
for 13C). The values of chemical shifts (δ) are reported in p.p.m. Coupling constants (J) are reported
in Hz. High-resolution mass spectra (HRMS) were recorded on Shimadzu HRMS with ESI using
a Shimadzu UPLC. HPLC purifications were performed on a reverse-phase column using a
Shimadzu HPLC system.
B. Experimental Protocols
General Synthetic Strategy for DcpS Targeting PROTACs
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Preparation of 6: was prepared according to US 20110060012

3-formylphenyl pivalate (6b):
To a stirred solution of 3-hydroxybenzaldehyde (4.0g, .0328mol), TEA (6.85mL, 0.0491mol) in
anhydrous THF (240mL) was added 2,2-dimethylpropanoyl chloride (5.24mL, .0426mol) at 0oC.
The mixture was warmed to room temperature and stirred for 24 hours. The reaction mixture was
concentrated under reduced pressure and diluted with EtOAc (200mL) and washed with a satd.
Aq. Solution of potassium carbonate (100mL, 3x). The resulting organic layer was dried over
Na2SO4 and purified by silica gel chromatography (0-30% EtOAc in Hexanes) to provide (3formylphenyl) 2,2-dimethylpropanoate as a colorless oil. LCMS [ESI, M+1]: 207

3-(hydroxymethyl)phenyl pivalate (6c):
NaBH4 (0.847 g, 0.0224 mol) was added portion-wise to a solution of (3-formylphenyl) 2,2dimethylpropanoate (3.08 g, 0.0149 mol) in methanol (80 mL) at 0oC and stirred for 1 h. The
reaction mixture was diluted with water (100 mL) and extracted with methylene chloride (100 mL,
three times). The combined organic solutions were dried (MgSO4), filtered, concentrated under
reduced pressure, and purified by chromatography on silica (0-50% ethyl acetate in hexane) to
provide [3-(hydroxymethyl)phenyl] 2,2-dimethylpropanoate (0 g, 0.0126 mol, yield: 84.6 %) as a
colorless oil. LCMS [ESI, M+1]: 209
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3-(bromomethyl)phenyl pivalate (6):
Br2 (0.712 mL, 0.0139 mol) was added to a mixture of (C6H5)3P (3.97 g, 0.0152 mol), Imidazole
(0.946 g, 0.0139 mol) in methylene chloride (50 mL) at 0oC and stirred. A solution of [3(hydroxymethyl)phenyl] 2,2-dimethylpropanoate (2.63 g, 0.0126 mol) in dichloromethane (25
mL) was added dropwise and the reaction mixture was warmed to room temperature and stirred
for 12 h. The reaction mixture diluted with water (50 mL) and the organic solvent was removed
under reduced pressure. The resulting solution was diluted with diethyl ether (150 mL) and washed
with water (50 mL, three times). The resulting organic solution was dried (MgSO4), filtered,
concentrated under reduced pressure, and purified by chromatography on silica (0-40% ethyl
acetate in hexane) to provide [3-(bromomethyl)phenyl] 2,2-dimethylpropanoate (3.18 g, 0.0117
mol, yield: 92.8 %) as a colorless oil. LCMS [ESI, M+1]: 271
Preparation of 8:

tert-butyl 4-((2-cyano-3-fluorophenoxy)methyl)piperidine-1-carboxylate (3):
NaH (60.0 %, 0.133 g, 0.00348 mol) was added to a solution of tert-butyl 4(hydroxymethyl)piperidine-1-carboxylate (0.500 g, 0.00232 mol) in anhydrous THF (10 mL) at 0o
C and stirred for 1 h under an atmosphere of argon. A solution of 2,6-difluorobenzonitrile (0.355
g, 0.00255 mol) in anhydrous THF (10 mL) and the reaction mixture was warmed to room
temperature and stirred for 12 h. The reaction mixture was diluted with water (25 mL) and
extracted with ethyl acetate (25 mL, three times). The combined organic solutions were dried
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(MgSO4), filtered, concentrated, and purified by chromatography on silica (0-30% ethyl acetate
in hexane) to provide tert-butyl 4-[(2-cyano-3-fluoro-phenoxy)methyl]piperidine-1-carboxylate
(0.328 g, 0.000979 mol, yield: 42.2 %) as a colorless oil.
1

H NMR (400 MHz, DMSO-d6) δ 7.67 (q, J = 8.1 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 7.02 (t, J =

8.8 Hz, 1H), 4.02 (d, J = 6.3 Hz, 2H), 3.95 (d, J = 13.1 Hz, 2H), 1.99 – 1.87 (m, 1H), 1.71 (dd, J
= 13.4, 3.5 Hz, 2H), 1.36 (s, 10H), 1.16 (qd, J = 12.5, 4.4 Hz, 2H).
13

C NMR (101 MHz, DMSO-d6) δ 164.81, 162.28, 161.79, 161.75, 154.32, 136.97, 136.86,

111.99, 109.73, 109.70, 108.51, 108.32, 90.69, 90.52, 78.97, 73.81, 35.50, 28.53, 28.40.
HRMS [C18H23FN2O3Na+] Cal: 358.1624; Obs: 358.1614

tert-butyl 4-(((2,4-diaminoquinazolin-5-yl)oxy)methyl)piperidine-1-carboxylate (4):
A high pressure vial was charged with a mixture of tert-butyl 4-[(2-cyano-3-fluorophenoxy)methyl]piperidine-1-carboxylate (4.09 g, 0.0122 mol) and Guanidine carbonate (2.46 g,
0.0135 mol) in N,N-Dimethylacetamide (100 mL). The reaction vial was sealed and heated at 140
o

C for 24 h. The reaction mixture was cooled to room temperature and diluted with water (100

mL). The resulting precipitate was isolated by filtration and washed with additional water. The
solid was dried under high vacuum to provide tert-butyl 4-[(2,4-diaminoquinazolin-5yl)oxymethyl]piperidine-1-carboxylate (5.00 g, 0.0111 mol, yield: 90.5 %) as a white solid.
1

H NMR (400 MHz, DMSO-d6) δ 7.31 (t, J = 8.2 Hz, 1H), 7.22 – 7.06 (m, 2H), 6.74 (d, J = 8.4

Hz, 1H), 6.51 (d, J = 8.0 Hz, 1H), 5.91 (s, 2H), 3.96 (t, J = 8.4 Hz, 4H), 2.91 (s, 3H), 2.75 (s, 4H),
2.12 – 1.98 (m, 1H), 1.92 (s, 3H), 1.72 (d, J = 12.9 Hz, 2H), 1.36 (s, 9H), 1.15 (qd, J = 12.6, 4.6
Hz, 2H).
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13

C NMR (101 MHz, DMSO-d6) δ 162.27, 161.09, 156.97, 155.58, 154.29, 132.86, 117.56,

102.07, 101.71, 79.01, 73.22, 37.88, 35.39, 34.92, 28.87, 28.54, 21.85.
HRMS [C19H28N5O3+] Cal: 374.2292; Obs: 374.2479

5-(4-piperidylmethoxy)quinazoline-2,4-diamine hydrochloride (5):
HCl in 1,4-dioxane (4.00 mol/L, 11.9 mL, 0.0478 mol) was added to a mixture of tert-butyl 4[(2,4-diaminoquinazolin-5-yl)oxymethyl]piperidine-1-carboxylate (3.57 g, 0.00956 mol) in
methanol (90 mL) and stirred for 2 h. The reaction mixture was concentrated under reduced
pressure and the resulting residue was diluted with water. The resulting solid was isolated through
filtration and dried under high vacuum to provide 5-(4-piperidylmethoxy)quinazoline-2,4diamine;hydrochloride as a white solid (quantitative), which was used in the next steps without
further purification.
HRMS [C14H20N5O+] Cal: 274.1668; Obs: 274.1658

3-((4-(((2,4-diaminoquinazolin-5-yl)oxy)methyl)piperidin-1-yl)methyl)phenyl pivalate (7):
A pressure vessel was charged with 5-(4-piperidylmethoxy)quinazoline-2,4-diamine hydrogen
chloride (1.41 g, 0.00455 mol), [3-(bromomethyl)phenyl] 2,2-dimethylpropanoate (1.23 g,
0.00455 mol), TEA (3.17 mL, 0.0228 mol) in anhydrous DMF (25 mL). The reaction vessel was
sealed and heated at 70 C for 24 h. The reaction mixture was diluted with ethyl acetate (100 mL)
and washed with water (50 mL, three times). The organic solution was dried (MgSO4), filtered,
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concentrated under reduced pressure and purified by chromatography on silica (0-15% methanol
in

methylene

chloride)

to

provide

[3-[[4-[(2,4-diaminoquinazolin-5-yl)oxymethyl]-1-

piperidyl]methyl]phenyl] 2,2-dimethylpropanoate (0.870 g, 0.00188 mol, yield: 41.2 %) as an tan
residue. The residue was immediately deprotected according to the following procedure and the
free alcohol 8 was fully characterized due to solubility issues of 7 in NMR solvents.
HRMS [C26H34N5O3+] Cal: 464.2662; Obs: 464.2647

3-((4-(((2,4-diaminoquinazolin-5-yl)oxy)methyl)piperidin-1-yl)methyl)phenol (8):
A 1 M of aqueous solution of LiOH · H2O (1.00 mol/L, 30.4 mL, 0.0304 mol) was added to a
solution of [3-[[4-[(2,4-diaminoquinazolin-5-yl)oxymethyl]-1-piperidyl]methyl]phenyl] 2,2dimethylpropanoate (4.70 g, 0.0101 mol) (0.172 g, 0.000372 mol) in methanol (30 mL) and stirred
at room temperature for 18 h. The reaction mixture was diluted with water (50 mL) and the pH
was adjusted to pH 7 using 1M aq. HCl. The resulting aqueous solution was extracted with ethyl
acetate (100 mL, four times). The combined organic solutions were dried (MgSO4), filtered,
concentrated under reduced pressure to provide 3-[[4-[(2,4-diaminoquinazolin-5-yl)oxymethyl]1-piperidyl]methyl]phenol (1.58 g, 0.00416 mol, yield: 41.0 %) as an tan solid.
1

H NMR (400 MHz, DMSO-d6) δ 7.30 (t, J = 8.2 Hz, 1H), 7.17 (s, 2H), 7.05 (t, J = 7.7 Hz, 1H),

6.74 (d, J = 8.4 Hz, 1H), 6.69 (s, 1H), 6.66 (d, J = 7.5 Hz, 1H), 6.59 (dd, J = 8.0, 2.4 Hz, 1H), 6.50
(d, J = 7.9 Hz, 1H), 5.94 (s, 2H), 4.05 – 3.86 (m, 2H), 2.94 – 2.73 (m, 2H), 1.99 – 1.74 (m, 3H),
1.75 – 1.64 (m, 2H), 1.31 (ddd, J = 24.5, 13.6, 4.7 Hz, 2H).
13

C NMR (101 MHz, DMSO-d6) δ 162.30, 161.07, 157.73, 157.09, 155.49, 140.41, 132.91,

129.42, 119.74, 117.46, 115.94, 114.22, 102.04, 101.68, 73.60, 62.88, 53.14, 35.59, 29.17.
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HRMS [C21H26N5O2+] Cal: 380.2087; Obs: 380.2080
Preparation of PROTAC JCS-3971 and Epimeric Control PROTAC JCS-3979:
1-[2-(2-iodoethoxy)ethoxy]-2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethane:

Iodine (635 mg, 2.5 eq, 2.5 mmol), triphenylphosphine (656 mg, 2.5 eq, 2.5 mmol), and imidazole
(204 mg, 3 eq, 3 mmol) were dissolved in anhydrous DCM (10mL) and stirred at room temperature
for 5 minutes. A solution of heptaethylene glycol (495 mg, 1eq, 1mmol) in anhydrous DCM (5mL)
was added dropwise to the mixture. The reaction was stirred at room temperature for 3 hours and
then quenched with saturated Na2S2O3 solution, organic separated, and aqueous extracted with
additional DCM. The combined organics were washed with brine and dried over Na2SO4 then
concentrated and purified by silica gel chromatography to afford the diodide 1-[2-(2iodoethoxy)ethoxy]-2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethane:
(402 mg, 80%) as a viscous oil.
1

H NMR (400 MHz, Chloroform-d) δ 3.73 (t, J = 6.9 Hz, 4H), 3.63 (d, J = 1.3 Hz, 17H), 3.23 (t,

J = 6.9 Hz, 4H).
13

C NMR (101 MHz, Chloroform-d) δ 71.96, 70.67, 70.59, 70.58, 70.21, 2.94.

5-((1-(3-((17-iodo-3,6,9,12,15-pentaoxaheptadecyl)oxy)benzyl)piperidin-4-yl)methoxy)
quinazoline-2,4-diamine (9b-5peg):

To

a

stirred

solution

of

3-[[4-[(2,4-diaminoquinazolin-5-yl)oxymethyl]-1-

piperidyl]methyl]phenol (8) (15.0 mg, .0000395 mol) in DMF (2mL) was added 1-[2-(2-
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iodoethoxy)ethoxy]-2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]ethane (198 mg, .000395 mol) and
Cs2CO3 (52 mg, .000158 mol). The reaction mixture was allowed to stir at room temperature for
3 hours. Upon completion the DMF was removed by rotary evaporation and the residue partitioned
between EtOAc and water. The organic layer was washed 3x with water, 1x with brine, and dried
over anhydrous Na2SO4. The solvent was removed and the product was purified by prep-TLC to
yield 9b-5peg (22mg, 74%) as a oil.
1

H NMR (400 MHz, Chloroform-d) δ 7.42 (t, J = 8.2 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.02 (d, J

= 8.4 Hz, 1H), 6.93 – 6.83 (m, 2H), 6.78 (dd, J = 8.1, 2.5 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 5.12
(s, 2H), 4.11 (t, J = 4.9 Hz, 2H), 3.97 (d, J = 6.1 Hz, 2H), 3.84 (t, J = 4.9 Hz, 2H), 3.72 (dd, J =
8.5, 5.7 Hz, 3H), 3.68 – 3.55 (m, 12H), 3.46 (s, 1H), 3.23 (t, J = 6.9 Hz, 2H), 2.98 – 2.88 (m, 2H),
2.01 (td, J = 11.6, 2.4 Hz, 2H), 1.89 (h, J = 5.0, 4.5 Hz, 1H), 1.78 (d, J = 12.9 Hz, 2H), 1.47 (qd,
J = 11.4, 10.7, 3.8 Hz, 2H).
13

C NMR (101 MHz, Chloroform-d) δ 162.68, 159.40, 158.79, 156.87, 139.76, 133.60, 129.11,

121.65, 116.81, 115.36, 113.07, 103.02, 101.89, 73.85, 71.94, 70.79, 70.63, 70.59, 70.55, 70.18,
69.75, 67.29, 63.15, 53.06, 35.67, 29.23, 2.92.
HRMS [C33H49IN5O7+] Cal: 754.2677; Obs: 754.2650
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(2S,4R)-N-(2-((17-(3-((4-(((2,4-diaminoquinazolin-5-yl)oxy)methyl)piperidin-1yl)methyl)phenoxy)-3,6,9,12,15-pentaoxaheptadecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide

(JCS-

3971):

To

a

stirred

solution

of

5-[[1-[[3-[2-[2-[2-[2-[2-(2

iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]methyl]-4piperidyl]methoxy]quinazoline-2,4-diamine (11mg, .0000146 mol) in DMF (1mL) was added
(2S,4R)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]-1-[(2S)-3-methyl-2(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2-carboxamide (8.8 mg, .0000161 mol) and Cs2CO3
(19 mg, .0000584 mol). The reaction was allowed to stir overnight at room temperature, then the
DMF was removed by rotary evaporation and the residue was purified by prep-HPLC to provide
JCS-3971 (8.0 mg, 47%).
1

H NMR (400 MHz, Methanol-d4) δ 8.84 (s, 1H), 8.53 (s, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.55 (q, J

= 7.4 Hz, 3H), 7.46 (t, J = 7.3 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.19 (q, J = 7.4, 6.9 Hz, 1H), 7.00
(d, J = 6.7 Hz, 2H), 6.94 – 6.79 (m, 5H), 4.64 – 4.36 (m, 6H), 4.18 (q, J = 4.3 Hz, 2H), 4.08 (dd, J
= 5.6, 3.6 Hz, 4H), 3.96 (d, J = 11.0 Hz, 1H), 3.89 – 3.82 (m, 3H), 3.82 – 3.76 (m, 2H), 3.69 (dd,
J = 5.7, 3.2 Hz, 2H), 3.67 – 3.51 (m, 15H), 3.28 (s, 15H), 2.98 (d, J = 11.3 Hz, 2H), 2.46 (s, 3H),
2.46 – 2.36 (m, 1H), 2.23 – 1.90 (m, 5H), 1.82 (d, J = 13.1 Hz, 2H), 1.46 (qd, J = 12.4, 3.8 Hz,
2H), 1.03 (d, J = 6.5 Hz, 3H), 0.80 (d, J = 6.6 Hz, 3H).
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13

C NMR (101 MHz, Methanol-d4) δ 172.67, 169.48, 169.18, 163.01, 158.96, 157.35, 156.67,

151.43, 147.72, 142.37, 137.95, 135.12, 132.02, 131.78, 131.54, 131.06, 128.99, 128.66, 127.75,
126.88, 122.97, 121.90, 121.38, 115.64, 113.29, 112.33, 105.20, 100.38, 73.78, 70.37, 70.32,
70.13, 70.11, 70.08, 69.41, 67.95, 67.12, 62.50, 59.23, 58.66, 55.71, 52.56, 38.07, 37.70, 34.93,
28.73, 28.04, 18.26, 17.58, 14.55.
HRMS [C62H80N9O12S+] Cal: 1174.5647; Obs: 1174.5622
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Synthesis of JCS-3979 (Epimeric PROTAC control)

To

a

stirred

solution

of

5-[[1-[[3-[2-[2-[2-[2-[2-(2

iodoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]methyl]-4piperidyl]methoxy]quinazoline-2,4-diamine (18mg, .0000239 mol) in DMF (1mL) was added
(2S,4S)-4-hydroxy-N-[[2-hydroxy-4-(4-methylthiazol-5-yl)phenyl]methyl]-1-[(2S)-3-methyl-2(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2-carboxamide (14.4 mg, .0000263 mol) and Cs2CO3
(31 mg, .0000955 mol). The reaction was allowed to stir overnight at room temperature, then the

67

DMF was removed by rotary evaporation and the residue was purified by prep-HPLC to provide
JCS-3979 (16.2 mg, 58%).
1

H NMR (600 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.37 (t, J = 5.9 Hz, 1H), 8.21 (s, 1H), 7.68 (d, J =

7.6 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.46 (dh, J = 9.9, 4.4 Hz, 1H), 7.43 – 7.28 (m, 3H), 7.17 (t, J =
8.0 Hz, 1H), 7.05 – 6.96 (m, 2H), 6.85 – 6.74 (m, 4H), 6.61 – 6.47 (m, 3H), 4.70 (d, J = 10.8 Hz,
1H), 4.57 – 4.35 (m, 3H), 4.35 – 4.23 (m, 3H), 4.23 – 4.14 (m, 3H), 4.07 – 3.98 (m, 4H), 3.98 –
3.90 (m, 2H), 3.72 (dt, J = 40.0, 4.6 Hz, 5H), 3.61 – 3.36 (m, 23H), 2.81 (d, J = 10.5 Hz, 3H), 2.44
(s, 9H), 2.35 – 2.26 (m, 2H), 1.96 – 1.92 (m, 2H), 1.85 (d, J = 13.9 Hz, 1H), 1.71 (dd, J = 12.6, 8.0
Hz, 3H), 1.32 (td, J = 12.2, 3.7 Hz, 2H), 0.94 (d, J = 6.5 Hz, 3H), 0.73 (d, J = 6.6 Hz, 3H).
13

C NMR (151 MHz, DMSO-d6) δ 172.54, 168.71, 168.02, 164.82, 162.43, 159.83, 158.86,

157.15, 156.33, 151.90, 148.37, 142.68, 140.51, 133.70, 132.05, 131.75, 131.67, 131.50, 129.58,
128.35, 128.23, 127.40, 124.05, 123.43, 121.49, 121.47, 115.56, 115.22, 113.15, 112.61, 103.09,
101.30, 73.75, 70.50, 70.36, 70.26, 70.24, 70.22, 70.20, 69.40, 69.31, 68.34, 67.39, 62.66, 59.17,
58.14, 55.45, 53.05, 47.18, 37.74, 37.59, 35.42, 29.09, 28.65, 19.29, 19.10, 16.45.
HRMS [C62H80N9O12S+] Cal: 1174.5647; Obs: 1174.5630
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Biological Methods
DcpS Degradation and PROTAC Mechanisms Assays: MOLM-14 cells were plated in 12 well
plates at a density of 1M/well and treated with PROTAC (with or without additional control) for
the indicated time and conditions. The cells were spun down 1min x 2500g and the PROTAC
containing media was removed. The cells washed with sterile cold PBS and spun down again. The
cells were then lysed using a RIPA buffer with added commercial protease and phosphatase
inhibitor cocktail (Roche). The lysates were analyzed for protein content by BCA and an equal
amount of each condition was loaded on SDS-PAGE gel. After electrophoresis the gel was
transferred to PVDF membrane at 76V for 2 hours at 4oC. The transferred blots were blocked with
5% OmniBlock in TBST for 1 hour at r.t., then probed with DcpS antibody (sc-393226) overnight
at 4oC.
CETSA for DcpS:
-

Use 10 million cells per PCR tube

-

2 µL of 25x stock of compound into 48 µL of lysate

Protocol:
1. Thaw two tubes of flash frozen MOLM-13 cells
2. Flash freeze in liquid N2 and thaw twice more (3 freeze thaws total) to lyse cells
3. Clear lysate at max speed in a cold centrifuge for 10 mins
4. Split lysate into PCR tubes (96 µL for a pair of tubes)
5. Treat lysate with compounds or DMSO and then split into 50 µL in each tube
a. Flick tubes to mix and then spin down in microfuge
b. Incubate for 30 min at room temperature
6. Pre-heat thermocycler to 68 C
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7. Incubate lysates for 3 min
8. Spin down tubes with microfuge
9. Let cool for 3 mins
10. Transfer to 1.5 mL Eppendorf tubes
11. Spin at max speed for 10 min at 4C
12. Mix 33 µL lysate with 11 µL 4x loading dye (10% BME)
13. Boil for 5 mins
14. Run 12 µL of each sample on a 6-18% gradient midi gel, transfer and blot as a normal western
MTS Assay:
Seeded 10,000 MOLM-14 into 96 well plate
Treat same day with 10, 25, 100, 250, 103, 104, 254 nM JCS3971 or JCS3979 in triplicate
•

75 µL of cells seeded

•

75 µL of 2x compound was added to the cells

After ~72 or ~120 hours 25 µL of MTS:PMS (19:1) was added
•

2 mL for two plates; so 1900 µL of MTS + 100 µL of PMS

Absorbance at 492 read on Envision plate reader after 1 minute of shaking
Cell Counting:
Same procedure as MTS but instead of adding MTS:PMS and reading absorbance cells were
counted by hand using a hemocytometer at the appropriate time points.
RNA TimeLapse-Seq:
The protocol was carried out by Andreas Urbana-Pintado at the Simon Lab (Yale West Campus)
according to their published procedure (reference 14). MOLM-14 cells were treated with
PROTAC, inhibitor, or epimer in duplicate for 6 or 24 hours with 500 µMs4U for the last 2 hours,
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and a single replicate control per cell line was not treated with s4U. Total RNA was isolated from
cell pellets using TRIzol reagent, followed by phenol/chloroform extraction and isopropanol
precipitation supplemented with 50 µM DTT. After being washed twice with 75% EtOH, the RNA
pellet was dried and resuspended in nuclease-free water and treated with Turbo DNase to remove
genomic DNA. RNA was isolated using RNAClean beads and then treated with TimeLapse
chemistry (2,2,2-trifluoroethylamine and sodium periodate) and purified as described by Schofield
et al.40 Purified recoded RNA was then sequenced using mammalian pico-input SMARTer
stranded Total RNA-seq kit version 2 (Takara Bio). Paired-end 100- or 150-nucleotide RNA
sequencing was performed using an Illumina Hiseq-4000 or Novaseq instrument.
qPCR:
Preparation of cDNA:
RNA was harvested from MOLM-14 cells treated for 6 hours with PROTAC, inhibitor, or epimer
following the TRIzol extraction protocol (Invitrogen). The RNA was quantified by nanodrop and
1 µg was suspended in 9 µL DEPC water. 3 µL of MasterMix 1 (10mM dNTPs, primers, and
DEPC water 8:1.6:14.4 µL) was then added to the 1 µg RNA and incubated for 5 minutes at 65oC.
The samples were spun down briefly and then 8 µL of MasterMix 2 (5X FS strand, 0.1M DTT,
M-MLV, and 1:7 dilution of RNAsin at ratio 32:16:8:8 µL) was then added to the samples and
then were spun down again to consolidate the solution. These samples were then cycled at 25oC
for 10 min, 42 oC for 45 min, and 72 oC for 15 minutes. At this stage the prepared CDNA can be
frozen at -20 oC or used directly for the qPCR.
qPCR experiment:
qPCR was carried out using the iTag SYBR green kit. 2 µL cDNA was added to clear bottom 96
well plate per condition. Plate is kept elevated at room temperature off bench surface to avoid
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contamination. Add 23 µL of the SYBR mix (9.5:0.5:0.5:12.5 ddWater:Primer1:Primer2:SYBR)
to each well, cover with adhesive film, briefly spin down, and pop any bubbles with a needle. Seal
the plate with adhesive film fully, then run qPCR (95 oC for 10 min, 95 oC for 15 seconds, 58 oC
for 30 seconds, and 72 oC for 20 seconds. Run 40-60 cycles for data analysis.
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Chapter 3: The Development of HER3 PROTACs
The work in section 3.2.1 was carried out by Shanique Alabi before my tenure in the lab
The work in Section 3.3. was carried out with assistance from Elle Anne and Sisi Zheng
3.1 HER3 Background and Disease Relevance
HER3 is a receptor tyrosine kinase implicated in various cancers.1 Unlike EGFR, HER2 and
HER4, HER3 does not have enzymatic kinase activity so it is referred to as a “pseudokinase”- a
kinase-like protein that influences signalling activity without possessing enzymatic activity of its
own. Upon activation by heregulin growth factors,2 HER3 functions as a scaffolding protein that
helps activate EGFR or HER2 to turn on downstream signaling pathways.3 Pseudokinases have
recently been understood as drivers of disease pathogenesis, and novel efforts to target them with
inhibitors and degraders have been reviewed.4,5 As of the writing of this thesis there are no
approved therapies targeting HER3.3,6 Our efforts to target HER3 have been ongoing and plagued
with difficultly – HER3 is easily destabilized by ligand binding and the amount of HER3 is
significantly influenced by cell density. Early efforts involved a collaboration between our lab and
the Gray lab at Harvard. We developed TX-85-1, a covalent ligand which binds HER3 and induces
its destabilization and degradation.6 The ligand alone was able to induce some degradation of
HER3, and adding an adamantane tag improved the degradatory efficiency through the
hydrophobic tagging mechanism. However, degradation was modest and required high
concentrations of TX-85-1 based compounds. Therefore both of our groups became interested in
improving on these hydrophobic degraders to target HER3 with PROTACs. Additional efforts
carried out by the Gray group at Harvard proved ultimately unsuccessful, as professor Gray shared
during a talk last summer that they had abandoned efforts towards targeting HER3. Current
industrial efforts to target this pseudokinase aim to inhibit its extracellular domain, which

76

decreases its ability to activate EGFR and HER2 but leaves the intracellular domain intact.7 Since
HER3 plays crucial scaffolding roles in cell signalling, degradation by a PROTAC may outperform
simple inhibition in a therapeutic context.
3.2 HER3-targeted PROTACs Design and Synthesis
3.2.1 Ligand Discovery by Screen of PKIS Library (Adapted from Shanique Alabi Thesis)
This work towards ligand discovery for HER3 was carried out by Shanique A before my tenure in
the lab, but is reproduced here to guide the story of the design of our successful HER3 PROTACs:
In collaboration with our lab, the Gray lab designed a covalent binding small molecule that
irreversibly binds HER3, TX1-85-1.6 Using TX1-85-1 attached to an adamantane group, they
successfully induce degradation of HER3 by a hydrophobic tagging mechanism. However, using
this method, the degradation observed was weak and occurred at micromolar concentration with
modest inhibition of pAKT levels. Thus, we hypothesized that a PROTAC mechanism of action
would enable more potent degradation and inhibition of downstream signaling. Using bosutinib,
as well as TX1-85-1 as a HER3 targeting warhead, previous Crews lab scientist have attempted to
degrade HER3 using a PROTAC mechanism of action with no success. These efforts included
generation of many VHL and CRBN recruiting PROTACs with a plethora of linker compositions.
Despite these past failures, we set to reinvestigate targeted HER3 degradation. To do this, we
decided to forgo known HER3 binding molecules in the literature and discover novel chemical
matter. To identify novel HER3 ligands, we turned to GlaxoSmithKline’s Published Kinase
Inhibitor Set (PKIS) of ATP mimetics. The PKIS contains over 800 disclosed small molecules and
was obtained by our lab for identifying novel drug/protein interactions. The PKIS molecules are
ATP mimetics, and HER3 binds ATP with high affinity, so we hypothesized we would discover
novel small molecule ligands in this set. Using the HER3 kinase domain purified by a previous
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graduate student, Daniel Bondeson, Shanique optimized a TR-FRET screen using Thermo Fisher’s
LanthaScreen technology. The LanthaScreen assay by Thermofisher utilizes a displaced
fluorescent tracer to estimate binding of small molecules (Figure 3.1A). The assay is optimized for
kinases and utilizes a set of undisclosed ATP mimetic-based tracers. As the assay is not optimized
for pseudokinases, Shanique first tested all 5 commercially available tracers to determine which
would be compatible with HER3. Conveniently through optimization she found that Tracer 178
binds HER3 (KD = 40.0 nM), and thus was amenable for screening purposes (Figure 3.1C).

Figure 3.1: Optimization of HER3 TR-FRET Assay (Shanique Alabi)
(A) Schematic of TR-FRET assay. In this displacement assay, a Europium bound antibody recognizes the HER3
kinase domain via a His tag. In the presence of a fluorescent ligand (Tracer 178), upon excitation of the
Europium antibody, there is a high degree of fluorescence resonance energy transfer (FRET) to the tracer
fluorophore (left). This energy transfer is lost in the presence of a competitive inhibitor (right). (B) Optimization
of Europium antibody using increasing concentrations of dasatinib. All 3 concentrations caused a dose
dependent decrease in signal; thus 2 nM was selected as the screen concentration. (n=2) (C) Determination of
Tracer 178 KD using increasing concentration of tracer with 2 nM Europium antibody (n=3) KD = 40.0 nM.

78

Shanique first optimized the assay to obtain a > 3-fold window and a Z’ factor of above 0.5 with
our positive control, dasatinib. She then performed the screen in duplicate as described at a final
concentration of 26.7 µM compound. Overall, she observed a signal window between >3-7 on all
plates. To analyze the screen results we calculated percent inhibition with respect to the control.
The mean inhibition of HER3 by all tested compounds was 14 % ± 31.01%; thus, we defined our
hits as 2 standard deviations above our mean. Overall, 46 compounds caused inhibition above our
cut off, with a hit rate of 5.1%. (Figure 3.2A). Furthermore, the screen was reproducible, giving
us confidence in our results (Figure 3.2B).

Figure 3.2: TR-FRET screen of PKIS for HER3 ligands (Shanique Alabi)
(A) Scatterplot showing aggregated summary of PKIS HER3 screen performed in duplicate. Inhibitors were
added to a final concentration of 26.6 µM. Percent inhibition is defined as a function of control. Overall, the
mean inhibition observed was 14%. The screen cut off was set to 2 standard deviations above the mean at 76%
inhibition. 46 compounds were selected as hits. (B) Scatterplot of technical replicates of screen on different
plates. Coefficient of determination (r2) of Plate B= 0.94, Plate C= 0.92 and Plate E=0.85.
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Shanique’s hits showed a modest variation in chemical structure, however, several compounds
contained very similar structures which we grouped by pharmacophores. Since they come from
the PKIS, the elucidated pharmacophores were previously developed for other uses.
Pharmacophore 1 compounds were originally developed as BRAFV600E inhibitors.8
Pharmacophore 2 compounds are disclosed as glycogen synthase kinase-3 (GSK) inhibitors.
Lastly, Pharmacophore 3 compounds have been shown to inhibit EGFR and SRC kinases (Figure
3.3).
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Figure 3.3: Structures of Pharmacophores identified in HER3 TR-FRET screen (Shanique Alabi):
(A) Pharmacophore 1 compounds contain an aryl sulfonamide headgroup, a thiazole core, and a fluorine ortho to
the sulfonamide nitrogen. They are disclosed BRAF V600E inhibitors. (B) Pharmacophore 2 compounds contain
a series of 6- aryl-pyrazolo[3,4-b]pyridines and were identified as glycogen synthase kinase-3 (GSK-3)
inhibitors. (C) Pharmacophore 3 compounds were developed as EGFR/SRC inhibitors.

To validate her hits, Shanique performed a 6-point dose response curve. We initially predicted
these inhibitors would have high micromolar IC50 values, and thus chose concentrations in that
range (83.3 – 0.034 µM). Surprisingly, our results showed that our small molecule hits were
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causing tracer displacement with IC50 values in the low micromolar range and some dose response
curves were incomplete and were thus repeated at lower concentrations to obtain more accurate
values. (Figure 3.4A). Of interest, we identified one small molecule from pharmacophore 1, I13,
which has an estimated IC50 of 0.015 µM, 10-fold lower than other Pharmacophore 1 inhibitors.
To identify small molecules that bind HER3 selectively, we performed a TR-FRET counter screen
with EGFR. Unsurprisingly, compounds from Pharmacophore 3 bound EGFR more selectively
than HER3, and thus were not pursued further. However, Pharmacophore 1 and 2 demonstrated
slight selectivity for HER3 over EGFR. We observed a ~28-fold selectivity for HER3 over EGFR
with I13 (Figure 3.4B).
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Figure 3.4: Determination of binding affinity and selectivity of TR-FRET HER3 hits (Shanique Alabi):
(A) IC50 values determined from 6-point dose response curves. Magenta= Pharmacophore1 compounds, blue =
pharmacophore 2 compounds, teal= pharmacophore 3 (B) Plot of HER3 IC50 values (from A) versus
EGFR IC50 values. EGFR IC50 values obtained from LanthaScreen TR-FRET assay detecting
phosphorylated peptide. Magenta= I13, blue = L14, teal= F22

Shanique, in collaboration with chemist Phil Cromm, went on to synthesize 10 PROTACs based
on I13, but the synthesis of these PROTACs proved very challenging. Using the route Phil
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developed he was unable to isolate 95%+ pure PROTACs with publishable characterization data.
Even with the impure (~80% by NMR) PROTACs he generated, some HER3 degradation was
observed. However, the HER3 project was tabled due to biological reproducibility issues
combined with the continued challenge of isolating pure PROTAC material. When I joined the lab
(after Phil and Shanique had departed) I used my synthetic expertise to revive this project by
improving the route to I13-based PROTACs to produce pure material and enable proper biological
testing towards publication.
3.2.2 Synthesis of PROTACs
I developed an improved synthetic route that enabled the synthesis of significant quantities of high
purity candidate HER3 PROTACs in good yields.
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Scheme 2: Improved HER3 PROTAC Synthetic Route

The strategy begins with the esterification of 3-amino-2-fluorobenzoic acid 1 with methanol in
sulfuric acid to generate methyl 3-amino-2-fluorobenzoate. This material is then condensed with
2,6-difluorobenzenesulfonyl chloride to furnish 2. In the next step LiHMDS mediates the
deprotonation of the benzyl carbon of 2-chloro-4-methylpyrmidine which then acts as a
nucleophile to displace the methyl ester of 2 to yield 3 as a mixture of keto-enol isomers. In this
step the order of addition, speed of addition, and temperature of addition is crucial to the outcome.
The best yields were achieved when 2 and LiHMDS were first mixed in THF at 0oC and then 2chloro-4-methylpyrimidine was rapidly added as a solution in THF, then allowed to warm to rt. 3
is then brominated by NBS before the addition and condensation of 2-methyl-propanethioamide
in situ to yield 4. The most challenging step of the synthesis is the attachment of linker 16 to 4.
The85reviouss strategy employed by Phil Cromm was a SNAr reaction in acid in the microwave at
200oC. This methodology never yielded more than 5% 5 and the isolation of pure material was
impossible by either HPLC or PTLC due to the numerous degradation products produced during
the high temperature reaction. Phil also attempted cross-coupling techniques to isolate 5
unsuccessfully. I screened >10 SNAr and cross-coupling conditions before I was able to isolate 5
in 40% clean yield by employing iPrOH and PTSA. In this reaction a transesterification of the tert85

butyl protected acid in 16 prevents its deprotection/self-immolation/degradation at the temperature
required to induce the SNAr reaction. By employing t-BuOH I had the option to keep the tert-butyl
protecting group intact, but solubility issues with the starting materials made iPrOH the better
choice for these substrates. Deprotection of 5 furnished acid 5b, prepared for coupling to CRBN
and VHL-ligand amines to generate the final PROTACs PC220 (6) and PC210 (6-VHL), which
were isolated in good yields, and clean characterization was finally obtained to enable proper
biological testing of these candidate PROTACs. Inactive control PROTACs 6-Me and 6-VHLinact were also synthesized successfully following this methodology.
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3.3 Biological Characterization of HER3 PROTACs in HER3 Driven Cancers
The biological data presented in this section was obtained in collaboration with Crews’ lab
biologists Elle Anne and Sisi Zheng
3.3.1 Pure PROTACs Appear to Mediate Degradation of HER3 in Relevant Cancer Lines
With the pure HER3 PROTACs in hand we moved on to try to validate their ability to degrade
HER3 in relevant cancer cell lines via a PROTAC mechanism. Before I optimized the synthesis,
the impure PROTACs generated by Phil had been tested by Shanique. These < 90% pure
PROTACs demonstrated degradation of HER3 but the signal was inconsistent between repeats
and the impact on downstream signalling was unclear. Importantly, no inactive control PROTACs
were ever generated in the initial campaign, so there was no confirmation that the degradation was
mediated by poly-ubiquitination and proteasomal degradation. I was concerned about the
possibility that engagement of HER3 is sufficient for degradation because in our study designing
TX-85-1 the ligand alone significantly destabilized HER3 leading to its degradation, even without
the hydrophobic adamantane tag appended. Therefore after completing the PROTAC synthesis I
moved on to quickly synthesize inactive epimeric controls of PC210 and PC220 that are crucial
for establishing that degradation is through a PROTAC mediated mechanism involving the
recruitment of an E3 ligase.
Initial testing was carried out on cell lines that were predicted to have significant HER3
dependency by analysis of the free online Cancer Dependency Map (DEPMAP) database. We first
observed potent and consistent HER3 degradation when testing our PROTACS in A431 cells
(Figure 3.5). A hook-effect was observed at high concentrations of PROTAC.
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Figure 3.5: PC220 and PC210 induce significant degradation of HER3 in A431 cells. Cells were treated with
PROTAC in serum free media for 24 hours before being lysed and harvested. Lysates were run on SDS-PAGE
4-15% acrylamide gels, transferred to PVDF membrane, and probed for HER3 (CST #4754s) and vinculin as a
loading control. Significance was determined by 2-way ANOVA * p < .05, ** p< .001

Encouraged by these result we moved on to interrogate other aspects of HER3 degradation in
A431s using our PROTACs. Neuregulin (NRG) and EGF are natural ligands of HER3 that
activate downstream signalling through AKT and ERK, so we were curious if PROTAC
treatment could significantly inhibit NRG/EGF-mediated activation of HER3 and downstream
kinases. To test this A431 cells were treated with PROTAC in serum free media for 24 hours
before being washed and stimulated with 50 ng/mL NRG or 100 ng/mL EGF before harvest.
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Figure 3.6: PC220 and PC210 significantly inhibit downstream activation of AKT, but not ERK. Cells were
treated with PROTAC in serum free media for 24 hours before being washed, stimulated for the appropriate time
and then lysed and harvested. Lysates were run on SDS-PAGE 4-15% acrylamide gels, transferred to PVDF
membrane, and probed.

These results were interesting because HER3 degradation was very consistent, and the amount of
phosphorylated (i.e. activated) HER3 was also highly diminished (Figure 3.6) However, similar to
the TX-85-1 mediated degradation, the impact on downstream signalling was less significant. We
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were encouraged that pAKT levels were downregulated, but unfortunately only by about 30%. On
the other hand when treating with NRG pERK levels were actually increased by PROTAC pretreatment, which we attribute to paradoxical activation of BRAF by the ligand, discussed in more
detail in the next section. With these results in hand we were still optimistic, although somewhat
discouraged by the limited impact on downstream signalling.
We moved on to determine the time-sensitivity of PROTAC-mediated depletion of HER3 in A431
cells (Figure 3.7).

Figure 3.7: PC220 and PC210 quickly engage and degrade HER3. Cells were treated with PROTAC in serum
free media for the indicated time before being washed, lysed and harvested. Lysates were run on SDS-PAGE 415% acrylamide gels, transferred to PVDF membrane, and probed.

These results were intriguing because HER3 levels were clearly different between the different
DMSO timepoints, which confirms previous work that demonstrated HER3 production in the cell
is regulated by cell density. This is a confounding variable that can significantly influence the
outcome of our experiments and especially the impact on downstream signalling. However,
assuming equal plating of the cells, the PROTACs were observed to induce degradation of HER3
compared to DMSO at all time points from 2-24 hours. Interestingly, PC220 was observed to more
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potently upregulate pERK via BRAF activation than PC210. There was little to no impact on
pAKT levels. We also confirmed that EGFR is not degraded by the PROTAC in this experiment,
confirming that the PROTAC has greater specificity than the ligand alone, which only exhibited
around 30x selectivity for HER3 over EGFR.
We also demonstrated HER3 degradation in several other relevant cell lines including metastatic
breast cancer line MD-MBA-453 and melanoma MeWo cells (Figure 3.8).

Figure 3.8: PC220 and PC210 induce HER3 degradation in other relevant cancer lines. Cells were treated with
PROTAC in serum free media for the indicated time before being washed, lysed and harvested. Lysates were run
on SDS-PAGE 4-15% acrylamide gels, transferred to PVDF membrane, and probed. Significance analyzed by
one-way ANOVA: ** p = .0044, **** p < .0001

3.3.2 Issues with HER3 PROTACs: Epimer Activity and Paradoxical BRAF Activation
While these initial datasets were encouraging, we needed to demonstrate that HER3 degradation
by the PROTACs was via a bonafide PROTAC mechanism, and we needed to further interrogate
downstream signalling. As described above, the I13 ligand was originally developed as a
BRAFV600E ligand. An ongoing issue during the studies of PC220 and PC210 is their inability
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to inhibit downstream signalling, in fact they activate downstream ERK. This is due to paradoxical
activation of BRAF kinase by the ligand, which was demonstrated to occur during the initial
development of the ligand.8 Therefore, our PROTACs antiproliferative efficacy in vitro is highly
limited and we do not fully understand all of the off-target effects that may be occuring.
Furthermore, due to the concern that engagement of HER3 is sufficient for degradation I moved
on to quickly synthesize inactive controls of PC210 and PC220 that are crucial for establishing
that degradation is through a PROTAC mediated mechanism involving the recruitment of an E3
ligase. Unfortunately, these control compounds demonstrated significant degradation of HER3,
indicating that the PROTAC mechanism is not at play (Figure 3.9).

Figure 3.8: Epimeric control PROTACs also mediate degradation of HER3, demonstrating that degradation is
likely via a destabilization mechanism rather than PROTAC induced poly-K mediated proteasomal degradation.
MD-MBA-453 cells were treated with PROTAC in serum free media for 20 hours before being washed, lysed
and harvested. Lysates were run on SDS-PAGE 4-15% acrylamide gels, transferred to PVDF membrane, and
probed.
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Unfortunately we observed that both control compounds PC210-Epimer, which cannot bind VHL,
and PC220-Nme, in which thalidomide is N-methylated and is no longer able to recruit CRBN,
are able to induce more significant degradation of HER3 than the active PROTAC PC210. This
suggests that the binding of the molecule to HER3 is causing degradation. In this case we would
expect the epimer to show more potent degradation because the active PROTAC can form
PROTAC:HER3 and PROTAC:VHL binary complexes while the epimer can form only
PROTAC:HER3 complexes. These results (validated by multiple repeats in multiple cell lines)
confirm our fears that engagement of HER3 alone is sufficient for degradation, as was observed
in the development of the TX-85-1 hydrophobic degraders. Therefore, we had no choice but to
suspend our extensive efforts towards development of HER3 PROTACs. If anything has been
gained from this project, we have developed a strong understanding of the factors that influence
HER3 levels and downstream signalling in the cell. As of the writing of this thesis we have not
determined a way to move this story any further towards publication. A future Crews’ lab scientist
may consider reviving this project by exploring pharmacophore 2 that was identified by Shanique’s
screen. It has good selectivity for HER3 over EGFR and it has the potential to build out additional
binding interactions by combining SAR and computational analysis.
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3.4 Synthetic Schemes and Characterization and Biological Methods
A. General considerations. Chemicals used for synthesis were purchased from commercial
sources and were used without further purification. Flash chromatography was performed using
Biotage flash chromatography system using pre-packed silica gel columns. 1H NMR and 13C NMR
spectra were recorded on an Agilent DD2 600 NMR spectrometer (600 MHz for 1H and 151 MHz
for 13C). The values of chemical shifts (δ) are reported in p.p.m. Coupling constants (J) are reported
in Hz. High-resolution mass spectra (HRMS) were recorded on Shimadzu HRMS with ESI using
a Shimadzu UPLC. HPLC purifications were performed on a reverse-phase column using a
Shimadzu HPLC system.
B. Experimental Protocols
Synthesis of Active PROTACs (6-CRBN and 6-VHL) and Inactive Control PROTACs (6CRBN-Inact and 6-VHL-Inact):

methyl 3-((2,6-difluorophenyl)sulfonamido)-2-fluorobenzoate (2):
A solution of 3-amino-2-fluorobenzoic acid (1.0 g, 6.45 mmol) in Methanol (30 mL) was cooled
to 0oC. To the cooled solution was added SOCl2 (1.41 mL, 19.34 mmol) and the reaction mixture
was brought to reflux for 24 hours. The solvent was evaporated and neutralized by addition of
saturated NaHCO3. The solution was extracted twice with EtOAc, and the organic layers were
combined and dried over Na2SO4. The product was then purified by flash chromatography using a
gradient of 10-100% EtOAc in Hexanes, to provide 991 mg of methyl 3-amino-2-fluorobenzoate
(5.86 mmol, 91% yield. 1H NMR (400 MHz, Chloroform-d) δ 7.55 – 7.49 (m, 1H), 7.22 (td, J =
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7.8, 7.4, 4.9 Hz, 2H), 4.19 (s, 3H). Intermediate Ester HRMS [C8H9FNO2+] Cal: 170.0617; Obs:
170. 0582
To a solution of the intermediate product methyl 3-amino-2-fluorobenzoate (200 mg, 1.32 mmol)
were added pyridine (0.21 mL, 2.65 mmol) and 2,6-difluorobenzenesulfonyl chloride (0.22 mL,
1.59 mmol) at room temperature. The mixture was stirred for 16 hours at and then the solvent was
removed. The residue was partitioned between water (acidified with a few drops of HCl) and
EtOAc. The aqueous layer was further extracted twice with EtOAc. The combined organic
fractions were dried over Na2SO4 and evaporated. The product was used in the next step without
further purification (quantitative yield). 1H NMR (400 MHz, Chloroform-d) δ 7.85 (ddd, J = 8.5,
7.2, 1.7 Hz, 1H), 7.68 (ddd, J = 8.2, 6.8, 1.8 Hz, 1H), 7.56 – 7.47 (m, 1H), 7.31 (s, 1H), 7.17 (td, J
= 8.0, 1.3 Hz, 1H), 7.03 – 6.96 (m, 2H), 3.90 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 164.04,
161.16, 158.61, 154.17, 151.60, 135.60 (t, J = 11.2 Hz), 128.44, 126.62, 125.30 (d, J = 12.5 Hz),
124.61 (d, J = 5.0 Hz), 119.34, 113.48 (d, J = 3.6 Hz), 113.25 (d, J = 3.7 Hz), 52.71. HRMS
[C14H11F3NO4S+] Cal: 346.0361; Obs: 346.0400

N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide (3):
A flask charged with methyl 3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-benzoate (500 mg,
1.45 mmol) in dry THF (10 mL) was cooled to 0oC. LiHMDS (6.52 mL, 1.0 M sol. In THF, 6.52
mmol) was added to the solution dropwise. Then, a solution of 2-chloro-4-methylpyrimidine (242
mg, 1.88 mmol) in dry THF (10 mL) was added quickly via syringe. The flask was removed from
the ice bath and allowed to warm to r.t. and stirring was continued for 3 hours. The THF was
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removed in vacuo and the residue neutralized with addition of 6N HCl (10mL). EtOAc was added
and the layers separated. The aqueous layer was further extracted two times with EtOAc (20mL x
2) and the combined organic layers were washed once with brine and dried over Na2SO4. The
product was purified by flash chromatography using a gradient of 0-40% EtOAc in Hexanes to
furnish

N-[3-[2-(2-chloropyrimidin-4-yl)acetyl]-2-fluoro-phenyl]-2,6-difluoro-

benzenesulfonamide (399 mg, 63%) as a mixture of keto and enol isomers which are used in the
next step to generate a single isomeric product. 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 5.0
Hz, 1H), 8.63 (d, J = 5.4 Hz, 1H), 7.74 (qd, J = 8.4, 5.9 Hz, 3H), 7.67 – 7.62 (m, 1H), 7.58
(d,J=7.2Hz,1H), 7.55 (d,J=5.1Hz,1H), 7.49 (d,J=5.4Hz,1H), 7.43 (td,J=7.7,1.8Hz,1H) ,7.30
(qd,J=9.2,8.0, 3.9 Hz, 6H), 6.13 (s, 1H), 4.49 (d, J = 1.9 Hz, 2H). 13C NMR (101 MHz DMSO-d6)
δ 166.23, 160.12, 159.95, 159.81, 157.39, 136.03, 131.62, 129.19, 128.02, 127.02, 124.78, 121.57,
50 117.30, 113.54, 113.32, 99.17, 50.06. HRMS [C18H11ClF3N3O3S+] Cal: 442.0240; Obs:
442.0278

N-(3-(5-(2-chloropyrimidin-4-yl)-2-isopropylthiazol-4-yl)-2-fluorophenyl)-2,6difluorobenzenesulfonamide (4):
To

a

solution

of

N-{3-[(2-chloro-4-pyrimidinyl)acetyl]-2-fluorophenyl}-2,6-

difluorobenzenesulfonamide (0.20 g, .453 mmol) in 5 mL DMF, 1.0 eq. NBS (0.0806 g, .453
mmol) was added and the solution was allowed to stir 15 min at rt. 2,2-dimethylpropanethioamide
(0.0531 g, .453 mmol) was then added at rt. The reaction was heated to 60 ºC for 3 hours. The
reaction mixture was diluted with water and extracted x 2 with EtOAc. The combined EtOAc
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washings were washed with water x 3 to remove DMA, dried over MgSO4, filtered and
concentrated onto silica gel. The crude material was chromatographed in 10-80% EtOAc in
Hexanes

to

provide

N-[3-[2-(2-chloropyrimidin-4-yl)acetyl]-2-fluoro-phenyl]-2,6-difluoro-

benzenesulfonamide, 160 mg (64%). 1H NMR (400 MHz, Chloroform-d) δ 8.31 (d, J = 5.3 Hz,
1H), 7.63 (td, J = 7.8, 1.8 Hz, 1H), 7.39 – 7.17 (m, 4H), 6.99 (tt, J = 8.4, 2.4 Hz, 1H), 6.73 (dd, J
= 5.3, 1.0 Hz, 1H), 3.35 (hept, J = 6.9 Hz, 1H), 1.43 (d, J = 6.9 Hz, 6H). 13C NMR (101 MHz,
Chloroform-d) δ 181.95, 164.02, 163.90, 161.48, 161.36, 161.32, 160.48, 159.47, 152.46, 149.99,
147.28, 142.24, 142.16, 132.06, 128.28, 128.26, 125.43, 125.39, 124.86, 124.73, 124.52, 123.41,
123.27, 114.72, 110.92, 110.83, 110.72, 110.63, 109.32, 109.07, 108.83, 33.74, 22.97. HRMS
[C22H17ClF3N4O2S2+] Cal: 525.0434; Obs: 525.0482

Isopropyl-3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2isopropylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)propanoate (5):
To a bomb flask were added N-(3-(5-(2-chloropyrimidin-4-yl)-2-isopropylthiazol-4-yl)-2fluorophenyl)-2,6-difluorobenzenesulfonamide (35.0 mg, .0667 mmol), tert-butyl 3-(3-((5aminopyridin-2-yl)amino)propoxy)propanoate (39.4 mg, 0.133 mmol), iPrOH (5 mL) and PTSA
(15.2 mg, .080 mmol). The bomb flask was sealed and heated to 100oC for 24 hours. The solution
was then concentrated and purified directly by HPLC to furnish
isopropyl

3-[3-[[5-[[4-[4-[3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-phenyl]-2-isopropyl-

thiazol-5-yl]pyrimidin-2-yl]amino]-2-pyridyl]amino]propoxy]propanoate (18 mg, 35%).
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1

H NMR (600 MHz, DMSO-d6) δ 10.91 (s, 1H), 9.35 – 9.13 (m, 1H), 8.27 – 8.06 (m, 2H), 7.71 –

7.51 (m, 2H), 7.50 – 7.38 (m, 3H), 7.38 – 7.30 (m, 1H), 7.30 – 7.15 (m, 3H), 7.08 (t, J = 7.3 Hz,
2H), 6.60 – 6.47 (m, 2H), 6.40 (t, J = 7.7 Hz, 1H), 6.25 (d, J = 24.8 Hz, 1H), 5.99 (t, J = 6.1 Hz,
1H), 4.94 – 4.81 (m, 1H), 3.57 (q, J = 8.4, 6.3 Hz, 3H), 3.44 (dd, J = 11.4, 6.1 Hz, 2H), 3.20 (p, J
= 6.5 Hz, 2H), 2.32 – 2.22 (m, 3H), 1.71 (h, J = 6.4 Hz, 2H), 1.40 – 1.31 (m, 6H), 1.15 (dt, J =
11.9, 4.9 Hz, 6H).

13

C NMR (151 MHz, DMSO-d6) δ 178.87, 171.14, 163.49, 160.65, 159.99,

158.28, 155.46, 154.12, 152.45, 146.20, 138.01, 138.01, 134.54, 128.48, 126.35, 125.93, 125.38,
125.35, 113.85, 113.69, 107.61, 106.77, 68.64, 67.55, 66.23, 38.79, 35.43, 33.17, 29.62, 29.62,
23.03, 22.03, 21.98, 21.21. HRMS [C36H39F3N7O5S2+] Cal: 770.2406; Obs: 770.2435

98

3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2-isopropylthiazol-5yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)propanoic acid (5B):
The isopropyl ester (8mg) was dissolved in THF (1mL) and 1M LiOH in H2O (0.5mL) was added.
The solution was stirred at r.t. for 24 hours until the reaction was complete by LCMS. The THF
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was blown down and the remaining aqueous solution was frozen and lyophilized to furnish the
product which was used in the subsequent amide coupling without further purification.
HRMS [C33H33F3N7O5S2+] Cal: 728.1937; Obs: 728.1940

3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2-isopropylthiazol-5yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3dioxoisoindolin-4-yl)oxy)ethyl)propenamide (6-CRBN):
To a solution of 3-[3-[[5-[[4-[4-[3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-phenyl]-2isopropyl-thiazol-5-yl]pyrimidin-2-yl]amino]-2-pyridyl]amino]propoxy]propanoic acid (7 mg,
.000962 mmol) in DMF (2mL) was added DIEA (.0165mL, .00962 mmol), 4-(2-aminoethoxy)-2(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (3.4 mg, .00106 mmol), and finally O-(7Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.2 mg, .00135
mmol). The solution was stirred at r.t. for 1 hour then concentrated in vacuo and purified directly
by HPLC to yield 6-CRBN (5.6 mg, 57%).
1

H NMR (800 MHz, Methanol-d4) δ 8.40 (s, 1H), 8.17 (d, J = 2.6 Hz, 1H), 8.08 (d, J = 5.2 Hz,

1H), 7.65 (t, J = 7.9 Hz, 1H), 7.57 (tdt, J = 11.4, 8.4, 3.7 Hz, 3H), 7.33 (d, J = 7.6 Hz, 3H), 7.27 (t,
J = 7.9 Hz, 1H), 7.05 (t, J = 9.1 Hz, 2H), 6.50 (d, J = 9.0 Hz, 1H), 6.19 (d, J = 5.2 Hz, 1H), 5.08
(dd, J = 12.7, 5.5 Hz, 1H), 4.24 (t, J = 5.3 Hz, 2H), 3.72 (t, J = 5.9 Hz, 2H), 3.68 – 3.59 (m, 2H),
3.55 (t, J = 5.8 Hz, 2H), 3.35 – 3.31 (m, 2H), 3.26 (t, J = 6.8 Hz, 2H), 2.83 (ddd, J = 17.3, 13.8,
5.4 Hz, 1H), 2.74 – 2.63 (m, 2H), 2.49 (t, J = 5.9 Hz, 2H), 2.08 (dtd, J = 13.2, 5.4, 2.3 Hz, 1H),
1.79

(p,

J

=

6.3

Hz,

2H),

1.42

100

(d,

J

=

6.9

Hz,

7H).

13

C NMR (201 MHz, Methanol-d4) δ 180.19, 173.15, 173.13, 170.14, 166.97, 166.41, 160.19,

160.15, 158.92, 158.90, 158.42, 157.91, 156.06, 154.28, 153.28, 152.03, 145.94, 136.64, 135.28,
135.22, 135.17, 134.27, 133.50, 128.30, 126.56, 126.15, 124.99, 124.92, 124.57, 124.55, 123.92,
123.85, 119.31, 117.46, 116.81, 115.54, 112.79, 112.77, 112.67, 112.66, 108.45, 107.14, 68.50,
67.96, 66.49, 49.05, 48.07, 47.96, 47.89, 47.86, 47.79, 47.75, 47.68, 47.66, 47.57, 47.47, 47.36,
47.34, 47.25, 39.26, 38.36, 36.32, 33.29, 30.73, 28.85, 22.25, 21.92.
HRMS [C48H46F3N10O9S2+] Cal: 1027.2843; Obs: 1027.2833
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3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2-isopropylthiazol-5yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)-N-(2-((2-(1-methyl-2,6-dioxopiperidin-3yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)propenamide (6-CRBN-Inact):
To a solution of 3-[3-[[5-[[4-[4-[3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-phenyl]-2isopropyl-thiazol-5-yl]pyrimidin-2-yl]amino]-2-pyridyl]amino]propoxy]propanoic acid (9.5 mg,
.00131 mmol) in DMF (2mL) was added DIEA (.0165mL, .00962 mmol), 4-(2-aminoethoxy)-2-
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(1-methyl-2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (6.5 mg, .00196 mmol), and finally O-(7Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (6.95 mg, .00183
mmol). The solution was stirred at r.t. for 1 hour then concentrated in vacuo and purified directly
by HPLC to yield 6-CRBN-Inact (11.5 mg, 85%).
1

H NMR (800 MHz, Methanol-d4) δ 8.40 (s, 1H), 8.17 (d, J = 2.6 Hz, 1H), 8.07 (d, J = 5.3 Hz,

1H), 7.65 (dd, J = 8.5, 7.3 Hz, 1H), 7.60 – 7.53 (m, 3H), 7.35 – 7.31 (m, 3H), 7.27 (t, J = 7.9 Hz,
1H), 7.05 (t, J = 9.1 Hz, 2H), 6.50 (d, J = 9.0 Hz, 1H), 6.19 (d, J = 5.2 Hz, 1H), 5.10 (dd, J = 13.0,
5.5 Hz, 1H), 4.25 (t, J = 5.3 Hz, 2H), 3.71 (t, J = 5.9 Hz, 2H), 3.67 – 3.61 (m, 2H), 3.55 (t, J = 5.8
Hz, 2H), 3.34 – 3.31 (m, 2H), 3.25 (d, J = 6.8 Hz, 2H), 3.12 (s, 3H), 2.89 – 2.80 (m, 2H), 2.64 (qd,
J = 12.9, 5.6 Hz, 1H), 2.49 (t, J = 5.8 Hz, 2H), 2.08 – 2.02 (m, 1H), 1.79 (p, J = 6.4 Hz, 2H), 1.42
(d,
13

J

=

6.9

Hz,

7H).

C NMR (201 MHz, Methanol-d4) δ 180.16, 173.12, 172.13, 169.86, 166.98, 166.41, 160.20,

160.18, 158.92, 158.90, 158.42, 157.89, 156.08, 154.38, 153.28, 152.03, 145.92, 136.66, 135.27,
135.21, 135.16, 134.29, 133.50, 132.62, 128.29, 126.56, 126.14, 125.00, 124.93, 124.57, 124.54,
123.92, 123.85, 119.32, 117.46, 116.79, 115.54, 112.79, 112.77, 112.67, 112.65, 108.36, 107.12,
68.52, 67.97, 66.50, 49.69, 48.07, 47.97, 47.89, 47.86, 47.79, 47.75, 47.68, 47.65, 47.57, 47.47,
47.36, 47.26, 39.26, 38.36, 36.32, 33.28, 31.02, 28.88, 25.95, 21.92, 21.49.
HRMS [C49H48F3N10O9S2+] Cal: 1041.2999; Obs: 1041.2992
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(3S,4R)-1-((S)-2-(3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2isopropylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)propanamido)-3,3dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-3-carboxamide
(6-VHL):
To a solution of 3-[3-[[5-[[4-[4-[3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-phenyl]-2isopropyl-thiazol-5-yl]pyrimidin-2-yl]amino]-2-pyridyl]amino]propoxy]propanoic acid (14.7 mg,
.00202 mmol) in DMF (2mL) was added DIEA (.0346mL, .02 mmol), (2S,4R)-1-[(2S)-2-amino3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2carboxamide;hydrochloride (10.4 mg, .00222 mmol), and finally O-(7-Azabenzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate (6.95 mg, .00183 mmol). The solution was
stirred at r.t. for 1 hour then concentrated in vacuo and purified directly by HPLC to yield 6-VHL
(14 mg, 61%).
1

H NMR (400 MHz, Methanol-d4) δ 8.80 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 8.04 (d, J = 5.2 Hz,

1H), 7.55 (dddd, J = 16.9, 14.4, 8.2, 4.3 Hz, 3H), 7.40 – 7.36 (m, 2H), 7.34 – 7.29 (m, 3H), 7.28 –
7.19 (m, 2H), 7.05 – 6.98 (m, 2H), 6.54 (d, J = 9.1 Hz, 1H), 6.15 (d, J = 5.2 Hz, 1H), 4.65 (s, 1H),
4.60 – 4.54 (m, 1H), 4.52 – 4.45 (m, 2H), 4.30 (d, J = 15.5 Hz, 1H), 3.88 (d, J = 11.0 Hz, 1H), 3.78
(dd, J = 11.0, 3.8 Hz, 1H), 3.74 – 3.64 (m, 2H), 3.62 – 3.51 (m, 2H), 3.35 (td, J = 6.6, 2.7 Hz, 2H),
2.58 – 2.46 (m, 2H), 2.40 (s, 3H), 2.35 (d, J = 9.1 Hz, 1H), 2.26 – 2.16 (m, 1H), 2.06 (ddd, J =
13.3, 9.2, 4.4 Hz, 1H), 1.87 (p, J = 6.4 Hz, 2H), 1.39 (d, J = 6.9 Hz, 7H), 1.02 (s, 10H).
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13

C NMR (151 MHz, Methanol-d4) δ 180.26, 180.16, 173.13, 173.01, 172.67, 172.55, 170.89,

170.80, 170.76, 160.41, 160.24, 158.70, 158.41, 157.96, 154.70, 153.49, 151.47, 151.38, 151.35,
147.64, 147.53, 146.03, 145.90, 138.83, 138.75, 138.70, 137.25, 135.20, 134.44, 134.34, 132.71,
131.95, 130.15, 130.03, 128.99, 128.90, 128.87, 128.48, 128.36, 128.26, 127.66, 127.57, 127.53,
126.51, 126.14, 125.53, 125.04, 124.95, 124.65, 124.56, 123.93, 117.50, 112.89, 112.77, 112.64,
108.25, 107.13, 107.03, 69.78, 69.69, 68.48, 68.38, 66.73, 66.63, 59.55, 59.45, 57.64, 57.54, 56.75,
56.64, 42.43, 42.33, 38.99, 38.90, 37.61, 37.52, 36.04, 35.92, 35.55, 35.47, 35.43, 33.38, 33.26,
29.05, 28.97, 28.93, 25.75, 25.71, 25.66, 25.63, 25.57, 22.05, 21.96, 21.93, 14.54, 14.42.
HRMS [C49H48F3N10O9S2+] Cal: 1140.3870; Obs: 1140.3869
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(3S,4S)-1-((S)-2-(3-(3-((5-((4-(4-(3-((2,6-difluorophenyl)sulfonamido)-2-fluorophenyl)-2isopropylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-2-yl)amino)propoxy)propanamido)-3,3dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-3-carboxamide
(6-VHL-Inact):
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To a solution of 3-[3-[[5-[[4-[4-[3-[(2,6-difluorophenyl)sulfonylamino]-2-fluoro-phenyl]-2isopropyl-thiazol-5-yl]pyrimidin-2-yl]amino]-2-pyridyl]amino]propoxy]propanoic acid (14.7 mg,
.00202 mmol) in DMF (2mL) was added DIEA (.0346mL, .02 mmol), (2S,4R)-1-[(2S)-2-amino3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2carboxamide;hydrochloride (10.4 mg, .00222 mmol), and finally O-(7-Azabenzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate (6.95 mg, .00183 mmol). The solution was
stirred at r.t. for 1 hour then concentrated in vacuo and purified directly by HPLC to yield 6-VHLInact (15.6 mg, 56%).
1

H NMR (400 MHz, Methanol-d4) δ 8.81 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 8.04 (d, J = 5.3 Hz,

1H), 7.62 – 7.47 (m, 3H), 7.42 – 7.28 (m, 5H), 7.24 (p, J = 8.8, 8.3 Hz, 2H), 7.07 – 6.97 (m, 2H),
6.54 (d, J = 9.1 Hz, 1H), 6.15 (d, J = 5.2 Hz, 1H), 4.54 (d, J = 16.0 Hz, 1H), 4.51 – 4.43 (m, 1H),
4.36 – 4.30 (m, 2H), 3.99 (dd, J = 10.6, 5.1 Hz, 1H), 3.72 – 3.65 (m, 3H), 3.56 (t, J = 5.9 Hz, 2H),
3.34 (t, J = 6.4 Hz, 3H), 2.52 (t, J = 5.8 Hz, 2H), 2.41 (s, 3H), 2.34 (s, 1H), 1.94 (dt, J = 13.4, 4.4
Hz, 1H), 1.85 (p, J = 6.3 Hz, 2H), 1.39 (d, J = 6.9 Hz, 6H), 1.01 (s, 9H).
13

C NMR (151 MHz, Methanol-d4) δ 180.13, 173.01, 172.54, 170.76, 160.41, 160.39, 160.24,

158.70, 158.67, 158.37, 157.92, 154.70, 153.47, 151.82, 151.35, 147.53, 145.90, 140.20, 138.71,
135.25, 135.18, 135.10, 134.32, 132.65, 131.95, 130.03, 129.04, 128.87, 128.36, 128.24, 127.95,
127.54, 126.51, 126.12, 125.54, 125.04, 124.95, 124.55, 124.52, 123.92, 123.83, 117.49, 112.79,
112.77, 112.64, 112.61, 108.22, 107.02, 69.66, 68.36, 66.61, 59.43, 57.52, 56.62, 42.31, 38.87,
37.50, 35.92, 35.43, 33.26, 28.93, 25.62, 25.57, 21.92, 19.88, 14.42.
HRMS [C55H61F3N11O7S3+] Cal: 1140.3870; Obs: 1140.3868
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Synthesis of CRBN ligands 8 and 10:

Scheme 3: Synthesis of CRBN ligands for HER3 PROTAC synthesis

t-butyl-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)carbamate (7):
To a solution of 2-(2,6-dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione (300 mg, 1.09
mmol) in DMF (3 mL) was added tert-butyl N-(2-bromoethyl)carbamate (294 mg, 1.31
mmol), KHCO3 (219 mg, 2.19 mmol) and KI (6.05 mg, 0.0365 mmol) at room temperature, the
reaction mixture was stirred at 60oC for 72 h. The reaction mixture was diluted with EtOAc (30
mL), washed with water (5x20 mL), dried (Na2SO4), and evaporated in vacuum. Crude product
was purified by PTLC (DCM:MB, 4:6, (MB = 60:10:1 DCM:MeOH:NH4OH)) to furnish tertbutyl N-[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyethyl]carbamate (121 mg,
.290 mmol, 27%). 1H NMR (500 MHz, DMSO-d6) δ 10.94 (bs, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.42
(s, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.04 (s, 1H), 5.12 (dd, J = 12.7, 5.0 Hz, 1H), 4.17 (t, J = 4.8 Hz,
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2H), 3.41 – 3.33 (m, 2H), 2.96 – 2.80 (m, 1H), 2.68 – 2.51 (m, 2H), 2.14 – 1.95 (m, 1H), 1.38 (s,
9H).

13

C NMR (101 MHz, DMSO-d6) δ 172.8, 170.0, 166.9, 166.8, 163.9, 155.7, 133.9, 125.3,

123.1, 120.8, 109.0, 77.9, 67.7, 49.0, 48.6, 31.0, 22.1. HRMS [C20H23N3O7Na+] Cal: 440.1434;
Obs: 440.1436.

4-(2-aminoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (8):
N-[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyethyl]carbamate

(40

mg)

was

dissolved in 1 mL DCM and 1mL TFA was added. The reaction was stirred until complete by
LCMS, then concentrated and used directly without further purification.

t-butyl-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)carbamate
(9):
To

a

solution

of

tert-butyl

N-[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-

yl]oxyethyl]carbamate (40 mg, .0958 mmol) in dry DMF (2 mL) was added K2CO3 (53 mg, .383
mmol) and MeI (7.2 uL, .115 mmol). The reaction was stirred overnight, concentrated, and purified
by PTLC (1:1 DCM:MB) to furnish t-butyl-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3dioxoisoindolin-4-yl)oxy)ethyl)carbamate (28 mg, 68%). 1H NMR (600 MHz, DMSO-d6) δ 7.81
– 7.68 (m, 1H), 7.53 – 7.33 (m, 2H), 6.96 – 6.83 (m, 1H), 5.15 – 5.02 (m, 1H), 4.23 – 4.10 (m,
2H), 3.26 – 3.19 (m, 1H), 3.01 – 2.89 (m, 4H), 2.76 – 2.62 (m, 1H), 2.04 – 1.90 (m, 1H), 1.38 –
111

1.23 (m, 10H). 13C NMR (151 MHz, DMSO-d6) δ 172.22, 172.14, 170.09, 170.02, 167.20, 165.65,
156.19, 156.10, 137.47, 133.70, 120.50, 116.88, 116.81, 115.93, 78.35, 78.29, 67.92, 49.72, 31.51,
31.45, 28.64, 28.57, 27.04, 21.67. HRMS [C21H25N3O7Na+] Cal: 454.1591; Obs: 454.1571

4-(2-aminoethoxy)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (10):
t-butyl-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethyl)carbamate
(40 mg) was dissolved in 1 mL DCM and 1mL TFA was added. The reaction was stirred until
complete by LCMS, then concentrated and used directly without further purification.
Synthesis of Linker:

Scheme 4: Synthesis of Linker for HER3 PROTACs
HO

O

OtBu
O

tert-butyl 3-(3-hydroxypropoxy)propanoate (11):
To a solution of propane-1,3-diol (2.26 ml, 31.21 mmol) and tert-butyl prop-2-enoate (2.29 ml,
15.6 mmol) in Acetonitrile (30 ml) Triton B (0.23 ml, 0.58 mmol) was added at r.t. and the reaction
mixture was stirred for 16 hours. The solvent was removed under reduced pressure and the crude
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product was purified by flash chromatography (12-100% Ethyl Acetate in Hexanes) to furnish tertbutyl 3-(3-hydroxypropoxy)propanoate (4.47 g, 65%).
1

H NMR (400 MHz, Chloroform-d) δ 3.75 (t, J = 5.6 Hz, 2H), 3.67 (t, J = 6.2 Hz, 2H), 3.63 (t, J =

5.7 Hz, 2H), 2.48 (t, J = 6.2 Hz, 2H), 1.81 (p, J = 5.6 Hz, 2H), 1.45 (s, 9H). 13C NMR (101 MHz,
Chloroform-d) δ 171.17, 80.94, 70.33, 66.90, 61.97, 36.37, 32.08, 28.21.

I

O

OtBu
O

tert-butyl 3-(3-iodopropoxy)propanoate (12):
To a suspension of Ph3P (523.9 mg, 2 mmol), Imidazole (135.98 mg, 2 mmol) and I2 (633.7 mg,
2.5 mmol) in dry Tetrahydrofuran (10 ml), tert-butyl 3-(3-hydroxypropoxy)propanoate (340 mg,
1.66 mmol) was added at r.t. After stirring at for 1 hour the reaction mixture was filtered to remove
the white precipitate, the solvent was evaporated and the crude mixture purified by flash
chromatography

(5-100%

Ethyl

acetate

in

Hexane) to

furnish

tert-butyl

3-(3-

iodopropoxy)propanoate (610 mg, 97%). 1H NMR (400 MHz, Chloroform-d) δ 3.67 (t, J = 6.4 Hz,
2H), 3.49 (t, J = 5.8 Hz, 2H), 3.25 (t, J = 6.8 Hz, 2H), 2.47 (t, J = 6.4 Hz, 2H), 2.03 (tt, J = 6.8, 5.8
Hz, 2H), 1.45 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 171.00, 80.71, 70.26, 66.72, 36.47,
33.53, 28.25, 3.50.
N3

O

OtBu
O

tert-butyl 3-(3-azidopropoxy)propanoate (13):
To a solution of tert-butyl 3-[3-iodopropoxy]propanoate (86 mg, 0.24 mmol) in N,NDimethylformamide (2 ml) was added NaN3 (155.98 mg, 2.4 mmol), and TBAI (8.86 mg, 0.02
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mmol) at room temperature. The reaction mixture was stirred at 60oC for 3 h. Reaction was diluted
with EtOAc (20 mL), washed with water (4x20 mL), dried (Na2SO4) and concentrated to furnish
tert-butyl 3-(3-azidopropoxy)propanoate, which was used without further purification
(quantitative). 1H NMR (400 MHz, Chloroform-d) δ 3.66 (t, J = 6.4 Hz, 2H), 3.51 (t, J = 6.0 Hz,
2H), 3.37 (t, J = 6.7 Hz, 2H), 2.47 (t, J = 6.4 Hz, 2H), 1.88 – 1.75 (m, 2H), 1.45 (s, 9H). 13C NMR
(101 MHz, cdcl3) δ 171.01, 80.70, 67.61, 66.70, 48.56, 36.43, 29.26, 28.24.
NH2

O

OtBu
O

tert-butyl 3-(3-aminopropoxy)propanoate (14):
A solution of tert-butyl 3-(3-azidopropoxy)propanoate (50 mg) in dry EtOH was purged with N2
for 15 minutes and then Pd/C (10% loading, 20mg) was added. The solution was further purged
with N2 and then hydrogen was bubbled through the solution for 15 minutes. The reaction was
stirred under 1atm hydrogen (balloon) for 12 hours, then filtered through Celite and concentrated
to furnish tert-butyl 3-(3-aminopropoxy)propanoate which was used without further purification
(quantitative).
O
BuOt

O

N
H

N

NO2

’

tert-butyl 3-(3-((5-nitropyridin-2-yl)amino)propoxy)propanoate (15):
To a solution of 2-chloro-5-nitropyridine (500 mg, 3.15 mmol) and tert-butyl 3-(3aminopropoxy)propanoate (646 mg, 3.47 mmol) in Ethanol (30 ml) TEA (0.66 ml, 4.73 mmol)
was added and the reaction mixture refluxed at 90° C for 16 h. The solvent was removed under
reduced pressure and the crude product purified by flash chromatography (20% - 100% Ethyl
Acetate in Hexane) to furnish tert-butyl 3-(3-((5-nitropyridin-2-yl)amino)propoxy)propanoate
(535 mg, 52%). 1H NMR (400 MHz, Chloroform-d) δ 9.00 (d, J = 2.7 Hz, 1H), 8.15 – 8.07 (m,
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1H), 6.48 (d, J = 9.3 Hz, 1H), 3.68 (t, J = 5.9 Hz, 2H), 3.61 (t, J = 5.5 Hz, 4H), 2.52 (t, J = 5.9 Hz,
2H), 1.93 – 1.83 (m, 2H), 1.46 (s, 9H).

13

C NMR (101 MHz, Chloroform-d) δ 171.40, 161.09,

146.72, 135.26, 132.47, 114.04, 80.94, 66.54, 58.46, 40.46, 36.16, 28.34, 28.10. HRMS
[C15H24N3O5+] Cal: 326.1716; Obs: 326.1755
O
BuOt

O

N
H

N

NH2

tert-butyl 3-(3-((5-aminopyridin-2-yl)amino)propoxy)propanoate (16):
A solution of tert-butyl 3-(3-((5-nitropyridin-2-yl)amino)propoxy)propanoate (50 mg) in dry
EtOH was purged with N2 for 15 minutes and then Pd/C (10% loading, 20mg) was added. The
solution was further purged with N2 and then hydrogen was bubbled through the solution for 15
minutes. The reaction was stirred under 1atm hydrogen (balloon) for 12 hours, then filtered
through celite and concentrated to furnish tert-butyl 3-(3-aminopropoxy)propanoate which was
rigorously purified by PTLC and then HPLC to ensure fidelity of the reaction with the prepared
HER3 ligand (4). 1H NMR (400 MHz, Chloroform-d) δ 7.66 (dd, J = 2.9, 0.8 Hz, 1H), 6.95 (dd, J
= 8.7, 2.9 Hz, 1H), 6.35 (dd, J = 8.7, 0.8 Hz, 1H), 3.66 (t,J=6.3Hz, 2H) , 3.55 (t, J=5.9Hz, 2H),
3.31 (t,J=6.6Hz, 2H), 2.49 (t, J=6.3Hz, 2H), 1.84 (p, J=6.3Hz, 2H), 1.44 (s,9H). 13C NMR (101
MHz, Chloroform-d) δ 171.18, 153.59, 135.21, 133.48, 127.32, 107.75, 80.73, 69.40, 66.70, 40.64,
36.50, 29.56, 28.26. HRMS [C15H26N3O3+] Cal: 296.1974; Obs: 296.1925
Biological Methods
TR-FRET Screen of PKIS: The TR-FRET screen as performed in duplicate from 3 source plates.
First using an Aquarious TouchDeepWash, 40 nL of 10 mM compound was added to a 384 well
plate. 5 µL of Kinase buffer A (50 mM HEPES, pH 7.5, 10 m M MgCl2, 1 mM EGTA, 0.01%
Brij- 35) was then added to the plate. LanthaScreen Eu-anti-His antibody diluted in Kinase Buffer
A was then added to a final concentration of 2nM. Antibody was centrifuged prior to use to
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decrease noise. HER3 kinase domain was then added to a final concentration of 16.6n. Lastly, 5
µL of Tracer 178 was added to the plate to a final concentration of 65 nM. The final volume of the
assay is 15 µL. The plate is then incubated for at least 30 minutes and read on a Perkin Elmer
Envision. Dose response experiments were wan identically. Some later experiments were read on
a SYNERGY 2 microplate reader (BioTek Instrument).
HER3 Degradation/Downstream Signalling Assay: A431 (or other relevant line) cells were plated
in 12 well plates at a density of 100k/well and grown to ~80% confluence overnight. The cells
were then washed with sterile PBS before being treated with PROTAC in serum-free media for 24
hours. The PROTAC containing media was removed and the cells washed with sterile cold PBS.
The cells were then lysed using a RIPA buffer with added commercial protease and phosphatase
inhibitor cocktail (Roche). The lysates were analyzed for protein content by BCA and an equal
amount of each condition was loaded on SDS-PAGE gel. After electrophoresis the gel was
transferred to PVDF membrane at 76V for 2 hours at 4oC. The transferred blots were blocked with
5% OmniBlock in TBST for 1 hour at r.t., then probed with HER3 antibody (CST #4754S)
overnight at 4oC.
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Chapter 4: Towards the development of Brachyury PROTACs
This work was in collaboration with Saul Jaime-Figueroa (Chemistry) and Adrian Bebenek, Mack
Krone, and Brian Linhares (Biology/Crystallography).
4.1 Brachyury Background and Disease Relevance
Deregulation of transcription factors (TFs) is significant in pediatric and lineage-dependent
tumorigenesis.1 In such tumors transcription factors that are necessary during early development
are not sufficiently silenced once development is complete. These tumors become addicted to the
aberrantly expressed transcription factors.2 Chordomas are locally invasive primary bone tumors
that are addicted to the TF Brachyury (T) and currently have no approved therapy.3 T has also been
implicated in advanced prostate cancer, and high T levels correlate with low rates of survival.
Further, T has been linked to general tumor progression in many cancers. T is a driver of the
epithelial-to-mesenchymal transition that is crucial for cancer metastasis and invasion.4
Chordomas are currently treated surgically, but incomplete removal of the tumor results in high
levels of recurrence.5 Recently, the Schreiber and Gray groups used genome-scale CRISPR-Cas9
screening and small-molecule sensitivity profiling to identify T as the top selectively essential gene
in chordomas.3,6 We therefore became interested in developing a PROTAC degrader of T as a
potential chordoma therapy and as a tool to interrogate T-driven diseases.
4.2 Brachyury-targeted PROTACs Design and Synthesis
4.2.1 Brachyury Ligand Development and Validation
Afatanib was developed as a small molecule covalent inhibitor of EGFR used to treat non-small
cell lung carcinoma.7 In 2018 a study was published demonstrating that afatanib is able to induce
the degradation of T at high µM concentration.8 While the authors did not a provide a mechanism
of action, we used in silico docking in MOE to postulate that afatanib binds to T covalently and
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destabilizes it to induce degradation. We went on to demonstrate by MS that afatanib binds T at a
specific single cysteine site (Fig 4.1).

Figure 4.1: Afatanib binds covalently to T confirmed by mass spectrometry and crystallography. Crystal
structure was collected by Professor Opher Gileadi at U. Oxford. (PDB 6ZU8)

With this encouraging data in hand we moved on to design and synthesize a panel of afatanib
analogs hoping to engineer in greater specificity for T over EGFR. The kinase-hinge binding motif
of afatanib has been well characterized and is crucial for EGFR affinity,9 so we decided to start
engineering covalent T ligands with an altered hinge motif. The MS strategy for target engagement
validated that several of these derivatives engage T covalently (Table 2) with HI4601 showing the
most significant engagement.
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Table 2: Synthesized afatanib analogs covalently engage T by mass spectrometry. HI4601 is the lead compound

Validation of HI4601 selectivity for T to EGFR was obtained by using the EGFR kinase assay
produced by Carna Biosciences. While afatanib has and IC50 of 5 pM in this assay the analog
HI4601 has IC50 of 11 µM, demonstrating a very significant improvement in selectivity for T over
EGFR. With binding and selectivity of HI4601 for T confirmed, we moved on to design and
synthesize a panel of candidate PROTACs CRBN and VHL-recruiting PROTACs based on this
warhead.
4.2.2 Rational Design of Brachyury PROTACs
Additional in silico analysis using MOE revealed solvent exposed vectors for the addition of a
linker and E3 warhead to HI4601 (Fig 4.2).
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Figure 4.2: Strategy for generation of HI4601-based Brachyury-targeting PROTACs

We chose to generate two series of T-targeting PROTACs based on two vector sites for linker
attachment on HI4601 that we elucidated by analysis in MOE. Series 1 features an amide linkage
off HI4601 while series 2 features a phenolic linkage. We planned to generate PROTACs of both
series featuring CRBN, LH-VHL, and RH-VHL E3 recruiting warheads.
4.2.3 Synthetic Schemes for Brachyury PROTAC Synthesis
We prepared two T-targeting warheads based on HI4601 to enable the facile synthesis of the two
series of PROTACs (Scheme 5).
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Scheme 5: Synthesis of T-targeting warheads for Series 1 and 2 PROTACs

With these two Brachyury warheads in hand we synthesized a panel of PROTAC candidates.
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Scheme 6: Synthesis of Series 1 T-targeting PROTACs

The series 1 warhead was condensed with (E)-4-bromobut-2-enoic acid to generate (E)-3-(4bromobut-2-enamido)-N-(3-chloro-4-fluorophenyl)-4-methoxybenzamide as a mixture of cis and
trans isomers. In the following substitution reaction the isomers resolve to the more stable trans
isomer when reacted with the prepared N-methyl amino-PEG-COOtBu linkers. The TFA
deprotection of this material and amide coupling to the free amine of an E3 ligase ligand yielded
the series 1 PROTACs (Scheme 6).
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Scheme 7: Synthesis of Series 2 T-targeting PROTACs

The series 2 PROTACs required less steps to generate (Scheme 2). The series two warhead was
reduced with raney nickel to furnish the aniline intermediate 3-amino-N-(3-chloro-4fluorophenyl)-4-hydroxybenzamide. This material was reacted with (E)-4-(dimethylamino)but-2enoic acid which was pre-activated for reaction as the acid chloride to generate the advanced
intermediate

(E)-N-(3-chloro-4-fluorophenyl)-3-(4-(dimethylamino)but-2-enamido)-4-

hydroxybenzamide. This material was reacted with a variety of TsO-PEG-COOtBu linkers. TFAmediated deprotection and amine coupling to the deprotected acid yielded the complete series 2
Brachyury PROTACs.
4.3 Efforts Towards Biological Characterization of T-PROTACs in Chordoma Cell Lines
As of the writing of thesis we have generated ~20 T-targeting PROTACs based on the series 1 and
2 warheads. The PROTACs have been screened for T degradation by treating UM-Chor-1 human
derived chordoma cells for 24 hours, then harvesting their lysates and running western blots to
quantify T. The most successful candidate PROTAC we have elucidated thus far is SJF-1420,
which features a RH-VHL E3 ligase ligand and a short linker (Figure 4.3). Degradation is moderate
but consistent with a DC50 of 929 nM and a DMax of ~75%. However, the degradation is only
observed when treating with serum-free media, indicating that the PROTAC is liable to serum124

protein binding. Moreover, I synthesized an epimeric control to IN1420, which induces more
potent degradation of T than the PROTAC. Similarly to HER3, these PROTACs may be acting to
destabilize T by binding rather than by a PROTAC mechanism of action. We are generating
epimers of other lead candidates to further investigate this. We are also considering generating
SERD-based or adamantane-based tags for T to induce more potent degradation if the mechanism
is through hydrophobic tagging. We are continuing to synthesize more candidate T-PROTACs to
try to improve potency and enable T-degradation in full-media conditions. This project will be
carried forward by Adrian and Saul as well as others in the Crews lab.

Figure 4.3: Degradation of T by current lead PROTAC IN1420 in UM-Chor-1 cells. Epimeric control PROTAC
degrades T with higher potency than the PROTAC. Cells were treated for 24 hours in serum-free media.
(Adrian)
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4.4 Synthetic Characterization and Biological Methods
Synthetic Methods
Synthesis of Afatanib Analogues (characterization data - Saul):
General Procedures:
General T3P Amide Coupling Protocol Example IB2010
IB2010: tert-butyl 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-methoxy-benzoate

To a stirred solution of tert-butyl 3-amino-4-methoxy-benzoate (34.0 mg, 0.152 mmol) in dry
CH2Cl2 (2.0 mL) was added (E)-4-(dimethylamino)but-2-enoic acid;hydrochloride (27.7 mg,
0.168 mmol), T3P (50.0 %, 194 mg, 0.305 mmol), and DIEA (0.156 mL, 0.914 mmol) at room
temperature. After stirring for 4 h at ambient temperature, the reaction mixture was diluted with
EtOAc (20 mL), washed with water (2x15 mL), organic layer was dried over Na2SO4, filtered, and
concentrated in vacuo. The residue was purified by PTLC (DCM:MB, 7:3, 2x) to give 17 mg of
product
1

(33%

yield).

Some

starting

material

was

recovered (~40%).

H NMR (400 MHz, Chloroform-d) δ 8.98 (s, 1H), 7.87 (s, 1H), 7.74 (dd, J = 8.5, 2.1 Hz, 1H),

6.95 (dt, J = 15.2, 6.2 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.28 (d, J = 15.3 Hz, 1H), 3.92 (s, 3H),
3.30
13

(d,

J

=

6.2

Hz,

2H),

2.42

(s,

6H),

1.56

(s,

9H).

C NMR (101 MHz, cdcl3) δ 165.96, 163.25, 151.57, 139.29, 128.70, 127.46, 126.64, 125.49,

121.46, 109.68, 81.25, 59.81, 56.43, 45.11, 28.67. HRMS (ESI); m/z [M+H]+: Calcd.
for C18H27N2O4, 335.1970. Found 335.1979.
General Boc-Deprotection Example HS3498:
HS3498 3-chloro-4-[[4-(trifluoromethyl)phenyl]methoxy]aniline
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To a solution of tert-butyl 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-methoxy-benzoate
(17.0 mg, 0.0508 mmol) in DCM (2 mL) was added TFA (1.00 mL) at room temperature. The
reaction mixture was stirred for 2 h at room temperature. Solvent was removed under vacuum
and crude was used in the next step.
General Amide Coupling Protocol Example HS3499:
HS3499 N-[3-chloro-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-3-[[(E)-4(dimethylamino)but-2-enoyl]amino]-4-methoxy-benzamide

To a stirred solution of 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-methoxy-benzoic acid
(14.1 mg, 0.0507 mmol), and 3-chloro-4-[[4-(trifluoromethyl)phenyl]methoxy]aniline (16.8 mg,
0.0557

mmol) in

DMF

(2

ml), was

added O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-

tetramethyluronium hexafluorophosphate (19.3 mg, 0.0507 mmol), and then DIEA (0.0867 mL,
0.507 mmol), the resulting mixture was stirred for 12 h (overnight) at room temperature. By TLC
new product formation and no starting material (DCM:MeOH, 9:1). Reaction mixture was diluted
with EtOAc (30 mL), washed with brine:water (1:1, 5x20 mL), dried (Na2SO4), and evaporated
under vacuum Crude product was purified by PTLC (DCM:MeOH, 9:1) to give 16 mg of product
(56% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.13 (s, 1H), 9.44 (s, 1H), 8.60 (d, J = 2.2 Hz,
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1H), 7.95 (d, J = 2.5 Hz, 1H), 7.79 (d, J = 8.1 Hz, 2H), 7.75 (dd, J = 8.6, 2.3 Hz, 1H), 7.69 (d, J =
8.0 Hz, 2H), 7.66 (dd, J = 9.0, 2.6 Hz, 1H), 7.23 (d, J = 9.0 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 6.74
(dt, J = 15.4, 6.0 Hz, 1H), 6.54 (d, J = 15.3 Hz, 1H), 5.32 (s, 2H), 3.92 (s, 3H), 3.06 (d, J = 5.6 Hz,
2H), 2.18 (s, 6H). 13C NMR (151 MHz, dmso) δ 165.29, 163.93, 153.04, 142.05, 142.04, 141.91,
134.02, 128.83 (q, J = 31.7 Hz), 128.27, 127.38, 126.91, 126.51, 126.47 (q, J = 272.0 Hz), 125.83
(q, J = 3.7 Hz), 124.94, 122.60, 122.37, 121.55, 120.49, 114.87, 110.98, 69.75, 60.21, 56.47, 45.55.
HRMS (ESI); m/z [M+1]+; Calcd. C28H28ClF3N3O4, 562.1720 . Found 562.1741.
(E)-4-(dimethylamino)but-2-enoyl chloride hydrochloride

To a stirred suspension of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride (100 mg, 0.604
mmol) in acetonitrile (2 mL) under N2 was added Dimethylformamide (0.000441 g, 6.04e-6 mol).
After 10 min Oxalyl chloride (0.0570 mL, 0.664 mmol) was added and the reaction mixture was
stirred for 12 h (overnight) at room temperature. this solution was used as such for next step.
Table 2 Afatanib Analogs Synthesis:
N-(3-chloro-4-fluoro-phenyl)-4-methoxy-3-nitro-benzamide

To a stirred solution of 4-methoxy-3-nitro-benzoic acid (1.91 g, 0.00969 mol) in DMF (15
ml), DIEA (4.15 mL, 0.0242 mol) was added and the mixture was stirred for 10 minutes. O-(7Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (3.68 g, 0.00969
mol) was added and the resulting mixture was stirred for 30 minutes at room temperature. The
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reaction mass cooled to O °C, 3-chloro-4-fluoro-aniline (1.41 g, 0.00969 mol) was added and the
mixture was stirred at room temperature for 12 h (overnight). By TLC new product formation and
no starting material (EtOAc:Hex, 3:7). Then, water (100 mL) was added to the reaction mixture
and stirred for 5 min. The precipitate was collected by filtration, washed with water (20 mL), and
dried under high vacuum to give 2.9 g of pure product (92 % yield). 1H NMR (500 MHz, DMSOd6) δ 10.50 (s, 1H), 8.52 (s, 1H), 8.27 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 6.7 Hz, 1H), 7.71 (ddt, J =
9.0, 4.5, 2.2 Hz, 1H), 7.53 (d, J = 8.9 Hz, 1H), 7.43 (td, J = 9.1, 1.8 Hz, 1H), 4.02 (s, 3H). 13C
NMR (151 MHz, DMSO-d6) δ 163.08, 154.53, 153.48 (d, J = 243.3 Hz), 138.67, 136.12 (d, J =
3.0 Hz), 133.96, 126.09, 124.61, 121.87, 120.72 (d, J = 6.9 Hz), 119.05 (d, J = 18.4 Hz), 116.88
(d,

J

=

21.8

Hz),

114.40,

57.21.

HRMS

(ESI);

m/z

[M+1]+;

Calcd. C14H11ClFN2O4, 325.0391. Found 325.0378
3-amino-N-(3-chloro-4-fluoro-phenyl)-4-methoxy-benzamide

To a suspension of N-(3-chloro-4-fluoro-phenyl)-4-methoxy-3-nitro-benzamide (552 mg, 1.70
mmol) in a mixture of ethanol (15mL) and acetic acid (15 mL) was added iron powder (380 mg,
6.80 mmol). The mixture was stirred at reflux for 2 h before it was cooled to room temperature.
Reaction mixture was filtered over a celite pad, washed with ethanol (30 mL), and the filtrate was
evaporated under vacuum. The residue was suspended in a mixture of EtOAc (100 mL) and
aqueous saturated solution of NaHCO3 (100 mL), the mixture was stirred for 20 min, then the
mixture was filtered through a celite pad to remove iron salts. The organic extract was dried
(Na2SO4), and evaporated under vacuum. Crude product was purified by flash column
chromatography (SiO2-40g, gradient Hex:EtOAc, 9:1 to 100% EtOAc in 15 min) to give 355 mg
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of product as a white solid (71% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.13 (s, 1H), 8.06 (d,
J = 6.9 Hz, 1H), 7.71 (ddt, J = 8.7, 4.2, 1.9 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.32 – 7.09 (m, 2H),
6.90 (d, J = 8.0 Hz, 1H), 4.95 (s, 2H), 3.84 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 165.94,
153.03 (d, J = 242.5 Hz), 149.18, 137.53, 136.86 (d, J = 2.9 Hz), 126.90, 121.39, 120.31 (d, J =
6.8 Hz), 118.86 (d, J = 18.0 Hz), 116.69 (d, J = 21.7 Hz), 116.20, 112.95, 109.52, 55.51. HRMS
(ESI); m/z [M+1]+; Calcd. C14H13ClFN2O2, 295.0649. Found 295.0664.
HI4601: N-(3-chloro-4-fluoro-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4methoxy-benzamide
O
Cl
F

H
N
O

N
H

O
N

To a solution of (E)-4-(dimethylamino)but-2-enoyl chloride;hydrochloride (112 mg, 0.611
mmol) in MeCN (2 mL (crude product from SJF-HI4600) was added 3-amino-N-(3-chloro-4fluoro-phenyl)-4-methoxy-benzamide (120 mg, 0.407 mmol) in THF (2mL), the reaction mixture
was stirred for 6 hrs at room temperature. The reaction mixture was suspended in EtOAc (30 mL)
and aqueous saturated solution of NaHCO3 was added carefully to adjust the (pH ~ 8), organic
extract was separated, dried (Na2SO4), and evaporated under vacuum. Crude was purified by flash
chromatography (SiO2-25g, gradient DCM 100% to DCM:MB, 1:1 in 15 min.). A second
purification was performed by PTLC (DCM:MB, 1:1) to give 35 mg of product (21% yield). 65
mg of SM were recovered. 1H NMR (500 MHz, DMSO-d6) δ 10.28 (s, 1H), 9.43 (s, 1H), 8.61 (s,
1H), 8.05 (dd, J = 7.0, 2.4 Hz, 1H), 7.87 – 7.63 (m, 2H), 7.39 (t, J = 9.1 Hz, 1H), 7.17 (d, J = 8.6
Hz, 1H), 6.73 (ddd, J = 15.3, 6.9, 5.2 Hz, 1H), 6.53 (d, J = 15.4 Hz, 1H), 3.91 (s, 3H), 3.04 (d, J =
6.0 Hz, 2H), 2.17 (s, 6H).13C NMR (151 MHz, DMSO-d6) δ 165.01, 163.39, 153.07 (d, J = 242.8
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Hz), 152.60, 141.43, 136.49 (d, J = 3.0 Hz), 126.88, 126.07, 125.90, 124.49, 122.04, 121.52,
120.40 (d, J = 6.7 Hz), 118.79 (d, J = 18.2 Hz), 116.60 (d, J = 21.5 Hz), 110.45, 59.66, 55.93,
45.01. HRMS (ESI); m/z: [M+H]+ Calcd. for C20H22ClFN3O3, 406.1333. Found 406.1322.
N-(3-chloro-4-hydroxy-phenyl)-4-methoxy-3-nitro-benzamide

Followed general amide coupling protocol above. Crude product was attempted to purified by CC
but product crystallized in the column. Column was washed out with DCM:MeOH (1:1) and crude
product was crystallized from MeOH:DCM to give 247 mg of pure product (29% yield).
1

H NMR (400 MHz, DMSO-d6) δ 10.24 (s, 1H), 10.01 (s, 1H), 8.50 (s, 1H), 8.25 (d, J = 8.8 Hz,

1H), 7.81 (s, 1H), 7.58 – 7.42 (m, 2H), 6.95 (d, J = 8.8 Hz, 1H), 4.01 (s, 3H).
13

C NMR (101 MHz, dmso) δ 162.54, 154.27, 149.49, 138.67, 133.77, 131.18, 126.52, 124.41,

122.09,

120.59,

119.01,

116.36,

114.29,

57.15.

HRMS

(ESI);

m/z

[M+1]+;

Calcd. C14H12ClN2O5, 323.0434. Found 323.0431.
3-amino-N-(3-chloro-4-hydroxy-phenyl)-4-methoxy-benzamide

To a suspension of N-(3-chloro-4-hydroxy-phenyl)-4-methoxy-3-nitro-benzamide (100 mg, 0.310
mmol) in a mixture MeOH:water (9:1, 10 mL) was added Zn (60.8 mg, 0.930 mmol), followed
by Ammonium chloride (99.5 mg, 1.86 mmol) at 25 °C. The temperature was raised to 50 °C, and
the stirring was continued for 3 h. Progress of the reaction was followed by TLC (DCM:MB, 7:3).
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Then, 20 mL of DCM:MeOH (9:1) was added to the reaction mixture and inorganic residues were
removed by filtration. The filtrate was washed with an aqueous saturated solution of NaHCO3 (20
mL) , dried (Na2SO4), and evaporated under vacuum. Crude product was purified by PTLC
(DCM:MB, 1:1) to give 36 mg of product (40% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.87 (s,
1H), 9.84 (s, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.46 (dd, J = 8.9, 2.1 Hz, 1H), 7.30 – 7.04 (m, 2H),
7.05 – 6.66 (m, 2H), 4.90 (s, 2H), 3.83 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 165.43, 148.89,
137.38, 131.99, 127.36, 121.70, 120.27, 118.88, 116.25, 115.99, 112.98, 109.48, 55.47. HRMS
(ESI); m/z [M+H]+: Calcd. for C14H14ClN2O3, 293.0693 . Found 293.0698.
HS3487 N-(3-chloro-4-hydroxy-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4methoxy-benzamide

Synthesized according to general T3P amide formation protocol above. The residue was purified
by PTLC (DCM:MB, 1:1, 2x) to give 3 mg of product (8% yield). It was recovered ~50% of
starting material (less polar product).1H NMR (400 MHz, DMSO-d6) δ 10.03 (s, 1H), 9.98 (bs,
1H), 9.49 (s, 1H), 8.56 (s, 1H), 7.80 (d, J = 2.5 Hz, 1H), 7.74 (dd, J = 8.6, 2.3 Hz, 1H), 7.48 (dd, J
= 8.8, 2.6 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.74 (dt, J = 15.5, 6.2 Hz,
1H), 6.58 (t, J = 12.9 Hz, 1H), 3.91 (s, 3H), 3.20 (d, J = 6.4 Hz, 2H), 2.28 (s, 6H).13C NMR (126
MHz, dmso) δ 164.67, 163.31, 152.59, 149.15, 139.74, 131.74, 127.12, 126.82, 126.68, 124.54,
122.30, 121.96, 120.50, 118.96, 116.32, 110.58, 59.28, 56.06, 44.60, 39.69. HRMS (ESI); m/z
[M+1]+; Calcd. C20H23ClN3O4, 404.1377. Found 404.1401.
tert-butyl N-(5-cyano-2-tetrahydrofuran-3-yloxy-phenyl)carbamate
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O

O
HN
O

CN
O

To a stirred, cooled (about 0°C) solution of tert-butyl N-(5-cyano-2-hydroxy-phenyl)carbamate
(120 mg, 0.512 mmol), triphenylphosphine (134 mg, 0.512 mmol), and tetrahydrofuran-3-ol (45.1
mg, 0.512 mmol) in dry tetrahydrofuran (4 mL) was added Diisopropyl azodicarboxylate (104 mg,
0.512 mmol). After stirring for 12 hours, the solution was concentrated under reduced pressure.
Crude product was purified by flash chromatography (SiO2-40g, gradient EtOAc:Hex, 2:8 to 100%
EtOAc in 20 min) to give 88 mg of product (56% yield). It was recovered ~ 50 mg of starting
material as a mixture of SM + Di-isoprpylurea. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H),
8.10 (d, J = 1.9 Hz, 1H), 7.51 (dd, J = 8.5, 2.1 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 5.14 (t, J = 5.3
Hz, 1H), 4.05 – 3.83 (m, 3H), 3.81 – 3.61 (m, 1H), 2.33 – 2.15 (m, 1H), 2.15 – 1.90 (m, 2H), 1.48
(s, 9H). 13C NMR (151 MHz, DMSO-d6) δ 152.73, 151.03, 128.91, v

128.31, 123.60,

119.08, 113.29, 102.49, 80.04, 78.65, 71.95, 66.49, 32.28, 28.00. HRMS (ESI); m/z:
[M+H]+ Calcd. for C16H21N2O4, 305.1501. Found 305.1474.
3-amino-4-tetrahydrofuran-3-yloxy-benzonitrile

A solution of tert-butyl N-(5-cyano-2-tetrahydrofuran-3-yloxy-phenyl)carbamate (75.0 mg, 0.246
mmol) in trifluoroethanol (TFE, 10 mL) was heated to 150oC under microwave assisted conditions.
Solvent was removed under vacuum, to give 50 mg of product (99% yield). Product was used in
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the next step without any further purification (>97% pure by NMR). 1H NMR (400 MHz, DMSOd6) δ 7.02 – 6.82 (m, 3H), 5.21 (s, 2H), 5.06 (td, J = 4.6, 2.3 Hz, 1H), 3.97 – 3.70 (m, 4H), 2.29 –
2.13 (m, 1H), 2.08 – 1.93 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 147.97, 139.73, 121.12,
120.27, 115.62, 112.89, 103.33, 78.21, 72.60, 66.91, 32.97. HRMS (ESI); m/z: [M+H]+ Calcd.
for C11H13N2O2, 205.0977. Found 205.0958.
GY7481 (E)-N-(5-cyano-2-tetrahydrofuran-3-yloxy-phenyl)-4-(dimethylamino)but-2-enamide

To a solution of (E)-4-(dimethylamino)but-2-enoyl chloride;hydrochloride (50.0 mg, 0.272 mmol)
in MeCN (2 mL, crude product from SJF-7479) was added 3-amino-4-tetrahydrofuran-3-yloxybenzonitrile (49.9 mg, 0.244 mmol) in THF (4 mL), the reaction mixture was stirred for 6 hrs at
room temperature, then NaHCO3 was added carefully to adjust the pH ~ 8, reaction mixture was
filtered and filtrate was evaporated under vacuum. Crude was purified by PTLC (MB:DCM, 1:1)
to give 17 mg of product (20% yield) 1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.48 (d, J =
2.1 Hz, 1H), 7.56 (dd, J = 8.5, 1.5 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 6.77 (dt, J = 15.3, 5.9 Hz,
1H), 6.57 (d, J = 15.4 Hz, 1H), 5.28 – 5.09 (m, 1H), 3.99 – 3.83 (m, 3H), 3.81 – 3.67 (m, 1H), 3.07
(dd, J = 5.9, 1.6 Hz, 2H), 2.36 – 2.22 (m, 1H), 2.18 (s, 6H), 2.13 – 2.03 (m, 1H). 13C NMR (151
MHz, dmso) δ 164.24, 151.44, 142.85, 129.47, 128.95, 126.07, 125.07, 119.51, 113.91, 102.89,
79.32,

72.37,

66.99,

60.11,

45.59,

32.82. HRMS

(ESI);

m/z:

[M+H]+ Calcd.

for C17H22N3O3, 316.1661. Found 316.1663.
GY7483 (E)-3-(4-(dimethylamino)but-2-enamido)-4-((tetrahydrofuran-3-yl)oxy)benzamide
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To

a

solution

of (E)-3-(4-(dimethylamino)but-2-enamido)-4-((tetrahydrofuran-3-

yl)oxy)benzamidein a mixture of EtOH:water (4:2 mL) was added Parkins catalyst (1.02 mg,
0.00238 mmol) and the solution was heated to 80 °C (in air) for 3 h. Reaction mixture was filtered
over a celite pad and filter was washed with EtOH (10 mL). Filtrate was evaporated under vacuum,
and crude product was purified by PTLC (DCN:MB, 1:1) to give 13 mg of product (82% yield).1H
NMR (500 MHz, DMSO-d6) δ 9.14 (s, 1H), 8.50 (bs, 1H), 7.82 (bs, 1H), 7.63 (dd, J = 8.5, 2.3 Hz,
1H), 7.17 (bs, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.74 (dt, J = 15.3, 6.0 Hz, 2H), 6.52 (d, J = 15.3 Hz,
1H), 5.15 – 5.06 (m, 1H), 4.01 – 3.83 (m, 3H), 3.75 (td, J = 8.1, 4.7 Hz, 1H), 3.09 (d, J = 6.0 Hz,
2H),
13

2.31

–

2.21

(m,

1H),

2.20

(s,

6H),

2.14

–

1.97

(m,

1H).

C NMR (101 MHz, DMSO-d6) δ 167.51, 163.34, 150.30, 141.09, 127.19, 126.49, 126.33,

124.21, 122.74, 111.99, 78.39, 72.12, 66.54, 59.63, 45.02, 32.55. HRMS (ESI); m/z [M+1]+;
Calcd.C17H24N3O4, 334.1766. Found 334.1752.
N-(3-chloro-4-fluoro-phenyl)-4-hydroxy-3-nitro-benzamide

To a stirred solution of 4-hydroxy-3-nitro-benzoic acid (1.53 g, 0.00838 mol) in DMF (10
ml), DIEA (3.59 mL, 0.0210 mol) was added and the mixture was stirred for 10 minutes.
HATU (3.19 g, 0.00838 mol) was added and the resulting mixture was stirred for 30 minutes at
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room temperature. The reaction mass cooled to O °C, 3-chloro-4-fluoro-aniline (1.22 g, 0.00838
mol) was added and the mixture was stirred at room temperature overnight. The reaction mixture
was diluted with EtOAc (100 mL) and water (50 mL), the pH of the water phase was adjusted to
a pH ~5.0, then the organic layer was separated, washed (water:brine,1;1, 50 mL, 4x), dried
(Na2SO4), and evaporated under vacuum. Crude product was purified by flash column
chromatography (SiO2-100g, gradient Hex:EtOAc 1:9 to 100% EtOAc in 20 min) to give 0.753 g
of the expected product (SJF-7485) and 0.600 g of a more polar product (SJF-7485-B, amide-ester
product). Plus ~ 1g of mixture. 1H NMR (400 MHz, DMSO-d6) δ 11.73 (bs, 1H), 10.45 (s, 1H),
8.55 (s, 1H), 8.13 (d, J = 8.7 Hz, 1H), 8.04 (d, J = 6.8 Hz, 1H), 7.70 (ddd, J = 8.6, 4.4, 1.9 Hz, 1H),
7.42 (t, J = 9.1 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H).
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C NMR (101 MHz, DMSO-d6) δ 163.31,

154.79, 153.43 (d, J = 243.2 Hz), 136.55, 136.21 (d, J = 3.0 Hz), 134.33, 125.07, 124.87, 121.85,
120.69 (d, J = 6.9 Hz), 119.10, 118.93, 116.85 (d, J = 21.7 Hz). HRMS (ESI); m/z [M+1]+;
Calcd. C13H9ClFN2O4, 311.0234. Found 311.0212.
N-(3-chloro-4-fluoro-phenyl)-3-nitro-4-tetrahydrofuran-3-yloxy-benzamide

To a stirred, cooled (about 0°C) solution of N-(3-chloro-4-fluoro-phenyl)-4-hydroxy-3-nitrobenzamide (381 mg, 1.23 mmol), triphenylphosphine (322 mg, 1.23 mmol), and tetrahydrofuran3-ol (108 mg, 1.23 mmol) in dry tetrahydrofuran (10 mL) was added Diisopropyl azodicarboxylate
(248 mg, 1.23 mmol). After stirring for 12 hours, the solution was concentrated under reduced
pressure. Crude product was purified by flash chromatography (SiO2-80g, gradient EtOAc:Hex,
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2:8 to 100% EtOAc in 20 min) to give 270 mg of product (58% yield). It was recovered 120 mg
of starting material. 1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.51 (s, 1H), 8.23 (d, J = 8.9
Hz, 1H), 8.05 (d, J = 6.8 Hz, 1H), 7.78 – 7.66 (m, 1H), 7.53 (dd, J = 8.9, 1.8 Hz, 1H), 7.43 (td, J =
9.1, 1.8 Hz, 1H), 5.49 – 5.24 (m, 1H), 4.00 – 3.66 (m, 4H), 2.39 – 2.23 (m, 1H), 2.08 – 1.98 (m,
1H). Small amount EtOAc/DCM solvent residues.
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C NMR (151 MHz, DMSO-d6) δ 163.51,

153.89 (d, J = 243.4 Hz), 152.86, 139.84, 136.53, 134.14, 126.69, 125.24, 122.25, 121.13 (d, J =
7.0 Hz), 119.47 (d, J = 18.4 Hz), 117.33 (d, J = 21.6 Hz), 116.23, 80.24, 72.45, 66.89, 32.87. Small
amount

EtOAc/DCM

solvent

residues

HRMS

(ESI);

m/z:

[M+H]+ Calcd.

for C17H15ClFN2O5, 381.0653. Found 381.0597.
3-amino-N-(3-chloro-4-fluoro-phenyl)-4-tetrahydrofuran-3-yloxy-benzamide

To a solution of N-(3-chloro-4-fluoro-phenyl)-3-nitro-4-tetrahydrofuran-3-yloxy-benzamide (270
mg, 0.709 mmol) in a mixture of ethanol (5mL) and acetic acid (5 mL) was added iron powder (158
mg, 2.84 mmol). The mixture was stirred at reflux for 2 h before it was cooled to room temperature.
Solvents were removed on rotavapor. The residue was suspended in a mixture of EtOAc (50 mL)
and aqueous saturated solution of NaHCO3 (50 mL), the mixture was stirred for 20 min, then the
mixture was filtered through a celite pad to remove iron salts. The organic extract was dried
(Na2SO4), and evaporated under vacuum. Crude product was purified by flash column
chromatography (SiO2-25g, gradient Hex:EtOAc, 9:1 to 100% EtOAc in 15 min) to give 188 mg
of product as a white solid (76% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.15 (s, 1H), 8.06
(dd, J = 6.9, 2.5 Hz, 1H), 7.70 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.23 (d, J =
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2.1 Hz, 1H), 7.17 (dd, J = 8.3, 2.2 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 5.06 (t, J = 5.4 Hz, 2H), 4.96
(bs, 2H), 4.08 – 3.58 (m, 4H), 2.30 – 2.17 (m, 1H), 2.10 – 1.95 (m, 1H).

13

C NMR (151 MHz,

DMSO-d6) δ 165.97, 153.05 (d, J = 242.7 Hz), 146.86, 138.23, 136.84 (d, J = 3.0 Hz), 127.19,
121.38, 120.30 (d, J = 6.6 Hz), 118.88 (d, J = 18.0 Hz), 116.70 (d, J = 21.5 Hz), 116.03, 113.24,
111.56,

77.61,

72.28,

66.50,

32.64. HRMS

(ESI);

m/z

[M+1]+;

Calcd. C17H17ClFN2O3, 351.0911. Found 351.0905.
GY7492

N-(3-chloro-4-fluoro-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-

tetrahydrofuran-3-yloxy-benzamide

To a solution of (E)-4-(dimethylamino)but-2-enoyl chloride;hydrochloride (50.0 mg, 0.272 mmol)
in MeCN (2 mL, crude product from SJF-7479) was added 3-amino-4-tetrahydrofuran-3-yloxybenzonitrile (49.9 mg, 0.244 mmol) in THF (4 mL), the reaction mixture was stirred for 6 hrs at
room temperature, then NaHCO3 was added carefully to adjust the pH ~ 8, reaction mixture was
filtered and filtrate was evaporated under vacuum. Crude was purified by PTLC (MB:DCM, 1:1),
product ~85% pure. A second purification was performed by PTLC (DCM:MeOH, 9:1) to give
35
1

mg

of

product

(22%

yield).

51

mg

of

SM

were

recovered.

H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.21 (s, 1H), 8.65 (s, 1H), 8.06 (ddd, J = 7.0, 2.7,

1.2 Hz, 1H), 7.82 – 7.60 (m, 2H), 7.38 (dd, J = 9.2, 1.1 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.88 –
6.66 (m, 1H), 6.55 (d, J = 15.4 Hz, 1H), 5.32 – 4.91 (m, 1H), 4.08 – 3.85 (m, 3H), 3.83 – 3.71 (m,
1H), 3.07 (d, J = 5.9 Hz, 2H), 2.36 – 2.24 (m, 1H), 2.18 (s, 6H), 2.15 – 2.03 (m, 1H).
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C NMR (101 MHz, dmso) δ 165.19, 163.56, 154.45, 152.04, 150.63, 141.83, 136.66, 136.63,

127.53, 126.37, 126.00, 124.50, 122.38, 121.66, 120.58, 120.51, 119.07, 118.89, 116.88, 116.66,
112.17,

78.52,

72.11,

66.59,

59.77,

45.18,

32.55.

HRMS (ESI); m/z: [M+H]+ Calcd. for C23H26ClFN3O4, 462.1595. Found 462.1565.
4-methoxy-3-nitro-N-[4-(p-tolylmethoxy)phenyl]benzamide

To a solution of crude 4-methoxy-3-nitro-benzoyl chloride (104 mg, 0.482 mmol, from SJFHS3472) in DCM (3 mL) was added 4-(p-tolylmethoxy)aniline (103 mg, 0.482 mmol) and TEA
(0.336 mL, 2.41 mmol) at room temperature. The reaction mixture was stirred for 12 h (overnight)
at room temperature. The reaction was diluted with DCM (50 mL), washed with aqueous NaHCO3
(1x30 mL), water (1x30 mL), dried (Na2SO4), and evaporated under vacuum. Crude product was
recrystallized from DCM:MeOH to give 129 mg of product (68% yield).1H NMR (400 MHz,
DMSO-d6) δ 10.23 (s, 1H), 8.50 (d, J = 2.3 Hz, 1H), 8.27 (dd, J = 8.8, 2.3 Hz, 1H), 7.64 (d, J =
8.5 Hz, 2H), 7.51 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 7.7 Hz, 2H), 7.19 (d, J = 7.7 Hz, 2H), 7.00 (d, J
= 8.6 Hz, 2H), 5.04 (s, 2H), 4.01 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, dmso) δ 162.68,
154.90, 154.33, 138.75, 137.17, 134.18, 133.93, 132.07, 129.09, 127.93, 126.82, 124.55, 122.20,
114.90, 114.36, 69.35, 57.25, 20.89.
3-amino-4-methoxy-N-[4-(p-tolylmethoxy)phenyl]benzamide
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To a suspension of 4-methoxy-3-nitro-N-[4-(p-tolylmethoxy)phenyl]benzamide (52.0 mg, 0.133
mmol) in a mixture MeOH:water (9:1, 5 mL) was added Zn (26.0 mg, 0.398 mmol), followed
by Ammonium chloride (42.5 mg, 0.795 mmol) at 25 °C. The temperature was raised to 50 °C,
and the stirring was continued for 3 h. Progress of the reaction was followed by TLC (DCM 100%).
Then, 20 mL of DCM:MeOH (9:1) was added to the reaction mixture and inorganic residues were
removed by filtration. The filtrate was washed with an aqueous saturated solution of NaHCO3 (20
mL), dried (Na2SO4), and evaporated under vacuum to give 44 mg of product (92% yield), it was
pure by NMR (>95% pure), it was used in the next step without any further purification. 1H NMR
(400 MHz, DMSO-d6) δ 9.83 (s, 1H), 7.64 (t, J = 6.6 Hz, 2H), 7.33 (t, J = 6.6 Hz, 2H), 7.28 – 7.05
(m, 4H), 6.96 (t, J = 7.1 Hz, 2H), 6.88 (t, J = 6.7 Hz, 1H), 5.02 (s, 2H), 4.91 (s, 2H), 3.83 (s, 3H),
2.30 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.40, 154.27, 148.80, 137.35, 136.96, 134.18,
132.79, 128.93, 127.75, 127.63, 121.70, 115.99, 114.65, 113.04, 109.47, 69.24, 55.46, 20.76.
LRMS (ESI); m/z [M+H]+: Calcd. for C18H27N2O4, 335.19708. Found 334.92.
HS3478

3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-methoxy-N-[4-(p-

tolylmethoxy)phenyl]benzamide

Synthesized according to general T3P amide formation protocol above. The residue was purified
by PTLC (DCM:MB, 1:1, 2x) to give 14 mg of product (24% yield). Significant amount of a more
polar product (26mg,?)(SJF-HS3478-B) 1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 9.44 (s,
1H), 8.58 (s, 1H), 7.80 – 7.69 (m, 1H), 7.64 (dd, J = 9.0, 1.8 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.18
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(ddd, J = 14.9, 8.4, 1.7 Hz, 3H), 6.98 (dd, J = 9.0, 1.8 Hz, 2H), 6.74 (dtd, J = 15.4, 6.0, 1.8 Hz,
1H), 6.53 (d, J = 15.3 Hz, 1H), 5.03 (s, 2H), 3.91 (s, 3H), 3.05 (d, J = 6.3 Hz, 2H), 2.31 (s, 3H),
2.17 (s, 6H).
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C NMR (126 MHz, dmso) δ 164.62, 163.46, 154.45, 152.41, 141.49, 136.97,

134.15, 132.54, 128.93, 127.76, 126.92, 126.86, 126.03, 124.38, 122.21, 121.89, 114.68, 110.47,
69.25, 59.79, 55.99, 45.14, 20.76. HRMS (ESI); m/z [M+1]+; Calcd. C28H32N3O4, 474.2393 Found
474.2416.
HS3475 N-[3-chloro-4-(p-tolylmethoxy)phenyl]-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]4-methoxy-benzamide

Followed general amide coupling protocol above 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1) to give 18 mg of
product (62% yield).

1

H NMR (400 MHz, DMSO-d6) δ 10.12 (s, 1H), 9.45 (s, 1H), 8.59 (s, 1H),

7.91 (s, 1H), 7.74 (d, J = 6.9 Hz, 1H), 7.63 (d, J = 5.9 Hz, 1H), 7.35 (d, J = 7.1 Hz, 2H), 7.28 –
7.08 (m, 4H), 6.73 (d, J = 14.4 Hz, 1H), 6.54 (d, J = 15.4 Hz, 1H), 5.13 (s, 2H), 3.91 (s, 3H), 3.07
(s, 2H), 2.30 (s, 3H), 2.18 (s, 6H).

13

C NMR (101 MHz, DMSO-d6) δ 164.84, 163.50, 152.63,

149.63, 141.38, 137.24, 133.66, 133.28, 129.06, 127.74, 126.93, 126.51, 126.19, 124.54, 122.22,
121.90, 121.11, 120.04, 114.49, 110.58, 70.16, 59.76, 56.07, 45.12, 20.83. HRMS (ESI); m/z
[M+1]+; Calcd. C28H31ClN3O4, 508.2003. Found 508.2028.
IB2005 N-[4-[(4-chlorophenyl)methoxy]phenyl]-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]4-methoxy-benzamide
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Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (MB:DCM, 1:1) to
give 20 mg of product (80% yield).

1

H NMR (500 MHz, DMSO-d6) δ 9.99 (s, 1H), 9.41 (s, 1H),

8.58 (s, 1H), 7.75 (dd, J = 8.7, 1.8 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.46 (dd, J = 8.4 Hz, 4H),
7.16 (d, J = 8.6 Hz, 1H), 6.99 (d, J = 8.6 Hz, 2H), 6.74 (ddd, J = 15.2, 6.6, 5.3 Hz, 1H), 6.53 (d, J
= 15.4 Hz, 1H), 5.09 (s, 2H), 3.91 (s, 3H), 3.06 (d, J = 5.9 Hz, 2H), 2.18 (s, 6H). 13C NMR (151
MHz, DMSO-d6) δ 164.65, 163.46, 154.22, 152.43, 141.37, 136.29, 132.75, 132.33, 129.48,
128.41, 126.91, 126.86, 126.13, 124.41, 122.22, 121.91, 114.72, 110.48, 68.50, 59.76, 56.01,
45.11. HRMS (ESI); m/z [M+1]+; Calcd. C27H29ClN3O4, 494.1846. Found 494.1863
HS3489 N-[4-[(4-tert-butoxyphenyl)methoxy]-3-chloro-phenyl]-3-[[(E)-4-(dimethylamino)but2-enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MeOH, 9:1)
to give 32 mg of product (70% yield).

1

H NMR (400 MHz, DMSO-d6) δ 10.13 (s, 1H), 9.46 (s,

1H), 8.70 – 8.45 (m, 1H), 7.92 (d, J = 2.5 Hz, 1H), 7.75 (dd, J = 8.6, 2.3 Hz, 1H), 7.66 (dd, J = 9.0,
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2.6 Hz, 1H), 7.39 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 9.1 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 7.01 (d, J
= 8.4 Hz, 2H), 6.74 (dt, J = 15.4, 6.0 Hz, 1H), 6.54 (d, J = 15.4 Hz, 1H), 5.12 (s, 2H), 3.92 (s, 3H),
3.09 (d, J = 6.0 Hz, 2H), 2.20 (s, 6H), 1.30 (s, 9H). 13C NMR (101 MHz, DMSO-d6) δ 164.82,
163.46, 154.89, 152.62, 149.71, 141.15, 133.32, 131.16, 128.64, 126.92, 126.50, 126.31, 124.54,
123.51, 122.23, 121.89, 121.08, 120.04, 114.47, 110.58, 78.06, 70.05, 59.70, 56.06, 45.05, 28.58.
HRMS (ESI); m/z [M+1]+; Calcd. C31H37ClN3O5, 566.2421. Found 566.2443.
IB2006

N-[4-[(4-tert-butylphenyl)methoxy]-3-chloro-phenyl]-3-[[(E)-4-(dimethylamino)but-2-

enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1) to
give 14 mg of product (50% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.11 (s, 1H), 9.43 (s, 1H),
8.60 (d, 1H), 7.92 (d, J = 2.6 Hz, 1H), 7.75 (dd, J = 8.6, 2.3 Hz, 1H), 7.65 (dd, J = 9.0, 2.6 Hz, 1H),
7.41 (q, J = 8.5 Hz, 4H), 7.23 (d, J = 9.1 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 6.74 (dt, J = 15.4, 6.0
Hz, 1H), 6.54 (d, J = 15.4 Hz, 1H), 5.14 (s, 2H), 3.92 (s, 3H), 3.07 (d, J = 5.5 Hz, 2H), 2.19 (s,
6H), 1.28 (s, 9H).

13

C NMR (151 MHz, DMSO-d6) δ 164.81, 163.47, 152.58, 150.40, 149.67,

141.38, 133.67, 133.25, 127.47, 126.93, 126.51, 126.13, 125.22, 124.49, 122.17, 121.90, 121.03,
120.04, 114.30, 110.54, 70.02, 59.75, 56.03, 45.10, 34.30, 31.12. HRMS (ESI); m/z [M+1]+;
Calcd. C31H37ClN3O4, 550.2472. Found 550.2494.

143

IB2024

N-[3-chloro-4-[(4-cyanophenyl)methoxy]phenyl]-3-[[(E)-4-(dimethylamino)but-2-

enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1) to
give 19 mg of product (73% yield). 1H NMR (500 MHz, DMSO-d6) δ 10.12 (s, 1H), 9.43 (s, 1H),
8.60 (s, 1H), 7.95 (s, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.75 (dd, J = 8.6, 2.3 Hz, 1H), 7.69 – 7.58 (m,
3H), 7.21 (d, J = 9.0 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 6.79 – 6.65 (m, 1H), 6.54 (d, J = 15.4 Hz,
1H), 5.31 (s, 2H), 3.92 (s, 3H), 3.06 (d, J = 5.8 Hz, 2H), 2.18 (s, 6H). 13C NMR (126 MHz, DMSOd6) δ 164.85, 163.49, 152.61, 149.19, 142.53, 141.46, 133.63, 132.47, 127.85, 126.94, 126.46,
126.07, 124.50, 122.17, 121.93, 121.12, 120.05, 118.74, 114.43, 110.56, 69.25, 59.76, 56.03,
45.11. HRMS (ESI); m/z [M+1]+; Calcd.C28H28ClN4O4, 519.1799. Found 519.1807.
HS3481

N-[3-chloro-4-[(4-chlorophenyl)methoxy]phenyl]-3-[[(E)-4-(dimethylamino)but-2-

enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1) to
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give 18 mg of product (62% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.11 (s, 1H), 9.42 (s, 1H),
8.59 (s, 1H), 7.93 (d, J = 2.5 Hz, 1H), 7.75 (dd, J = 8.6, 2.3 Hz, 1H), 7.65 (dd, J = 9.0, 2.6 Hz, 1H),
7.56 – 7.42 (m, 4H), 7.22 (d, J = 9.1 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 6.74 (dt, J = 15.4, 6.0 Hz,
1H), 6.53 (d, J = 15.4 Hz, 1H), 5.19 (s, 2H), 3.92 (s, 3H), 3.05 (d, J = 5.5 Hz, 2H), 2.18 (s, 6H).
13

C NMR (101 MHz, DMSO-d6) δ 165.27, 163.93, 153.05, 149.82, 141.94, 136.20, 133.92,

132.94, 129.77, 128.93, 127.38, 126.92, 126.48, 124.93, 122.61, 122.33, 121.57, 120.46, 114.97,
111.00,

69.86,

60.22,

56.48,

45.57.

HRMS

(ESI);

m/z

[M+1]+;

Calcd. C27H28Cl2N3O4, 528.1456. Found 528.1459.
IB2032 N-[4-[(4-carbamoylphenyl)methoxy]-3-chloro-phenyl]-3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1, 3x)
to give 17.4 mg of product (53% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.12 (s, 1H), 9.44 (s,
1H), 8.59 (s, 1H), 8.09 – 7.82 (m, 4H), 7.75 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.54 (d,
J = 7.9 Hz, 2H), 7.38 (s, 1H), 7.20 (dd, J = 20.4, 8.9 Hz, 2H), 6.74 (dt, J = 13.1, 6.1 Hz, 1H), 6.54
(d, J = 15.1 Hz, 1H), 5.26 (s, 2H), 3.92 (s, 3H), 3.07 (d, J = 6.0 Hz, 2H), 2.19 (s, 6H). 13C NMR
(101 MHz, DMSO-d6) δ 167.62, 164.84, 163.48, 152.61, 149.44, 141.35, 139.91, 133.87, 133.46,
127.67, 127.06, 126.93, 126.48, 126.14, 124.52, 122.20, 121.92, 121.13, 120.04, 114.48, 110.56,
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69.72,

59.73,

56.04,

45.09.

HRMS

(ESI);

m/z

[M+1]+;

Calcd.C28H30ClN4O5, 537.19047. Found 537.1018.
IB2018

N-[3-chloro-4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]-3-[[(E)-4-

(dimethylamino)but-2-enoyl]amino]-4-methoxy-benzamide

Followed general amide coupling protocol above from 3-[[(E)-4-(dimethylamino)but-2enoyl]amino]-4-methoxy-benzoic acid. Crude product was purified by PTLC (DCM:MB, 1:1) to
give 18 mg of product (62% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 1H), 9.46 (s, 1H),
8.59 (s, 1H), 7.94 (s, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 7.9 Hz,
2H), 7.42 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 6.74 (dtd, J = 15.5,
6.0, 1.5 Hz, 1H), 6.54 (d, J = 15.3 Hz, 1H), 5.23 (s, 2H), 3.92 (s, 3H), 3.06 (d, J = 5.8 Hz, 2H),
2.18 (s, 6H). 13C NMR (151 MHz, DMSO-d6) δ 164.83, 163.48, 152.61, 149.40, 147.91, 141.40,
136.25, 133.50, 129.38, 126.93, 126.47, 126.11, 124.50, 122.18, 121.91, 121.13, 121.10, 120.09
(q, J = 256.2 Hz), 120.05, 114.45, 110.56, 69.30, 59.75, 56.04, 45.11. HRMS (ESI); m/z [M+1]+;
Calcd. C28H28ClF3N3O5, 578.1669. Found 578.1681.
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Synthesis of HI4601-Based PROTACs:
Representative Synthesis of Series 1 PROTACs:
2S,4R)-4-hydroxy-N-[[2-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethoxy]-4-(4-methylthiazol-5yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide

A solution of (2S,4R)-4-hydroxy-N-[[2-[2-[2-(2-iodoethoxy)ethoxy]ethoxy]-4-(4-methylthiazol5-yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide (synthesized according to the procedure below for the one peg shorter version) (23.0
mg, 0.0291 mmol) in methanamine (30.0 %, 1.00 mL, 7.30 mmol) was stirred for 4h at room
temperature. The reaction mixture was evaporated in vacuum. Crude product was purified by
PTLC (DCM:MB, 4:6) to give 17 mg of product (86% yield). 1H NMR (400 MHz, DMSO-d6) δ
8.96 (s, 1H), 8.37 (t, J = 5.6 Hz, 2H), 7.68 (d, J = 7.6 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.51 – 7.41
(m, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.02 (s, 1H), 6.98 (d, J = 7.9 Hz, 1H), 4.68 (d, J = 10.8 Hz, 1H),
4.47 (dd, J = 18.2 Hz, 3H), 4.39 – 4.08 (m, 5H), 3.86 – 3.41 (m, 11H), 2.63 (t, J = 5.4 Hz, 2H),
2.44 (s, 3H), 2.35 – 2.26 (m, 1H), 2.27 (s, 3H), 2.05 – 1.95 (m, 1H), 1.94 – 1.73 (m, 1H), 0.93 (d,
J = 6.3 Hz, 3H), 0.70 (d, J = 6.4 Hz, 3H).

13

C NMR (151 MHz, DMSO-d6) δ 171.59, 168.11,

167.50, 155.88, 151.51, 147.95, 142.21, 131.61, 131.38, 131.27, 131.00, 127.93, 127.71, 127.18,
123.64, 123.03, 121.10, 112.17, 70.05, 69.71, 69.01, 68.62, 67.94, 58.72, 57.79, 55.44, 54.93,
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50.24, 46.82, 38.11, 37.09, 35.47, 28.40, 18.89, 18.63, 16.04. LRMS (ESI); m/z [M+1]+;
Calcd. C36H48N5O7S, 694.3. Found 694.4.
2S,4R)-4-hydroxy-N-[[2-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethoxy]-4-(4-methylthiazol-5yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide

To a solution of (2S,4R)-4-hydroxy-N-[[2-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethoxy]-4-(3methyl-2-thienyl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2yl)butanoyl]pyrrolidine-2-carboxamide (19.8 mg, 0.0286 mmol) in NMP (0.500 mL) was
added DIEA (0.00538 mL, 0.0314 mmol) and 3-[[(E)-4-bromobut-2-enoyl]amino]-N-(3-chloro4-fluoro-phenyl)-4-methoxy-benzamide (15.1 mg, 0.0343 mmol) at room temperature. The
resulting mixture was stirred at room temperature for 24 hours (TLC showed > 80% product
formation, Hex:EtOAc, 7:3 and DCM:MB, 1:1). The reaction mixture was partitioned between
ethyl acetate (15 ml) and water (10 ml), the organic layer was washed with water (5x10 ml), dried
over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude residue
which was purified by PTLC (DCM:MB, 4:6) to afford 14 mg of product (47% yield). 1H NMR
(400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.41 (s, 1H), 8.94 (s, 1H), 8.57 (s, 1H), 8.35 (s, 1H), 8.14
– 7.97 (m, 1H), 7.89 – 7.41 (m, 6H), 7.40 – 7.24 (m, 3H), 7.14 (d, J = 8.6 Hz, 1H), 7.01 (s, 1H),
6.97 (d, J = 8.0 Hz, 1H), 6.71 (dt, J = 13.7, 6.0 Hz, 1H), 6.49 (d, J = 15.2 Hz, 1H), 5.08 (s, 1H),
4.68 (d, J = 10.9 Hz, 1H), 4.57 – 4.01 (m, 8H), 3.87 (s, 3H), 3.82 – 3.42 (m, 7H), 3.13 (d, J = 4.8
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Hz, 4H), 2.49 (s, 2H), 2.43 (s, 3H), 2.34 – 2.22 (m, 1H), 2.17 (s, 3H), 2.02 (dd, J = 13.2, 10.4 Hz,
1H), 1.90 (dd, J = 8.6, 3.8 Hz, 1H), 0.93 (d, J = 5.9 Hz, 3H), 0.70 (d, J = 6.2 Hz, 3H). 13C NMR
(151 MHz, DMSO-d6) δ 172.00, 168.54, 167.92, 165.57, 163.94, 156.30, 153.63 (d, J = 242.8
Hz), 153.18, 151.88, 148.36, 142.62, 142.13, 137.04 (d, J = 2.9 Hz), 132.01, 131.80, 131.69,
131.41, 128.33, 128.11, 127.60, 127.43, 126.42, 125.05, 124.04, 123.44, 122.62, 122.09, 121.51,
120.97 (d, J = 6.8 Hz), 119.35 (d, J = 18.2 Hz), 117.23, 117.09, 112.59, 111.02, 70.50, 70.19,
69.44, 69.06, 68.36, 59.14, 58.69, 58.21, 56.53, 56.49, 55.86, 49.04, 47.24, 42.94, 38.54, 37.52,
28.82,

19.31,

19.05,

16.45.

LRMS

(ESI);

m/z

[M+1]+;

Calcd.C54H62ClFN7O10S, 1054.40. Found 1054.41.
Representative Synthesis of Series 2 PROTACs:
3-amino-N-(3-chloro-4-fluorophenyl)-4-hydroxybenzamide
OH
Cl
F

H
N

NH2
O

ref. WO 2018/119441: To a round bottom flask charged with a magnetic stir bar was added a
solution of N-(3-chloro-4-fluoro-phenyl)-4-hydroxy-3-nitro-benzamide (100mg, .32mmol) in
THF (5mL). Raney Ni (50mg) was added under inert atmosphere, and then argon was swapped
for hydrogen balloon. Stir at r.t. until complete by TLC, then filter carefully through Celite to be
sure to remove all of the Ni, and use directly in the next step without further purification (85mg,
94%) isolated as a brown solid. LCMS (ESI) [M+1]: 281
N-(3-chloro-4-fluoro-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-hydroxybenzamide
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To

a

solution

of

3-amino-N-(3-chloro-4-fluoro-phenyl)-4-hydroxy-benzamide

(200mg,

.712mmol) in anhydrous DMF (3mL) was added EDCI-HCl (150mg, 1.1eq, .784mmol), HOBt
(120mg, 1.1eq, .784mmol), and (E)-4-(dimethylamino)but-2-enoic acid (101mg, 1.1eq,
.784mmol). The solution was stirred at r.t. overnight then concentrated down under vacuum. The
residue was partitioned between EtOAc and water and the organic layer was washed 5x with water
and then 1:1 bicarb:water and finally 1:1 brine:water. The organic layer was dried over Na2SO4
and then purified by PTLC with DCM:MB (1:3) to furnish N-(3-chloro-4-fluoro-phenyl)-3-[[(E)4-(dimethylamino)but-2-enoyl]amino]-4-hydroxy-benzamide (250mg, 89%). 1H NMR (600 MHz,
DMSO-d6) δ 10.19 (s, 1H), 9.54 (s, 1H), 8.42 (d, J = 2.2 Hz, 1H), 8.03 (dd, J = 6.9, 2.6 Hz, 1H),
7.68 (ddd, J = 9.1, 4.3, 2.6 Hz, 1H), 7.61 (dd, J = 8.5, 2.3 Hz, 1H), 7.36 (t, J = 9.1 Hz, 1H), 6.95
(d, J = 8.4 Hz, 1H), 6.72 (dt, J = 15.4, 6.1 Hz, 1H), 6.50 (d, J = 15.3 Hz, 1H), 3.06 (dd, J = 6.0,
1.6 Hz, 2H), 2.17 (s, 6H). 13C NMR (151 MHz, DMSO-d6)) δ 165.69, 164.18, 154.37, 152.76,
152.17, 141.80, 137.17, 137.15, 126.45, 125.38, 125.32, 123.26, 122.00, 120.90, 120.86, 119.39,
119.27, 117.20, 117.06, 117.06, 115.56, 60.12, 45.46. HRMS (ESI); m/z [M+1]+;
Calcd. C19H20ClFN3O3, 392.1177. Found 392.1186.
tert-butyl

3-[2-[2-[4-[(3-chloro-4-fluoro-phenyl)carbamoyl]-2-[[(E)-4-(dimethylamino)but-2-

enoyl]amino]phenoxy]ethoxy]ethoxy]propanoate
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To a solution of N-(3-chloro-4-fluoro-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4hydroxy-benzamide (20mg, .051mmol) in anhydrous DMF (1mL) was added tert-butyl 3-[2-(2bromoethoxy)ethoxy]propanoate (16.7mg, 1.1eq, .056mmol) and Cs2CO3 (67mg, 4eq). The
resulting solution was stirred at 50oC for 24 hours, then concentrated under vacuum and purified
by PTLC using 1:10 DCM/MeOH to furnish tert-butyl 3-[2-[2-[4-[(3-chloro-4-fluorophenyl)carbamoyl]-2-[[(E)-4-(dimethylamino)but-2enoyl]amino]phenoxy]ethoxy]ethoxy]propanoate (18.3mg, 59%). This material was deprotected
according to the TFA-mediated deprotection conditions above and used in the next step without
further purification. 1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.21 (s, 1H), 8.58 (s, 1H),
8.03 (dd, J = 6.9, 2.6 Hz, 1H), 7.69 (ddd, J = 10.2, 6.6, 2.5 Hz, 2H), 7.37 (t, J = 9.1 Hz, 1H), 7.19
(d, J = 8.7 Hz, 1H), 6.72 (dt, J = 15.4, 6.0 Hz, 1H), 6.47 (d, J = 15.4 Hz, 1H), 4.22 (t, J = 4.7 Hz,
2H), 3.80 (t, J = 4.7 Hz, 2H), 3.61 – 3.53 (m, 5H), 3.48 (dd, J = 5.8, 3.6 Hz, 2H), 3.05 (d, J = 6.0
Hz, 2H), 2.86 (s, 1H), 2.70 (s, 1H), 2.37 (t, J = 6.2 Hz, 2H), 2.16 (s, 6H), 1.34 (s, 11H). 13C NMR
(101 MHz, DMSO-d6) δ 170.82, 165.53, 163.83, 162.73, 154.84, 152.42, 141.96, 137.06, 137.03,
127.77, 126.90, 126.48, 124.97, 122.67, 122.08, 121.00, 120.93, 119.44, 119.26, 117.28, 117.06,
112.50, 80.15, 70.32, 70.12, 69.08, 69.05, 66.65, 60.13, 45.52, 36.23, 31.20, 28.16. HRMS (ESI);
m/z [M+1]+; Calcd. C30H40ClFN3O7, 608.2539. Found 608.2553.
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N-(3-chloro-4-fluoro-phenyl)-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-4-[2-[2-[3-[2-[2(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyethylamino]-3-oxopropoxy]ethoxy]ethoxy]benzamide

This material was prepared following the standard HATU-amide coupling protocol above.
Material was purified by HPLC. 1H NMR (600 MHz, DMSO-d6) δ 11.07 (s, 1H), 10.26 (d, J = 4.3
Hz, 1H), 9.22 (s, 1H), 8.57 (s, 1H), 8.33 (s, 1H), 8.12 – 7.98 (m, 2H), 7.76 (dd, J = 8.5, 7.2 Hz,
1H), 7.69 (tq, J = 7.1, 2.3 Hz, 2H), 7.50 (d, J = 8.5 Hz, 1H), 7.45 – 7.28 (m, 2H), 7.18 (d, J = 8.7
Hz, 1H), 6.72 (dt, J = 15.5, 6.0 Hz, 1H), 6.47 (d, J = 15.4 Hz, 1H), 5.05 (dd, J = 12.9, 5.5 Hz, 1H),
4.26 – 4.15 (m, 4H), 3.78 (dd, J = 5.7, 3.8 Hz, 2H), 3.61 – 3.52 (m, 5H), 3.47 (dd, J = 5.8, 3.7 Hz,
2H), 3.42 (q, J = 5.8 Hz, 3H), 3.02 (dd, J = 6.1, 1.6 Hz, 2H), 2.85 (ddd, J = 17.0, 13.9, 5.5 Hz,
1H), 2.61 – 2.49 (m, 2H), 2.31 (t, J = 6.5 Hz, 2H), 2.14 (s, 6H), 1.99 (ddq, J = 10.6, 5.6, 3.1, 2.7
Hz, 1H).

13

C NMR (151 MHz, DMSO-d6) δ 173.21, 171.03, 170.36, 167.21, 165.67, 165.53,

163.89, 156.12, 154.44, 152.83, 142.19, 137.45, 137.05, 137.03, 133.70, 127.74, 126.89, 126.34,
125.00, 122.09, 120.99, 120.95, 120.51, 119.41, 119.29, 117.24, 117.10, 116.95, 115.98, 112.51,
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70.28, 70.02, 69.08, 69.02, 67.89, 67.13, 60.18, 49.18, 45.58, 38.41, 36.40, 31.38, 22.45. HRMS
(ESI); m/z [M+1]+; Calcd. C41H46ClFN6O11, 851.28194. Found 851.2823.
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(2S,4R)-1-[(2S)-2-[3-[2-[2-[4-[(3-chloro-4-fluoro-phenyl)carbamoyl]-2-[[(E)-4(dimethylamino)but-2-enoyl]amino]phenoxy]ethoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
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This material was prepared following the standard HATU-amide coupling protocol above.
Material was purified by HPLC. 1H NMR (600 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.22 (s, 1H),
8.95 (s, 1H), 8.61 – 8.47 (m, 2H), 8.33 (s, 1H), 8.03 (dd, J = 6.9, 2.7 Hz, 1H), 7.89 (d, J = 9.4 Hz,
1H), 7.70 (ddd, J = 9.1, 7.8, 3.2 Hz, 2H), 7.41 – 7.32 (m, 5H), 7.19 (d, J = 8.7 Hz, 1H), 6.72 (dt, J
= 15.4, 6.0 Hz, 1H), 6.47 (d, J = 15.4 Hz, 1H), 4.52 (d, J = 9.4 Hz, 1H), 4.41 – 4.36 (m, 2H), 4.32
(dq, J = 6.5, 3.6, 3.0 Hz, 1H), 4.24 – 4.17 (m, 3H), 3.79 (dd, J = 5.7, 3.9 Hz, 2H), 3.67 – 3.63 (m,
1H), 3.62 – 3.53 (m, 6H), 3.48 (qt, J = 10.6, 4.7 Hz, 3H), 3.03 (dd, J = 6.1, 1.6 Hz, 2H), 2.52 –
2.48 (m, 1H), 2.41 (s, 3H), 2.14 (s, 6H), 2.05 – 1.95 (m, 1H), 1.87 (ddd, J = 13.0, 8.6, 4.6 Hz, 1H),
0.90 (s, 9H). 13C NMR (151 MHz, DMSO-d6) δ 172.34, 170.34, 169.96, 165.54, 163.89, 154.44,
152.83, 151.88, 148.15, 142.18, 139.94, 137.06, 137.04, 131.59, 130.08, 129.08, 127.86, 127.76,
126.90, 126.36, 122.73, 122.10, 121.00, 120.95, 119.41, 119.29, 117.24, 117.10, 112.52, 70.33,
69.95, 69.29, 69.11, 69.02, 67.39, 60.19, 59.14, 56.80, 56.72, 45.60, 42.08, 38.40, 36.07, 35.80,
26.76, 16.38. HRMS (ESI); m/z [M+1]+; Calcd. C48H60ClFN7O9S, 964.3846. Found 964.3856.
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Synthesis of current lead PROTAC RH-VHL-Based IN1420:
(2S,4R)-4-hydroxy-N-(2-(2-(2-iodoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-3methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide

To a mixture of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-3methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide

(60.0

mg,

0.109

mmol) and 1-iodo-2-(2-iodoethoxy)ethane (405 mg, 1.24 mmol) in DMF (2 mL) was added
Cs2CO3 (71.3 mg, 0.219 mmol). After stirring at room temperature for 12 hrs (overnight), the
reaction mixture was diluted with EtOAc (10 mL) and washed with water (5x10 mL), organic
phase was dried (Na2SO4, and evaporated under vacuum. Crude product was purified by flash
column chromatography (SiO2-12g, gradient Hex:EtOAc, 2:8 to a 100% EtOAc in 15 min) to
give 80 mg of product (about 60% pure). Product was purified again by PTLC (DCM:MB, 1:1) to
give 46 mg of pure product. 1H NMR (600 MHz, DMSO-d6) δ 8.99 (s, 1H), 8.37 (t, J = 5.6 Hz,
1H), 7.71 (d, J = 7.4 Hz, 1H), 7.66 – 7.57 (m, 2H), 7.50 (t, J = 7.0 Hz, 1H), 7.35 (d, J = 7.7 Hz,
1H), 7.06 (s, 1H), 7.02 (d, J = 7.8 Hz, 1H), 5.10 (d, J = 3.7 Hz, 1H), 4.72 (d, J = 10.8 Hz, 1H), 4.51
(dd, 2H), 4.41 (t, J = 7.9 Hz, 1H), 4.38 – 4.24 (m, 3H), 4.24 – 4.16 (m, 2H), 3.89 – 3.81 (m, 2H),
3.81 – 3.65 (m, 4H), 3.37 (t, J = 6.3 Hz, 2H), 2.48 (s, 3H), 2.37 – 2.26 (m, 1H), 2.09 – 2.02 (m,
1H), 2.00 – 1.83 (m, 1H), 0.97 (d, J = 6.3 Hz, 3H), 0.74 (d, J = 6.5 Hz, 3H).

13

C NMR (151 MHz,

DMSO-d6) δ 171.56, 168.10, 167.48, 155.84, 151.49, 147.95, 142.21, 131.59, 131.38, 131.26,
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131.00, 127.91, 127.73, 127.18, 123.63, 123.02, 121.11, 112.15, 71.09, 68.63, 68.49, 67.88, 58.71,
57.78, 55.43, 46.82, 38.11, 37.15, 28.40, 18.91, 18.63, 16.06, 5.52. LRMS (ESI); m/z [M+1]+;
Calcd. C33H40IN4O6S, 747.17. Found 747.13.
(2S,4R)-4-hydroxy-N-[[2-[2-[2-(methylamino)ethoxy]ethoxy]-4-(4-methylthiazol-5yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide

A

solution

of (2S,4R)-4-hydroxy-N-[[2-[2-(2-iodoethoxy)ethoxy]-4-(4-methylthiazol-5-

yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide (38.0 mg, 0.0509 mmol) in methanamine (30.0 % in THF, 1.00 mL, 7.30 mmol) was
stirred for 4h at room temperature. The reaction mixture was evaporated in vacuum. Crude product
was purified by PTLC (MB 100%) to give 30 mg of product (90% yield). 1H NMR (400 MHz,
DMSO-d6) δ 8.97 (s, 1H), 8.37 (t, J = 4.9 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.63 – 7.55 (m, 2H),
7.49 – 7.40 (m, 1H), 7.31 (d, J = 7.4 Hz, 1H), 7.09 – 6.84 (m, 2H), 4.68 (d, J = 10.6 Hz, 1H), 4.47
(dd, J = 20.3, 19.1 Hz, 2H), 4.39 – 4.07 (m, 6H), 3.87 – 3.54 (m, 6H), 2.95 – 2.81 (m, 2H), 2.44
(s, 3H), 2.42 (s, 3H), 2.36 – 2.20 (m, 1H), 2.08 – 1.96 (m, 1H), 1.93 – 1.78 (m, 1H), 0.93 (d, J =
5.6 Hz, 3H), 0.71 (d, J = 5.8 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 172.02, 168.54, 167.91,
156.24, 151.96, 148.38, 142.62, 132.03, 131.80, 131.66, 131.44, 128.36, 128.13, 127.55, 124.06,
123.46, 121.55, 112.46, 69.38, 69.04, 68.17, 67.95, 59.14, 58.21, 55.88, 49.46, 47.23, 38.55, 37.51,
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34.58,

28.81,

19.31,

19.06,

16.47.

LRMS

(ESI);

m/z

[M+1]+;

Calcd. C34H44N5O6S, 650.30. Found 650.29.
IN1420

To a solution of 3-[[(E)-4-bromobut-2-enoyl]amino]-N-(3-chloro-4-fluoro-phenyl)-4-methoxybenzamide (15.0 mg, 0.0339 mmol) in NMP (0.500 mL) was added DIEA (0.00638 mL, 0.0372
mmol) and(2S,4R)-4-hydroxy-N-[[2-[2-[2-(methylamino)ethoxy]ethoxy]-4-(4-methylthiazol-5yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide (22.0 mg, 0.0339 mmol) at room temperature. The resulting mixture was stirred at
room temperature for 24 hours (TLC showed > 80% product formation, Hex:EtOAc, 7:3 and
DCM:MB, 1:1). The reaction mixture was partitioned between ethyl acetate (15 ml) and water (10
ml), the organic layer was washed with water (5x10 ml), dried over anhydrous sodium sulfate, and
concentrated under reduced pressure to give a crude residue which was purified by PTLC to afford
15 mg of IN1420 (44% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.41 (s, 1H), 8.95
(s, 1H), 8.58 (s, 1H), 8.35 (bs, 2H), 8.02 (d, J = 6.8 Hz, 1H), 7.80 – 7.62 (m, 3H), 7.62 – 7.52 (m,
2H), 7.49 – 7.41 (m, 1H), 7.36 (t, J = 9.0 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 8.5 Hz,
1H), 7.02 (s, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.72 (dt, J = 12.0, 5.2 Hz, 1H), 6.50 (d, J = 15.2 Hz,
1H), 5.06 (s, 1H), 4.67 (d, J = 10.9 Hz, 1H), 4.46 (dd, 2H), 4.39 – 4.08 (m, 6H), 3.87 (s, 3H), 3.81
– 3.50 (m, 6H), 3.17 (bs, 2H), 2.56 (bs, 2H), 2.43 (s, 3H), 2.33 – 2.24 (m, 1H), 2.20 (s, 3H), 2.06
– 1.96 (m, 1H), 1.93 – 1.83 (m, 1H), 0.92 (d, J = 5.7 Hz, 3H), 0.69 (d, J = 5.9 Hz, 3H). 13C NMR
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(126 MHz, DMSO-d6) δ 171.99, 168.54, 167.90, 165.56, 163.94, 156.30, 153.63 (d, J = 242.8
Hz), 153.17, 151.88, 148.36, 142.61, 142.23, 137.04, 131.99, 131.79, 131.68, 131.41, 128.32,
128.06, 127.60, 127.45, 126.62, 126.43, 125.04, 124.02, 123.43, 122.61, 122.10, 121.51, 120.97
(d, J = 6.6 Hz), 119.35 (d, J = 18.4 Hz), 117.15 (d, J = 21.6 Hz), 112.62, 111.02, 69.35, 69.05,
68.31, 59.15, 58.70, 58.21, 56.57, 56.48, 55.85, 55.34, 47.22, 42.94, 38.53, 37.51, 28.81, 19.30,
19.03, 16.45. HRMS (ESI); m/z [M+1]+; Calcd. C52H58ClFN7O9S, 1010.3689. Found 1010.3698.
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IN1420 Epimeric Control (non-VHL Binding)

To a solution of 3-[[(E)-4-bromobut-2-enoyl]amino]-N-(3-chloro-4-fluoro-phenyl)-4-methoxybenzamide (15.0 mg, 0.0339 mmol) in NMP (0.500 mL) was added DIEA (0.00638 mL, 0.0372
mmol) and(2S,4S)-4-hydroxy-N-[[2-[2-[2-(methylamino)ethoxy]ethoxy]-4-(4-methylthiazol-5yl)phenyl]methyl]-1-[(2S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl]pyrrolidine-2carboxamide (22.0 mg, 0.0339 mmol) at room temperature. The resulting mixture was stirred at
room temperature for 24 hours (TLC showed > 80% product formation, Hex:EtOAc, 7:3 and
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DCM:MB, 1:1). The reaction mixture was partitioned between ethyl acetate (15 ml) and water (10
ml), the organic layer was washed with water (5x10 ml), dried over anhydrous sodium sulfate, and
concentrated under reduced pressure to give a crude residue which was purified by PTLC to afford
9.7 mg of IN1420 Epimer (28% yield). 1H NMR (600 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.40 (s,
1H), 8.95 (s, 1H), 8.64 – 8.53 (m, 1H), 8.40 (t, J = 6.0 Hz, 1H), 8.03 (dd, J = 6.9, 2.5 Hz, 1H), 7.73
(dd, J = 8.6, 2.3 Hz, 1H), 7.71 – 7.65 (m, 2H), 7.57 (q, J = 4.6, 3.2 Hz, 2H), 7.46 (td, J = 6.4, 5.0,
3.3 Hz, 1H), 7.37 (t, J = 9.1 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.03 (d, J
= 1.6 Hz, 1H), 6.97 (dd, J = 7.8, 1.6 Hz, 1H), 6.72 (dt, J = 15.5, 5.9 Hz, 1H), 6.50 (d, J = 15.4 Hz,
1H), 4.70 (d, J = 10.8 Hz, 1H), 4.55 – 4.37 (m, 2H), 4.35 – 4.27 (m, 2H), 4.23 (dd, J = 16.3, 5.9
Hz, 1H), 4.17 (q, J = 4.2 Hz, 3H), 3.92 (dd, J = 10.4, 5.7 Hz, 1H), 3.88 (s, 3H), 3.77 (t, J = 4.5 Hz,
2H), 3.61 (t, J = 6.0 Hz, 2H), 3.50 (dd, J = 10.3, 5.0 Hz, 1H), 3.16 (d, J = 6.1 Hz, 2H), 2.54 (t, J =
5.9 Hz, 2H), 2.33 – 2.24 (m, 2H), 2.19 (s, 3H), 1.73 (dt, J = 12.0, 5.6 Hz, 1H), 0.94 (d, J = 6.5 Hz,
3H), 0.72 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 172.54, 168.71, 168.02, 165.57,
163.97, 156.33, 154.43, 153.17, 152.82, 151.92, 148.38, 142.68, 142.29, 137.07, 137.05, 132.04,
131.74, 131.68, 131.49, 128.34, 128.16, 127.45, 127.39, 126.62, 126.38, 125.03, 124.04, 123.43,
122.61, 122.09, 121.49, 120.99, 120.94, 119.40, 119.28, 117.24, 117.10, 112.63, 111.02, 69.52,
69.34, 69.30, 68.31, 59.18, 58.78, 58.14, 56.62, 56.49, 55.44, 47.17, 43.01, 37.75, 37.60, 28.64,
19.30,

19.09,

16.46.

HRMS

(ESI);

1010.3689. Found 1010.3698
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m/z

[M+1]+;

Calcd. C52H58ClFN7O9S,
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Biological Methods
Brachyury preparation and purification (by Adrian Bebenek):
TBXTA-c006 was expressed in E. coli Rosetta™ 2 DE3 Competent bacterial cells. Competent
cells were transformed with 100 ng of plasmid DNA encoding TBXTA-c005 and transformed cells
were plated on kanamycin containing LB plates. The following day, cells were inoculated into a
100 mL LB starter culture and incubated at 37° until OD600 reached 0.6. The culture was spun
down and pellet resuspended in 2 L of TB media under selection of kanamycin (selection for
TBXT-c005) and chloramphenicol (selection for Rosetta 2 pRARE-2 plasmid). Culture was grown
at 37° in a shaker until OD600 reached 1.2. The culture was induced with 0.3 mM IPTG and
incubated overnight at 18° in a shaker. Cells were subject to lysis in buffer A (50mM HEPES pH
7.5, 500mM NaCl, 10mM imidazole, 5% glycerol, 1mM β-ME) by exposing cells to 10 min
of sonication using 50% Dutt Cycle and 35% output control on the Branson Sonifier 450. Clarified
lysate was applied to 5 mL Ni column on the AktaPure and eluted over 15 column volumes using
buffer B (50mM HEPES pH 7.5, 500mM NaCl, 300mM imidazole, 5% glycerol, 1mM β-ME).
Fractions were resolved by SDS-PAGE. Pooled fractions were subject to dialysis against 4 L
Dialysis Buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, and 1 mM β-ME) at 4°
overnight. Protein was aliquoted and flash frozen at 50 µM by liquid nitrogen. For crystallization,
c006 was further purified by size exclusion chromatography using a Superdex 75 10/300 GL
column. Protein was eluted into crystallization buffer (25mM HEPES, 300mM NaCl, 1mM
TCEP). TBXTA-c006 was a gift from Opher Gileadi (Addgene plasmid # 139755).
Mass spec binding assay: To determine the ability of the synthesized afatanib analogs for
Brachyury the isolated protein was dissolved in 50mM HEPES, 500mM NaCl, 1mM BME and
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diluted 10x to a final concentration of 5uM in a solution of 50uM ligand in ddH2O. This solution
was incubated overnight at 37oC before being submitted for target engagement analysis by MS.
Kinase assay: this assay was performed adhering to the provided protocols for Carna Biosciences
Product code 08-115
Mass Spec binding assay: Compounds (10 uM) were incubated with purified T (1uM) for 2 hours
at 37oC then the solutions tested by MS on our in-house LCMS (ThermoFisher).
PROTAC T-Degradation Assay: UM-CHOR-1 cells were plated in 12 well plates at a density of
100k/well and grown to ~80% confluence overnight. The cells were then washed with sterile PBS
before being treated with PROTAC in serum-free media for 24 hours. The PROTAC containing
media was removed and the cells washed with sterile cold PBS. The cells were then lysed using a
RIPA buffer with added commercial protease and phosphatase inhibitor cocktail (Roche). The
lysates were analyzed for protein content by BCA and an equal amount of each condition was
loaded on SDS-PAGE gel. After electrophoresis the gel was transferred to PVDF membrane at
76V for 2 hours at 4oC. The transferred blots were blocked with 5% OmniBlock in TBST for 1
hour at r.t., then probed with Brachyury antibody (CST #81694) overnight at 4oC.
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Chapter 5: Towards the Development of Phosphatase Recruiting Chimeras (PhosTACs)
5.1 Background Rationale for PhosTAC Strategy and Previous Work
Since PROTACs demonstrated the ability to use small molecules to influence cell biology through
proximity-driven effects, great interest has been directed towards applying this methodology to
co-opt other important cellular systems. For example, acute control of substrate phosphorylation
would provide huge therapeutic benefit if we could affect a desired response in the cell. The
delicately balanced phospho-proteome plays a crucial rule in pathogenesis of many serious
diseases.1 Kinases and phosphatases are the enzymes that phosphorylate and dephosphorylate
residues on phosphoproteins to activate or deactivate them. PP1 and PP2a, the focus of this project,
are the two phosphatases in the human proteome that act on the most substrates.2
Pioneering efforts towards generating bifunctional molecules that can specifically recruit these
enzymes to induce phosphorylation or dephosphorylation of a substrate phosphoprotein have been
disclosed in the past few years. Phosphorylation inducing chimeras (PHICS) were first disclosed
in a joint publication by the Schreiber and Choudhary groups in 2020.3 They developed small
bifunctional molecule PHICS recruiting the kinases AMPK and PKC to phosphorylate target
substrates. JQ-1 was the substrate ligand targeting BRD4. Allosteric small molecule ligands of
AMPK and PKC were modified with a linker to allow the synthesis of the PHICS. These PHICS
induced phosphorylation of BRD4, a substrate that AMPK and PKC normally do not
phosphorylate. They also show that the induced phosphorylation is signalling competent because
downstream BTK is also phosphorylated as a result of PHIC-mediated BRD4 phosphorylation.
This demonstrates that with enzymes as active as kinases and phosphatases a competent ternary
complex might not be required, mere proximity may be sufficient to induce activity. Moreover we
can hijack these systems and bias them towards acting on substrates they would not normally
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affect. This publication helped inform a working “cloud effect” theory during the development of
our PhosTACs, in other words we expected that we could induce dephosphorylation of a substrate
by recruiting an active phosphatase “cloud” to its vicinity even if a cooperative ternary complex
cannot be formed.
A research group led by Steven Staben at Genentech published on the first bifunctional molecules
that recruit the human PP1 phosphatase to induce dephosphorylation of a phosphosubstrate.4 These
molecules were based on the PP1 activator peptides designed by the Köhn lab.X These peptides
bind to the major activating groove of PP1 known as the RVxF motif. The first iteration of these
molecules incorporated the full 18 amino acid activating peptides linked to an allosteric AKT
inhibitor. A second iteration determined the minimum binding requirement for PP1 to be the RVSF
motif alone. The data presented for the second class of compounds remains dubious to us
considering the lack of strong controls and the negative results we observed using similar but much
stronger PP1-binding heterobifunctional molecules (section 5.2.1). This publication also came
from an industry lab, so we do not know the full details of why the project was likely suspended
and submitted to the general literature without intellectual property protection. Nonetheless, this
publication provided evidence that recruitment of a phosphatase was a viable strategy. Another
publication from this year reported on the generation of large bifunctional peptidic constructs that
recruit PP2a to dephosphorylation pathogenic tau, which the authors name Dephosphorylation
Targeting Chimeras (DEPTACs).5 We set out to improve on these strategies for recruiting
phosphatases by generating completely small-molecule and drug-like heterobifunctional small
molecules capable of recruiting an active phosphatase to a desired substrate protein and inducing
its dephosphorylation.
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5.2 Rational Design and Synthesis of PhosTACs Targeting PP1 and PP2a
5.2.1 Design of PP1-targeting PhosTACs
Phosphatases have long been considered undruggable because they feature intrinsically disordered
pockets and shallow, indistinct binding clefts.6 They are also naturally promiscuous, cellular
regulation is achieved by diverse regulatory and scaffolding subunits. Furthermore, the substrate
of phosphatases is charged, which makes creating good drug mimics difficult because charged
species suffer from low bioavailability.7 To compound on these challenges, we need to avoid
deleterious uncontrolled phosphatase activation. Therefore, designing bifunctional molecules that
enable spatiotemporal control of phosphatase activity is a daunting challenge.
Halda, a new biotechnology company recently founded by Craig, had begun efforts towards
developing PhosTAC technology. When I joined Craig’s lab I picked up where Halda left off on
the development of PhosTACs targeting PP1. Halda’s efforts were largely focused on smallmolecule PP1 ligand discovery. Previously disclosed binding peptides were large and unwieldy,
so Halda carried out iterative SAR to generate a small non-canonical tetrapeptide ligand that bound
the well-characterized RVxF motif

8,9,10,11

of PP1 with 500 nM affinity by fluorescence

polarization (FP). Towards proof-of-principle, Halda generated PhosTACs that included this
ligand linked to a chloroalkane tag that would covalently react with the HaloTag moiety in an
engineering HaloTag-substrate cell line and recruit PP1. However, they did not observe any
positive results with these compounds. I sought to improve the affinity of the tetrapeptide by
continued SAR. To this end I identified additional potential interactions along the binding interface
and determined that extending the tetrapeptide into a pentapeptide might significantly increase
affinity. I used solid phase peptide synthesis (SPPS) to synthesize 6 novel peptides combining
these insights with those made by Halda during their SAR campaign. I found that several of my
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pentapeptide PP1 ligands bound with sub 100 nM affinity, demonstrating a significant
improvement.

Figure 5.1: Pentapeptide PP1 ligands with Ki measured by FP (FP by David Puleo at Halda)

5.2.2 Synthesis of PP1-targeting PhosTACs.
The best binders were pentapeptides that included a m-Cl phenylalanine residue at the C-terminus
and a diaminobutyric acid (DAB) residue near the N-terminus. I used SPPS to append a
chloroalkane-tagged linker to these peptides at either the N or C-terminus to generate a small
library of tight binding PP1 PhosTACs.
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Figure 5.2: Small Library of prepared PP1-Haloalkane PhosTACs

These PhosTACs were confirmed to maintain strong affinity for PP1 by FP assay carried out by
Chris Forbes at Halda. For this assay PP1 was preincubated with TAMRA-labeled PNUTS, and
then the PhosTACs were titrated into the solution. After incubation for 2 hours, the plate was read
using a plate reader and the resulting parallel and perpendicular polarization data was analyzed
according to the protocol outlined in [1] Renxiao Wang, Zaneta Nikolovska-Coleska, Xueliang
Fang and Shaomeng Wang, "From IC50 to Ki: A General Mathematical Solution for FluorescenceBased Competitive Binding Assays", (to be submitted). This data was used to generate binding
curves for the PhosTAC compounds:
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Figure 5.3: PP1 PhosTACs retain strong PP1 affinity by FP

With these tight binding PP1-Haloalkane PhosTACs in hand I moved on to testing them in a range
of HaloTag-Substrate cell lines we had generated in the lab (section 5.3.1).
5.2.3 Design of PP2a-targeting PhosTACs
I did not want to limit myself to targeting PP1 with PhosTACs, especially considering the limited
success of Halda’s efforts. Therefore, I decided to design and synthesize another class of
PhosTACs to recruit the phosphatase PP2a to a substrate protein for dephosphorylation. At the
time I was thinking about the design of these PhosTACs, two papers disclosing novel small
molecule allosteric PP2a activators were published.12,13 PP2a activity is regulated by a variety of
scaffolding subunits in the cell.14 The authors disclosed small molecule activators of protein
phosphatase 2a (SMAPs) which were proposed to drive dephosphorylation of pathogenic
substrates by biased stabilization of specific PP2a-scaffolding complexes. In the case of SMAP
the proposed mechanism was through stabilization of the PP2a-B56a interface, and the authors
had presented a 2.8 angstrom cryo-EM structure of SMAP bound to the PP2a complex (Fig 5.4).
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Figure 5.4: Proposed mechanism of SMAP action on PP2a (Figure adapted from Ref 13)

Using this cryo-EM structure for guidance I determined that the phenoxazine ring of the SMAP
was solvent exposed and could be modified by a linker for PhosTAC synthesis (Fig 5.5).
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Figure 5.5: Analysis of SMAP binding mode to determine vector for linker attachment

I then moved on to synthesize a small library of PP2a recruiting SMAP-based PhosTACs
(SMAPTACs) with chloroalkane handles to test alongside the PP1-pentapeptide based
PhosTACs in the bioengineered HaloTag-Substrate cell lines we had generated.
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5.2.4 Synthesis of PP2a-targeting PhosTACs

Scheme 8: Synthesis of SMAPTACs

The synthesis of SMAPTACs (Scheme 8) commenced with the bromination of cyclohexanone to
generate 2-bromocyclohex-2-en-1-one. This was followed by an enantioselective reduction of the
enone using (R)-diphenylprolinol to furnish (S)-2-bromocyclohex-2-en-1-ol in good yield. The
bromine functionality that had been installed to enable the stereoselective transformation was then
removed by treatment with n-BuLi to yield (S)-cyclohex-2-en-1-ol. This material was converted
to the epoxide in a stereoselective manner by treatment with vanadium acetate and peroxide to
generate (1S,2S,6R)-7-oxabicyclo[4.1.0]heptan-2-ol. The secondary alcohol was then benzyl
protected to enable lewis acid mediated regioselective epoxide opening with phenoxazine to
provide

(1R,2S,6S)-2-(benzyloxy)-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol.

The

benzyl

protecting group was then removed by hydrogenation. The resultant diol was protected using
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sulfuryl

chloride

to

generate

(3aR,4S,7aS)-4-(10H-phenoxazin-10-

yl)hexahydrobenzo[d][1,3,2]dioxathiole 2,2-dioxide. This protected diol was treated sodium azide
and then worked up with acid to induce the deprotection of the sulfonate to yield (1R,2R,6S)-2azido-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol. The azide was reduced with triphenylphosphine
to provide (1S,2R,6S)-2-amino-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol. Finally this material
was reacted with 4-(trifluoromethoxy)benzenesulfonyl chloride to generate the published SMAP
compound DT-061. Gratifyingly, we found that treatment of SMAP with sub-stoichiometric NBS
furnished the mono-brominated SMAP which was primed for linker attachment by any variety of
cross-coupling strategies. I would like to thank Ke Li for his fantastic help with the final linker
couplings and purifications of the SMAPTACs. Using this approach we generated SMAPTACs
with PEG linkers n = 2-12. We also generated control SMAPTACs featuring a fluoroalkane that
is not competent to engage HaloTag covalently.15 I then moved on to test these compounds, along
with the PP1-targeting haloalkane PhosTACs, in the substrate-HaloTag cell lines we established
(section 5.3.2)
5.3 Towards Biological Characterization of PhosTACs in Bioengineered Cell Lines
5.3.1 PP1 PhosTACs
As discussed, we planned to use a HaloTag-fusion protein based chemical biology approach to
demonstrate the viability of small molecule PhosTACs in vitro (Fig 5.6).
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Figure 5.6: HaloTag-Substrate system and PhosTAC experimental workflow

Towards this goal my colleague Po-Han Chen devoted a great deal of effort to generate stable
substrate-HaloTag cell lines using lentiviral transfection. He generated over 20 HaloTag-substrate
cell lines which we used to test our various Haloalkane-PhosTACs.
I tested my PP1-recruiting PhosTACs for activity in these cell lines by treating the cells with the
PhosTAC constructs then harvesting their lysates and western blotting for the phosphorylated
substrate protein (Fig 5.6). The HaloTag substrate protein was easily differentiated on the blot
from the native substrate because of the additional 30 kDa HaloTag moiety. I tested these
constructs in a variety of different substrate cell lines under conditions that included serum
starvation, serum starvation followed by stimulation, full media, or full media followed by
stimulation. Unfortunately, I was never able to observe a significant impact on HaloTag-substrate
phosphorylation using these constructs. My hypothesis was that our small PP1 ligands cannot
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adequately de-inhibit PP1 in the cell to induce its activity (PP1 has been shown to be 99% bound
by its natural inhibitors I-1 and I-2 in the cell).16
In an effort to interrogate this hypothesis and the competence of the PP1 peptides to activate PP1
I attempted to recapitulate an experiment conducted during the Köhn lab’s work towards
developing their larger PP1 activating peptides.16 However, I was unable to replicate the effects
they observed on downstream signalling (ERK, MEK phosphorylation level) when treating with
my PP1 peptides or PhosTACs. With these experiments failing I gained confidence in my
hypothesis that my ligands, although strong binders by FP, were unable to activate PP1 from its
natural inhibitors in the cell. Therefore after these repeated failures when testing these compounds
in numerous substrate-HaloTag cell lines, and trying to validate target engagement, this direction
was abandoned. I concluded that my PP1 ligands are not competent to activate PP1 in the cell
despite being tight-binders by FP when using purified proteins.
5.3.2 PP2a PhosTACs SMAPTACs
I began testing the SMAPTAC library by treating our engineered HaloTag-Substrate cells with the
SMAPTAC molecules, then harvesting their lysates and western blotting for the phosphorylated
substrate protein. The HaloTag substrate protein was easily differentiated on the blot from the
native substrate because of the additional 30 kDa HaloTag moiety. I tested the constructs in a
variety of different substrate cell lines under conditions that included serum starvation, serum
starvation followed by stimulation, full media, or full media followed by stimulation.
The first signs of SMAPTAC activity were observed when I treated Halotag-PDCD4 (programmed
cell death protein 4) expressing HeLa cells with PEG 7 and PEG 9 SMAPTACs for 24 hours in
serum free media and then stimulated with full media for 10 minutes before harvesting their lysates
(Fig 5.7). This experiment demonstrated dose dependent dephosphorylation (Dmax 88%, DC50
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500nM), an evident hook-effect at 10 µM SMAPTAC-7, and even competition of
dephosphorylation by another chloroalkane (TMR-Cl). These results were extremely exciting and
we believed we had active SMAPTACs with good evidence of a ternary complex mediated
mechanism of action.
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Figure 5.7: Western blot with quantitation demonstrating what appeared to be SMAPTAC-mediated
dephosphorylation of PDCD4-HaloTAG substrate in an engineered PDCD4-Halotag HeLa cell line. Cells were
treated for 24 hours in serum free media, washed once with PBS, and then stimulated with serum-containing
media for 10 minutes before being lysed and harvested

I moved on to repeat this experiment and a second repeat provided similar results. However, the
signal vanished completely on my third attempt and no dephosphorylation was evident. I tried
identical conditions two more times, with both of these repeats also failing. I made every effort to
deduce the reason for the differences, swapping out different reagents and media one-by-one to
determine if any of them could be implicated in the loss of signal. New batches of PhosTACs were
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also synthesized although no abnormalities in the DMSO stocks were observed by LCMS.
Unfortunately I was never able to recover this potent dephosphorylation phenotype or determine
its initial source in the first two convincing experiments. Testing the SMAPTACs in several other
HaloTag-substrate cell lines did not provide new leads, so I returned to try different conditions in
the PDCD4-HaloTag line. I was able to recover some dephosphorylation phenotype (~40% Dmax
with DC50 2.5uM) when I changed the treatment conditions to a 24-hour treatment with the
SMAPTAC in full media, with no additional stimulation before harvesting. However, at this point
I had synthesized the appropriate fluoroalkane control compounds that should be inactive because
fluoroalkanes do not engage HaloTag covalently. Unfortunately these compounds exhibited
similar activity to their chloroalkane counterparts, so I took a step back from this project to focus
on the lead compounds I had elucidated for the DcpS and HER3 projects. I planned to return to
further interrogate SMAPTACs before graduation, but as the following subsection will outline, the
entire project was likely undertaken under false pretenses of the SMAPs mechanism of action.
Considering this compelling rebuttal of the two SMAP publications that guided this work, no
further work on SMAPTACs will be carried out in our lab. We are still unsure of the source of the
original signal observed in PDCD4-HaloTag cells.
5.3.2b New paper completely invalidates PP2a SMAP ligands
Shortly after I suspended my efforts working on SMAPTACs because of issues with
reproducibility and the activity of the control compounds, a paper was published in pre-print by
the Nilsson group that disputes the mechanism of action of SMAPs and proves they actually do
not engage or act on PP2a at all.17 Nilsson did not observe PP2a activation in vitro with SMAPs.
They attempted to confirm the binding of SMAP to PP2a by ITC, NMR, and pulldowns, but were
unable to observe any evidence of PP2a engagement. Further, they reanalyzed the cryo-EM
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structures that were published and determined that the density was incorrectly assigned and that
the SMAP molecule was not present in the real structure. Rather, they postulate that the C-terminal
tail of one of the PP2a complex subunits has folded back to occupy the supposed SMAP-binding
pocket, tricking the original authors into believing they had demonstrated compound occupancy.
They went on the confirm this by demonstrating that knockout of the B56 subunit implicated in
SMAP activity does not abrogate the toxicity of the compound. They finally demonstrate that
SMAP is actually a disrupter of the Golgi and endoplasmic reticulum leading to granularization
(consistent with the formation of dark punctae I observed at high concentrations of SMAPTAC).
This study provided many logical explanations for the issues we uncovered during the study of
SMAPTACs, and demonstrated that even publications in top-tier journals like Cell cannot be
trusted implicitly. Therefore, I did not return to study SMAPTACs any further and my efforts to
design PhosTACs recruiting PP1 and PP2a were ultimately unsuccessful. I do not know how or
why the first set of SMAPTAC experiments showed such strong dephosphorylation, perhaps some
unknown additional mechanism was at play or the cells were otherwise compromised and biased
towards PDCD4 dephosphorylation.
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5.4 Synthetic Schemes and Characterization and Biological Methods
SPPS synthesis of PP1 peptides and derived PhosTACs:
The peptides were synthesized according to standard Fmoc-SPPS protocols on CTC resin (SigmaAldrich) for C-terminal carboxylate peptides and using Wang resin for C-terminal amide peptides.
The CTC resin was loaded using 4eq of the C-terminal amino acid in dry DCM with 10eq DIPEA
stirring for 24 hours under argon. The Wang resin was loaded according to the following protocol:
1. In a round bottom flask suspend the resin in 9:1 v/v CH2Cl2/DMF (approximately 15 mL
per gram of resin).
2. In a separate flask dissolve 1.5 to 2.5 equivalents (relative to the resin) of the
Fmoc-amino acid in a minimum amount of DMF. Add the same equivalency of
HOBt. Stir the mixture until the HOBt dissolves. If the HOBt does not dissolve
completely, add just enough DMF to bring it into solution. Add this solution to the
resin.
3. In a separate flask dissolve 0.1 equivalent (relative to the resin) of DMAP in a
minimum amount of DMF.
4. Add 1.0 equivalent (relative to the amino acid) of DIC to the resin mixture then
add the DMAP solution. Fit a drying tube onto the flask.
5. Agitate the mixture with a mechanical shaker for 2 to 3 hours at room
temperature. Add 2 equivalents (relative to the resin) of acetic anhydride and
pyridine to the reaction flask and mix an additional 30 minutes at room
temperature to end cap any unreacted hydroxyl groups on the resin.
6. Filter

the

resin

in

a

filter

syringe

and

wash

it

3

times

with

DMF, then 3 times with DCM, and finally 3 times with methanol. In each wash
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use enough solvent to slurry the resin. After the final methanol wash, dry the
resin in vacuo to a constant weight. The substitution of the resin can be
estimated from the weight gain of the resin. For an accurate measurement of the
resin substitution, the amount of Fmoc released from a weighed sample of resin
can be measured spectrophotometrically.
Both types of loaded resins were always washed with 5x DMF, 5x DCM, 5x DMF between each
deprotection, coupling, and capping step. Deprotections used 20% piperidine in DMF 2x3 minutes.
Couplings used 4 eq amino acid, 4 eq K-Oxyma, and 4 eq DIC for 1 hour. Capping used 10%
Ac2O in Pyridine for 5 minutes. When the peptide was ready for cleavage from the resin, it was
washed 10x with dry DCM before addition of the cleavage cocktail (95:2.5:2.5 TFA:H2O:TIPS),
which was allowed to react for 2 hours. The solution containing the crude cleaved peptides were
then mixed with cold diethyl ether to induce precipitation. The peptides were spun down in the
centrifuge at max speed and then resolubilized in H2O/MeCN for HPLC purification. All peptides
and PhosTAC constructs were purified on HPLC and their identities confirmed by HRMS before
they were used in experiments.
The synthesis of N-terminally linked PhosTACs was carried out completely on resin with the
chloroalkane-carboxylate ligand being treated as the final coupling partner in the sequence.
Synthesis of C-terminally linked PP1-PhosTACs involves some further manipulation off-resin:
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Scheme 9: Synthesis of PP1-peptide based PhosTACs off resin

For the synthesis of these constructs SPPS was carried out as above on CTC resin. (Example
protocol – PEG8 construct) Protected peptide was cleaved from 2-CTC resin with 1:1:8
AcOH:TFE:DCM for 30 minutes. The protected peptide was purified by HPLC. To a solution of
the protected peptide (5.5 mg) was added the amine containing peg linker (2.6 mg, 1 eq) and
DIPEA (4 eq). Finally, HATU (2.1mg, 1.5 eq) was added and the reaction was allowed to stir at
r.t. under an inert atmosphere for one hour. The reaction was concentrated and purified directly by
HPLC. The purified material was subjected to 1:1 TFA:DCM until all protecting groups were gone
by LCMS. The solution was then concentrated down and subjected to a drop of DBU in THF to
remove Fmoc. After LCMS confirmed removal of Fmoc the solution was again concentrated and
purified by HPLC to yield the pure PhosTAC.
PP1-PhosTAC Mass Spec Characterization:
PHTAC1: HRMS [C51H86Cl2N11O11+] Cal: 1098.5887; Obs: 1098.6344
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PHTAC2: HRMS [C51H85Cl2N10O12+] Cal: 1099.5726; Obs: 1099.6074
PHTAC4: HRMS [C53H90Cl2N11O12+] Cal: 1142.6148; Obs: 1142.6124
PHTAC5: HRMS [C53H88Cl2N10O13+] Cal: 1143.5988; Obs: 1143.6704
PHTAC8: HRMS [C55H96Cl2N11O14+] Cal: 1204.6516; Obs: 1204.6062
PHTAC9: HRMS [C59H104Cl2N11O16+] Cal: 1292.7040; Obs: 1292.6959
PHTAC10: HRMS [C67H120Cl2N12O19Na+] Cal: 1490.8038; Obs: 1490.7898
PHTAC11: HRMS [C57H98Cl2N11O15+] Cal: 1246.6622; Obs: 1246.6418
PHTAC12: HRMS [C61H105Cl2N11O17Na+] Cal: 1356.6966; Obs: 1356.7019
Synthesis of linkers for PP1-PhosTACs:
Synthesis of SMAP and SMAPTACs

Scheme 8: Synthesis of SMAPTACs
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Angew. Chem., Int. Ed. Engl. 2006, 45, 7600–7603. Was followed for the synthesis of (S)cyclohex-2-en-1-ol:

2-bromocyclohex-2-en-1-one
To a stirred solution of 2-cyclohexen-1-one (5) (6 mL, 62 mmol) in CH2Cl2 (160 mL) at 0 °C was
added a solution of bromine (3.24 mL, 63.2 mmol) in CH2Cl2 (160 mL) over 1 h. Et3N (14.4 mL,
103.5 mmol) was added and the resulting mixture was allowed to warm at room temperature and
stirred for 1.5 h before it was quenched with HCl (1.06M aq., 100 mL). The layers were separated
and the organic layer was washed with brine (100 mL), dried (Na2SO4) and concentrated in vacuo
to afford 2-bromo-2-cyclohexen-1-one (6) (10.63 g, 98%), where the 1H and 13C NMR
spectroscopic data matched those reported in literature. Angew. Chem., Int. Ed. Engl. 2006, 45,
7600–7603. (2) NOTE: This product is extremely unstable to moisture and temperature. HBr
evolution risk. Store in freezer under inert gas with parafilm! Still may decompose after a few
weeks!

(S)-2-bromocyclohex-2-en-1-ol
A solution of (R)-α,α-diphenylprolinol (1.11 g, 4.38 mmol) and B(OMe)3 (600 µL, 5.26 mmol) in
THF (75 mL) was stirred at room temperature for 1 h before being cooled at −5 °C and the addition
of BH3•N,N-diethylaniline (7.76 mL, 43.8 mmol). A solution of 2- bromo-2-cyclohexen-1-one (6)
(7.67 g, 43.8 mmol) in THF (75 mL) was added over 75 min and the reaction mixture was allowed
to warm to room temperature and stirred for 16 h before it was quenched by a slow addition of
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MeOH (50 mL) and HCl (1.0 M aq., 100 mL). The layers were separated, and the organic layer
was extracted with Et2O (2 × 100 mL), washed with brine (100 mL), dried (Na2SO4) and
concentrated in vacuo. Flash column chromatography (silica gel, hexanes:EtOAc 8:2) afforded
(S)-2-bromo-cyclohex-2-en-1-ol (7) (6.96 g, 90%) as a colorless oil, whose 1H, 13C NMR, and
optical rotation spectroscopic data matched those reported in the literature. Angew. Chem., Int.
Ed. Engl. 2006, 45, 7600–7603.

(S)-cyclohex-2-en-1-ol
(S)-cyclohex-2-en-1-ol (8): To a stirred solution of (S)-2-bromo-cyclohex-2-en-1-ol (7) (2.46 g,
13.9 mmol) in Et2O (250 mL) at −78 °C was added a solution of n-BuLi (2.0 M in cyclohexane,
24 mL, 48.7mmol). The reaction mixture was stirred for 1 h and warmed to −10 °C and stirred for
further 1.5 h before it was quenched with H2O (100 mL). The layers were separated, and the
organic layer was washed with brine (100 mL), dried (Na2SO4) and concentrated in vacuo to
afford (S)-cyclohex-2-en-1-ol (8) (1.09 g, 80%) as a colorless oil, whose 1H, 13C NMR and optical
rotation spectroscopic data matched those reported in the literature. Angew. Chem., Int. Ed. Engl.
2006, 45, 7600–7603.
SMAP DT-061 was then synthesized following the procedures of 10.1021/jo00145a004:

(1S,2S,6R)-7-oxabicyclo[4.1.0]heptan-2-ol

188

To a solution of (S)-cyclohex-2-en-1-ol (50 mg, 0.51 mmol, 1.0 eq.) in dry toluene (1 mL) was
added Vo(acac)2 (1.9 mg, 0.007 mmol, 0.014 eq.). The solution was refluxed and TBHP (62.5 µL,
0.56 mmol, 1.1 eq) was added dropwise. The reaction was stirred for 1.5 h whereby TLC analysis
indicated that the reaction went to completion. The solution was cooled to rt and a solution of
acetic anhydride (200 µL) and dry pyridine (275 µL) was added. The resulting solution was stirred
overnight and then poured onto ice. Et2O (4 mL) was added and the organic layer was washed
with water (2 mL), HCl aq (2 mL, 1.0 M), NaHSO3 satd. aq. sol. (2mL), NaHCO3 satd. aq. sol.
(2 mL) and brine (2 mL), dried over Na2SO4, filtered and concentrated. The crude was purified
by flash column chromatography (8:2 hexane/EtOAc, Rf: 0.28) to afford (1S,2S,6R)-7oxabicyclo[4.1.0]heptan-2-ol as an oil (38 mg, 65%). [α]25D: -67.8 (c 1.02, CHCl3). The spectral
data matched those reported in the literature.
OBn
O

(1R,2S,6R)-2-(benzyloxy)-7-oxabicyclo[4.1.0]heptane
To a suspension of NaH (14 mg, 60% in mineral oil, 0.35 mmol, 2.0 eq.) in dry THF (750 µL) was
added BnBr (20.5 µL, 0.17 mmol, 0.96 eq.) and the suspension was warmed up to 50 °C. A solution
of (1S,2S,6R)-7-oxabicyclo[4.1.0]heptan-2-ol (50 mg, 0.18 mmol, 1.0 eq.) in dry THF (500 µL)
was added and the resulting solution was stirred at 55 °C for 18 h whereby TLC analysis indicated
that the reaction went to completion. The solution was cooled down to rt and quenched with water.
Et2O (2 mL) was added, the organic layer was collected, washed with water (2 mL), dried over
Na2SO4, filtered and concentrated. The crude was purified by flash column chromatography
(85:15 hexane/EtOAc, Rf: 0.34) to afford (1R,2S,6R)-2-(benzyloxy)-7-oxabicyclo[4.1.0]heptane
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as an oil (25 mg, 68%). [α]25 D: -39.4 (c 0.95, CHCl3). The spectral data matched those reported
in the literature.
OBn
OH
N
O

(1R,2S,6S)-2-(benzyloxy)-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol
To a solution of phenoxazine (218 mg, 1.18 mmol, 2.4 eq.) in dry 1,2-dichloroethane (1.65 mL)
was added (1R,2S,6R)-2-(benzyloxy)-7-oxabicyclo[4.1.0]heptane (100 mg, 0.49 mmol, 1.0 eq.)
followed by Yb(OTf)3 (91 mg, 0.15 mmol, 0.3 eq.). The reaction was stirred overnight whereby
TLC analysis indicated that the reaction went to completion. The suspension was filtered over
Celite and washed thoroughly with EtOAc then concentrated. The crude was purified by flash
column chromatography (85:15 hexane/EtOAc, Rf: 0.34) to afford (1R,2S,6S)-2-(benzyloxy)-6(10H-phenoxazin-10-yl)cyclohexan-1-ol as a silver foam (175 mg, 93%). [α] 25 D: +19.9 (c 0.93,
CHCl3). The spectral data matched those reported in the literature.
OH
OH
N
O

(1S,2R,3S)-3-(10H-phenoxazin-10-yl)cyclohexane-1,2-diol
To a solution of (1R,2S,6S)-2-(benzyloxy)-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol (143 mg,
0.37 mmol, 1.0 eq.) in dry THF/MeOH 4 mL, 1:1) was added Pd/C (7.5 mg, 0.037 mmol, 0.1 eq.)
and the flask was purged with a balloon of H2. Stirred at rt for 5h whereby TLC analysis indicated
that the reaction went to completion. The suspension was filtered over Celite, concentrated to
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afford (1S,2R,3S)-3-(10H-phenoxazin-10-yl)cyclohexane-1,2-diol as a brown powder (129 mg,
92%). Rf: 0.29 (6:4 hexane/EtOAc) [α] 25D: -25.8 (c 0.67, CHCl3). The spectral data matched
those reported in the literature.
O
O

S

O

O
N
O

(3R,4S,7S)-4-(10H-phenoxazin-10-yl)hexahydrobenzo[d][1,3,2]dioxathiole 2,2-dioxide
To a suspension of (1S,2R,3S)-3-(10H-phenoxazin-10-yl)cyclohexane-1,2-diol (20 mg, 0.067
mmol,

1.0

eq.)

in

dry

CH2Cl2

(1.2

mL)

was

added

dry

Et3N

(93 µL, 0.67 mmol, 10.0 eq.) and the resulting solution was cooled to -78 °C whereby SO2Cl2
(804 µL, 0.5 M in CH2Cl2, 0.402 mmol, 6.0 eq.) was added dropwise. The solution was stirred at
-78 °C for 2 h, then cannulated to another flask containing CH2Cl2 (5 mL) with a NaHCO3 satd.
aq.sol. (5 mL). The aqueous layer was extracted with CH2Cl2 (5 mL). The combined organic layers
were washed with brine (5 mL), dried over Na2SO4, filtered, concentrated. The crude was
purified by flash column chromatography (7:3 hexane/EtOAc, Rf: 0.25) to afford (3R,4S,7S)-4(10H-phenoxazin-10-yl)hexahydrobenzo[d][1,3,2]dioxathiole

2,2-dioxide

as

a

brown

oil (24 mg, 58% of yield, 75% of conversion). [α]2D: +48.9 (c 0.43, CHCl3). The spectral data
matched those reported in the literature.
N3
OH
N
O

(1R,2R,6S)-2-azido-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol
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To a solution of (3R,4S,7S)-4-(10H-phenoxazin-10-yl)hexahydrobenzo[d][1,3,2]dioxathiole 2,2dioxide (36 mg, 0.1 mmol, 1.0 eq.) in dry DMF (2.0 mL) was added NaN3 (11.7 mg, 0.18 mmol,
1.8 eq.) and the reaction was stirred at 80 °C for 3.5 h whereby TLC analysis indicated that the
reaction went to completion. The solution was concentrated and diluted with Et2O (7 mL). A
H2SO4 aq. (7mL, 20% w/w) was added and the biphasic mixture was stirred for 1 h whereby TLC
analysis showed no more sulfonate. NaHCO3 was slowly added dropwise to the solution until no
more gas formation was observed. The aqueous layer was extracted with Et2O (7 mL). The
combined organic layers were washed with brine (1 x 7 mL), dried over Na2SO4, filtered,
concentrated. The crude was purified by flash column chromatography (9:1 hexane/EtOAc, Rf:
0.3) to afford (1R,2R,6S)-2-azido-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol as an oil (30 mg,
94%). [α] 25 D: -9.3 (c 0.30, S-11 CHCl3). The spectral data matched those reported in the
literature.
NH2
OH
N
O

(1S,2R,6S)-2-amino-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol
To a solution of (1R,2R,6S)-2-azido-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol (26 mg, 0.081
mmol, 1.0 eq.) in dry THF (1 mL) cooled to 0 °C was added water (7.3 µL, 0.81 mmol, 10.0 eq.)
followed by PPh3 (53 mg, 0.202 mmol, 2.5 eq.). The solution was stirred at 0 °C for 5 min then
warmed up to 50 °C for 6h whereby TLC/mass analyses indicated that the reaction went to
completion. The mixture was concentrated. The crude was purified by flash column
chromatography (9:1 CH2Cl2 /MeOH, Rf: 0.45) to afford (1S,2R,6S)-2-amino-6-(10H-phenoxazin-
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10-yl)cyclohexan-1-ol as orange crystals (23 mg, 96%). [α]25 D: -4.7 (c 0.43, CHCl3). The
spectral data matched those reported in the literature.
O
S
NH
O

F3CO

OH
N
O

N-((1R,2R,3S)-2-hydroxy-3-(10H-phenoxazin-10-yl)cyclohexyl)-4(trifluoromethoxy)benzenesulfonamide
To a solution of (1S,2R,6S)-2-amino-6-(10H-phenoxazin-10-yl)cyclohexan-1-ol (5.0 mg, 0.017
mmol,

1.0

eq.)

in

dry

CH2Cl2

(135

µL)

cooled

to

0

°C

was

added dry Et3N (95 µL, 0.068 mmol, 4.0 eq.). A solution of 4-(trifluoromethoxy)benzenesulfonyl
chloride (38 µL, 0.019 mmol, 1.1 eq.) was then added over 1h. The solution was allowed to reach
rt and stirred for an additional 1 h whereby TLC analysis indicated completion. Water (300 µL)
was added and the biphasic solution was diluted with CH2Cl2 (300 µL). The aqueous layer was
extracted with CH2Cl2 (1mL). The organic layers were combined, washed with brine, dried over
Na2SO4, filtered, concentrated. The crude was purified by flash column chromatography (8:2
hexane/EtOAc,

Rf:0.23)

to

afford

N-((1R,2R,3S)-2-hydroxy-3-(10H-phenoxazin-10-

yl)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide (SMAP DT-061) as an oil (10 mg, 81%).
The spectral data matched those reported in the literature.
Synthesis of SMAPTAC from SMAP DT-061:
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O
S
NH
O

F3CO

OH
N
O

Br

N-((1R,2R,3S)-3-(3-bromo-10H-phenoxazin-10-yl)-2-hydroxycyclohexyl)-4(trifluoromethoxy)benzenesulfonamide:
To

a

solution

of N-[(1R,2R,3S)-2-hydroxy-3-phenoxazin-10-yl-cyclohexyl]-4-

(trifluoromethoxy)benzenesulfonamide (4.00 mg, 0.00768 mmol) in THF (0.2 mL) was added
dropwise a solution of NBS (0.684 mg, 0.00384 mmol) in THF (0.1 mL) at 0oC. The mixture was
stirred at 0oC for 0.5h. Concentrated and purified by prep-TLC (EA/HEX = 30%) to give N[(1R,2R,3S)-3-(3-bromophenoxazin-10-yl)-2-hydroxy-cyclohexyl]-4(trifluoromethoxy)benzenesulfonamide (5.70 mg, 0.00951 mmol, yield: 61.9 %). HRMS
[C25H23BrF3N2O5S+] Cal: 599.0464; Obs: 599.0452. HRMS was used to confirm isolated identity
because a clean NMR could not be obtained (rotamers? Baseline issue?) so the cross-coupling was
carried out and then purified further by HPLC to yield the pure SMAPTACs.
Example SMAPTAC synthesis - SMAPTAC9
F3CO
O
S
O

O

NH
abs
abs
abs

O

O

O

O

O

O

O

O

O

OH
N
O

N-((1R,2R,3S)-3-(3-(4-((33-chloro-3,6,9,12,15,18,21,24,27-nonaoxatritriacontyl)oxy)phenyl)10H-phenoxazin-10-yl)-2-hydroxycyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide:
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Cl

To a tube was added N-[(1R,2R,3S)-3-(3-bromophenoxazin-10-yl)-2-hydroxy-cyclohexyl]-4(trifluoromethoxy)benzenesulfonamide (3.00 mg, 0.00500 mmol), 2-[4-[2-[2-[2-[2-[2-[2-[2-[2-[2(6-chlorohexoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.42 mg, 0.00601 mmol), Pd(dppf)Cl2 (0.366 mg,
0.000500 mmol), K2CO3 (1.04 mg, 0.00751 mmol) and N,N-dicyclohexylmethylamine (0.978
mg, 0.00500 mmol), exchanged with N2, and degassed THF (0.4 mL) was added. The mixture was
stirred at 66oC for 4 h. The mixture was filtered, concentrated. Purified by Prep-HPLC
(MeCN/H2O = 5-95%) to give desired cpd N-[(1R,2R,3S)-3-[3-[4-[2-[2-[2-[2-[2-[2-[2-[2-[2-(6chlorohexoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]pheno
xazin-10-yl]-2-hydroxy-cyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide (1.20 mg, 0.00106
mmol, yield: 21.3 %) 1H NMR (800 MHz, Methanol-d4) δ 8.02 – 7.99 (m, 2H), 7.49 – 7.46 (m,
2H), 7.44 – 7.42 (m, 2H), 7.11 (dd, J = 8.3, 2.2 Hz, 1H), 7.00 – 6.93 (m, 5H), 6.88 (td, J = 7.6, 1.5
Hz, 1H), 6.80 (td, J = 7.6, 1.4 Hz, 1H), 6.75 (dd, J = 7.9, 1.5 Hz, 1H), 4.64 – 4.56 (m, 2H), 4.19 –
4.11 (m, 2H), 3.91 – 3.83 (m, 3H), 3.72 – 3.70 (m, 2H), 3.68 – 3.65 (m, 2H), 3.65 – 3.63 (m, 2H),
3.63 – 3.58 (m, 24H), 3.55 – 3.51 (m, 4H), 3.46 – 3.42 (m, 3H), 3.11 (ddd, J = 11.5, 9.2, 4.3 Hz,
1H), 1.97 – 1.94 (m, 1H), 1.87 – 1.77 (m, 2H), 1.76 – 1.67 (m, 3H), 1.55 (dq, J = 7.9, 6.6 Hz, 2H),
1.43 (dtd, J = 9.2, 7.9, 7.4, 6.2 Hz, 2H), 1.38 – 1.25 (m, 5H). 13C NMR (201 MHz, Methanol-d4) δ
168.86, 163.15, 158.25, 151.53, 149.52, 149.04, 140.82, 135.24, 132.63, 129.07, 126.93, 123.24,
122.25, 120.97, 120.65, 118.39, 118.14, 115.31, 114.58, 113.10, 72.67, 70.73, 70.34, 70.15, 70.14,
70.09, 70.07, 70.06, 70.04, 69.72, 69.46, 68.73, 67.28, 59.15, 44.30, 44.29, 32.33, 32.17, 29.12,
28.47, 26.31, 25.07, 22.14. HRMS [C55H75ClF3N2O15S+] Cal: 1127.4529; Obs: 1127.4536
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Biological Methods:
Generation of HaloTag-Substrate cell lines by lentiviral transfection (Po-Han Chen):
Lentivirus transfection:
1. Virus production
1. Seeding 293T (293T is used for transfection and generate virus particle, use 6 well)
2. Next day, when confluency reaches 70-80%, co-transfection of the virus plasmids by
lipofectamine 2000 (or other appropriate reagents)
3. If total transfected plasmid amount is 2.5ug/6well plate, then start with 1.2ug
transfer plasmid (pReceiver Halo-PDCD4, etc.), 0.12ug pMD2.G, and 1ug
psPAX2 (start with 10:1:10 ratio for those three plasmids) (Day 1)
4. 24h (or overnight) after transfection, remove medium and replace with fresh
medium (Day 2)
5. 48h after changing medium, collect medium and pass through 0.45uM filter set
with 3 ml syringe. Virus will be in the filtered medium, and you can use the virus
freshly or aliquot them into 1ml per vial and store them in -80 oC (Day 4)
6. If you would like to collect more virus, you can put fresh medium into the 6 well
plate and collect them 24 or 48h later same way as step 5. (Day 6)
2. Virus transduction
1. Seeding Hela 2x10^5 (or other cell lines that you would like to infect virus)
into 6 well
2. Next day, prepare 500ul virus aliquot (use fresh from step 5 or thaw in water bath) and
polybrene (8mg/ml). (Day 1)
3. Transduction: remove medium and replace with fresh medium and add
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polybrene (final 8ug/ml). Drop the virus aliquot *(0.5ml/6 well plate) into the
plate and gently shake it. Incubate for two days. (Day 1 to 3)
* Alternatively, you can prepare multiple plates/wells and try different amount of virus
for infection so you will know what is the most effective infection dose for this batch
virus.
4. Two days after the infection, remove medium and replace with fresh medium
for additional 24h (do not add selection drug at this point). (Day 3 to 4)
5. Add appropriate selection drug (2ug/ml puromycin for pReceiver vector in HeLa and
293) into the medium. (Day 4)
6. Replace medium and add selection drug every 2-3 days.
7. Most uninfected cells will die in one week with puromycin.
8. Check Halo protein expression with selected cells by western blot.
PhosTAC dephosphorylation assays:

Figure 5.8: PhosTAC Dephosphorylation Assay Protocol Performed in Substrate-HaloTag Engineered HeLa or
HEK293T cells

PDCD4-HaloTag (or other substrate-HaloTag) expressing HeLa cells were plated in 12 well plates
at a density of 100K/well. After allowing the cells to grow to 80% confluence overnight they were
washed once with sterile PBS and then treated with PhosTAC in serum free or full media for 24
hours. After the treatment time the cells (if the conditions employed called for stimulation) were
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stimulated by full media or cytokine for an appropriate time. Then the cells were placed on ice,
the media was removed, and they were washed with cold PBS. 50uL of RIPA lysis buffer
supplemented with 1x commercial PHOSTOP (Roche) phosphatase inhibitor cocktail and protease
inhibitors was then added. The cells were lysed for 30 minutes, scraped from the plate, and
collected in microfuge tubes. The lysates were spun down and separated from the pellet. The
lysates were ran on SDS-PAGE gel and transferred to PVDF membrane for 2 hours at 76V at 4oC.
The blots were blocked with 5% OmniBlock in TBST for 1 hour. The blots were probed with
PDCD4-S457 phosphoantibody (ThermoFisher # PA5-38806) and HaloTag (Promega # G9211)
and GAPDH as a control (CST # 5174) in 5% BSA in TBST overnight at 4oC. The blots were then
washed 3x5 min with TBST and subjected to secondary HRP-conjugated antibodies (Amersham,
Cytiva) for 1 hour at r.t. in 5% OmniBlock in TBST. The blots were then imaged and the data
quantified using the Image Lab software (Bio-Rad).
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Chapter 6: Development of a Novel Method for Synthesis of Isoquinolones
This chapter is adapted from publication: https://doi.org/10.1021/acs.joc.1c00472
6.1 Background on Isoquinolones and Successful Strategies for Their Synthesis
The isoquinolone scaffold is a privileged structural motif present in many natural products1, 2 and
small molecules with pharmacological and biological activities. Compounds of this class are
known for their antitumor3-5, antihypertensive6,7, antithrombotic8, anti-inflammatory9, and
analgesic properties10. The isoquinolin-1(2H)-one scaffold is present in a wide variety of smallmolecule ligands that bind kinases7, ion-channels10, folate-dependent enzymes11, tissue factors8,
glucocorticoid receptors9, and several other pharmacologically relevant protein classes (Figure
6.1).

Figure 6.1: Examples of some approved and/or experimental drugs containing an isoquinolone motif
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As a result, several synthetic methodologies have been developed to synthesize this important
building block. These approaches include classical methods12, typically multi-step syntheses that
use harsh reaction conditions, and the recently developed elegant syntheses of isoquinolones from
benzoic acid derivatives using metal-catalyzed ortho-C–H activation13-28, which require a directing
group on the carboxylic moiety. Unfortunately, the later are not applicable to the synthesis of 3,4unsubstituted isoquinolones. Furthermore, they rely on very elaborate noncommercial starting
materials, and they lack regioselectivity (Scheme 10).

Scheme 10: Current transition-metal-catalyzed C-H activation methods to prepare isoquinolones

On the other hand, current synthetic approaches for 3,4-unsubstituted isoquinolones are scarce,
and consist of mainly multi-step processes 12, 14, 29, 30. Therefore, there is still a need for new-simple
methodologies to access this important chemical scaffold. In this work we report an improvement
of our previously published method31, consisting of an expeditious two step synthesis of 3,4unsubstituted isoquinolones from 2-halo-benzonitriles that use a vinyl boronate as an “acetylene
equivalent”, which is installed by a Suzuki process (Scheme 11).
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Scheme 11: Synthesis of 3,4-unsubstituted isoquinolones by a Suzuki cross-coupling followed by cyclization

In one of our current research projects we had to synthesize a library of 3,4-unsubstituted
isoquinolones, and therefore needed a robust, short, efficient, and versatile synthetic approach. We
envisioned that 2-bromobenzonitriles could be an excellent synthon to replace the N-tertbutylbenzamides that we used in our previous work31 with the advantage of avoiding an extra-step
and harsh conditions to deprotect the final cyclic N-tert-butyl-isoquinolone as well as being
scalable if required. Additionally, there are a wide variety of inexpensive, commercially available
2-bromobenzonitriles to allow for rapid derivatization.
6.2 Discovery of Novel Method for Isoquinolone Synthesis
For the first step in this new approach, the palladium-catalyzed cross coupling reaction, we used
the same optimized reaction conditions described in our previous work31 which proved to be a very
robust and general protocol. Thus, the Suzuki coupling reaction between a range of 2-bromo or 2iodobenzonitriles 1 and the simple-commercially available vinyl boronate ester 4 provides the
corresponding vinyl ether intermediates 2 from moderate to high yields (51-88% yield, Tables 1
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and 2). For the second step, we hypothesized that the hydrolysis of the nitrile and the vinyl ether
could be achieved simultaneously by heating 2 in an aqueous solvent and under the appropriate
conditions. We envisioned that the amide-aldehyde intermediate 2’ generated would cyclize
spontaneously to the give isoquinolone 3 under these reaction conditions (Scheme 3). To address
this challenge, we choose Parkins catalyst32,

33

an air-stable hydride-platinum(II) complex to

achieve nitrile hydrolysis. This platinum catalyzed process offers mild conditions, high reactivity,
and compatibility with many chemical functionalities like aldehydes, alcohols, acetals, azides, and
most protecting groups33. To our delight, efficient hydrolysis of both the nitrile and the vinyl ether
on the parent unsubstituted compound 2a, followed by cyclization of the carboxamide-aldehyde
intermediate 2’, provided the corresponding 3,4-unsubstituted isoquinolone 3a in the same reaction
step (87% yield, Table 3).
Encouraged by this result we next examined the impact of the electronics of the substituents
present on the starting benzonitrile core. Our synthesis proved to be robust as vinyl ether
intermediates bearing both strong electrons withdrawing groups (2d-f) and strong electron
donating groups (2g, 2i, and 2l) were prepared and converted into their corresponding
isoquinolones in moderate to great yield (47-91%). Of note, we were able to greatly improve the
yield of 6-dimethylamine isoquinolone 3e from 16% in previous methodologies14 to 82% in the
present study. The high yields for 3d and 3e highlights the ability of our method to efficiently
generate isoquinolones substituted with amine functionalities as useful chemical handles for
further derivatization. Additionally, we also examined the use of otho-chloro, and ortho-triflatebenzonezonitriles to further expand the availability of the starting benzonitriles, especially if the
later can be prepared from the corresponding phenols. We demonstrated that the vinyl ethers 2a
can also be prepared from otho-chloro, and ortho-triflate-benzonezonitriles in good yields (entries
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3, 4, 14 and 17 on Table 1). Remarkably, when we use 2,5-dichlorobenzonitrile as starting material,
we mainly obtained the desired ortho-substituted vinyl ether and just traces of the 5-substitued
product (<7% by NMR, entry 17 on Table 3).
In previous reports of 3,4 unsubstituted isoquinolone syntheses, a major challenge was obtaining
good product yields from ortho-substituted starting materials14,

30, 31, 34

. Excitingly, our new

strategy was able to efficiently generate 5 and 8-substituted isoquinolones 3b and 3n in moderate
to good yield (81% and 55% respectively). Previous attempts at synthesizing 8-methoxyisoquinolones had failed14, making the successful synthesis of 3n noteworthy. Another issue
encountered by other synthetic routes has been regioselectivity when generating 5- or 7-substituted
isoquinolones30. Since our methodology does not rely on an ortho directing group on the
carboxylic moiety, the regioselectivity of the reaction is fully dictated by the position of the halosubstituent in the starting benzonitrile. Therefore, we were able to synthesize 5- or 7-substituted
isoquinolones (3b, 3k and 3l) in a regiospecific manner and in good yields (80-83%).
Scheme 3. Synthesis of 3,4-unsubstituted isoquinolin-1(2H)-ones via a putative amide-aldehyde
intermediate.
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Yield*
Entry

Reactant 1

X

R

2*

Yield** Isoquinolone 3
*

1

1a

-I

-H

2a

81%

2

1aa

-Br

-H

2a

52%

3

1ab

-Cl

-H

2a

66%

3a

87%

4

1ac

OTf -H

2a

60%

5

1b

-Br

3-Me

2b

80%

3b

81%

6

1c

-Br

4-Cl

2c

82%

3c

91%

2d

64%

3d

88%

4-(N7

1d

-Br

pyrrolidinyl)
4-

8

1e

-Br

Dimethylamine

2e

87%

3e

82%

9

1f

-Br

4-OMe

2f

88%

3f

47%

10

1g

-Br

4-CHO

2g

66%

3g

52%

411

1h

-Br

Hydroxymethyl

2h

71%

3h

82%

12

1i

-Br

4-CF3

2i

73%

3i

47%

13

1j

-Br

4-F

2j

77%
3j

79%

14

1ja

OTf 4-F

2j

63%

15

1k

-Br

5-F

2k

76%

3k

83%

16

1l

-Br

5-NO2

2l

64%

3l

80%
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17

1m

-Cl

5-Cl

2m

51%

3m

79%

18

1n

-Br

6-OMe

2n

64%

3n

55%

19

1o

-Br

2o

85%

3o

78%

* In some cases, small amounts of the Z-isomer were formed (detected by NMR). **Isolated
yields,
Table 3: Substrate scope of the synthesis of isoquinolones from ortho-X-benzonitriles.

To further demonstrate the versatility of our novel process, we applied the same approach to the
synthesis of other heterocycles, by using ortho-halo-cyano-arens other than orthohalobenzonitriles as starting materials (Table 2). In our previous work we were able to produce diaza-heterocycles; however, the isolated products in every case were N-tert-butyl-azaisoquinolones that required harsh conditions of neat TFA at 150 oC (microwave) to remove the
tert-butyl group31. Our new approach bypasses the N-tert-butylisoquinolone intermediates to give
a variety of nitrogenous heterocycles (7a-d) in moderate to good yield (60-91%). Two of these
heterocycles, 7c and 7d, could not be prepared with our previous method because of the high
stability of the corresponding N-tert-butylisoquinolones31. Therefore, this work is a substantial
improvement over our previous methodology because it enables the formation of complex
isoquinolones bearing acid-sensitive functional groups.
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Entry Reactant 5

Intermediate 6*

Yid**

1

2
5b

91%

68%

69%
7b

83%
5c

Yield**

69%

6b

3

4

Product 7

6c

80%
7c

72%

5d
6d

7d

60%

Table 4: Synthesis of benzo- and aza-3,4-unsubstituted isoquinolin-1(2H)-ones.

* In some cases, small amounts of the Z-isomer were formed (detected by NMR).
**Isolated yield.
A major advantage of our new synthetic approach is that the mild reaction conditions are
compatible with a wide array of functional groups that can be used to further derivatize the
isoquinolone products. We successfully synthesized 3,4-unsubsituted isoquinolones bearing amine
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(3d and 3e), carbaldehyde (3g), hydroxyl (3h), and BOC protecting groups (3o). Previous
strategies generated only trace amounts of 3h14, further highlighting the power of our two-step
synthesis. To underscore the potential utility of our synthetic approach in generating diverse
libraries of isoquinolones, we heated 6-fluoro-2H-isoquinolin-1-one (3j) in neat pyrrolidine for 48
hours to form the SNAR product 6-pyrrolidin-1-yl-2H-isoquinolin-1-one in excellent yield (94%,
fully characterized as 3d). Finally, the versatility of this methodology was further demonstrated in
an ongoing project in our lab when we prepared gram quantities of compound 3o, which was a
critical starting material for the construction of a library of 6-substituted isoquinolones (Scheme
12).

Scheme 12: Synthetic approach to isoquinolone 3o

Although we did not perform a comprehensive mechanistic study of our novel synthetic route, we
hypothesize that isoquinolones generated through this strategy undergo a sequential hydrolysis of
the nitrile followed by hydrolysis of the vinyl ether to the aldehyde, after which cyclization to the
isoquinolone is spontaneous. This is inferred from the isolation of the primary amide of 7d’ that
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retains the intact vinyl ether moiety during the uncomplete reaction to produce 7d. We verified
this intermediate by LC-MS and 1H-NMR, which contained prominent amide and vinyl ether
peaks.
In conclusion, we developed an efficient and expeditious synthesis of 3,4-unsubstituted
isoquinolin-1(2H)-ones using mild conditions with simple, affordable starting materials in two
steps. The wide availability of the starting materials, the mild neutral reaction conditions, and
experimental simplicity allows the present methodology to have rapid access to these very
important isoquinolone scaffolds, some of which were not accessible using previous
methodologies.
6.3 Synthetic Schemes and Characterization
General Information. Unless otherwise indicated, common reagents or starting materials were
obtained from commercial source and used without further purification. Flash column
chromatography was performed using silica gel 60 (230-400 mesh). Preparative and analytical thin
layer chromatography (PTLC and TLC) was carried out on Merck silica gel plates with QF-254
indicator and visualized by UV or KMnO4. 1H and 13C NMR spectra were recorded on an Agilent
DD2 500 (500 MHz 1H; 125 MHz 13C) or Agilent DD2 600 (600 MHz 1H; 150 MHz 13C) or Agilent
DD2 400 (400 MHz 1H; 100 MHz 13C) spectrometer at room temperature. Chemical shifts were
reported in ppm relative to the residual CDCl3 (d 7.26 ppm 1H; d 77.00 ppm 13C), CD3OD (d 3.31
ppm 1H; d 49.00 ppm 13C), or DMSO-d6 (d 2.50 ppm 1H; d 39.52 ppm 13C). NMR chemical shifts
were expressed in ppm relative to internal solvent peaks, and coupling constants were measured
in Hz. (bs = broad signal). Mass spectrometric measurements were obtained using electrospray
ionization (ESI) and performed with a Shimadzu Scientific Instruments QToF 9030 LC-MS
system, equipped with a Nexera LC-40D xs UHPLC, consisting of a CBM-40 Lite system
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controller, a DGU-405 Degasser Unit, two LC-40D XS UHPLC pumps, a SIL-40C XS
autosampler and a Column Oven CTO-40S. UV data was collected with a Shimadzu Nexera
HPLC/UHPLC Photodiode Array Detector SPD M-40 in the range of 190 - 800nm. Mass spectra
were subsequently recorded with the quadrupole time-of-flight (QToF) 9030 mass spectrometer.
tert-Butyl ((1-(5-bromo-4-cyano-2-fluorophenyl)pyrrolidin-3-yl)methyl)carbamate (1o). tertButyl N-(pyrrolidin-3-ylmethyl)carbamate (463 mg, 2.31 mmol) was added to a solution of 2bromo-4,5-difluoro-benzonitrile (462 mg, 2.12 mmol) in MeCN (4.00 mL) at room temperature.
The orange solution was stirred for 12 h at room temperature, then concentrated in vacuo and the
residue purified by flash chromatography (SiO2-100g, Gradient Hex:EtOAc, 95:5 to 7:3 in 20
min) to afford 585 mg of the desired product (67% yield). 1H NMR (400 MHz, CDCl3) δ 7.13 (dd,
J = 13.5, 1.9 Hz, 1H), 6.70 (dd, J = 8.0, 2.1 Hz, 1H), 4.66 (bs, 1H), 3.72 – 3.40 (m, 3H), 3.32 –
3.01 (m, 3H), 2.60 – 2.35 (m, 1H), 2.16 – 1.99 (m, 1H), 1.82 – 1.56 (m, 1H), 1.43 (s, 9H). 13C
NMR (101 MHz, CDCl3) δ 155.97, 148.93 (d, J = 243.6 Hz), 140.94 (d, J = 9.9 Hz), 121.39 (d, J
= 2.3 Hz), 120.76 (d, J = 25.7 Hz), 117.91 (d, J = 5.9 Hz), 117.79 (d, J = 1.7 Hz), 79.69, 53.06 (d,
J = 5.7 Hz), 49.19 (d, J = 5.7 Hz), 42.75, 39.21, 28.71, 28.33. 19F NMR (376 MHz, CDCl3) δ 130.08. HRMS (ESI); m/z [M+H]+: Calculated for C17H22BrFN3O2, 398.0879. Found 398.0896
and 400.0877.
General procedure for the synthesis of (E)-2-(2-ethoxyvinyl)-nitriles (2) and (6). To a solution
of the ortho-substituted-benzonitrile compound (1) or (5) (1.15 mmol) and 2-[(E)-2-ethoxyvinyl]4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.15 mmol) in Dioxane (15 ml) was added K2CO3 (3.44
mmol) followed by Water (5 ml). The reaction mixture was degassed under vacuum and purged
with argon (5x). Then PCy3 (0.11 mmol), and Pd(dba)2 (0.05 mmol) were added. The reaction
mixture was heated with vigorous stirring at 80 °C and stirred for 2 to 4 h. The reaction mixture
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was diluted with EtOAc (50 mL) and filtered over a Celite® pad, filtrate was diluted with EtOAc
(50 mL), washed with an aqueous saturated solution of NaCl (30 mL), dried (Na2SO4) and
concentrated in vacuo. The crude material was purified by flash column chromatography or PTLC
to give the product (2) or (6).
(E)-2-(2-Ethoxyvinyl)benzonitrile (2a). This compound was prepared following the procedure
described above (81% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.70 (dd, J = 7.9, 1.4 Hz, 2H),
7.62 – 7.40 (m, 2H), 7.27 (t, J = 7.6 Hz, 1H), 5.99 (d, J = 12.7 Hz, 1H), 3.98 (q, J = 7.0 Hz, 2H),
1.28 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 152.86, 140.03, 133.15, 132.87, 125.86,
124.01, 118.15, 108.17, 101.48, 66.08, 14.68. HRMS (ESI); m/z [M+H]+: Calculated for
C11H12NO, 174.0918. Found 174.0920.
(E)-2-(2-Ethoxyvinyl)-3-methylbenzonitrile (2b). This compound was prepared following
the procedure described above (80% yield). 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.43 (m, 1H),
7.33 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.7 Hz, 1H), 6.97 (d, J = 13.0 Hz, 1H), 5.84 (d, J = 12.9 Hz,
1H), 3.98 (q, J = 7.0 Hz, 2H), 2.32 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3)
δ 152.77, 139.00, 137.22, 134.33, 131.33, 126.02, 119.81, 110.59, 101.02, 66.20, 20.86, 14.90.
HRMS (ESI); m/z [M+H]+: Calculated for C12H13NO 188.1075. Found 188.1082.
4-Chloro-2-[(E)-2-ethoxyvinyl]benzonitrile (2c). This compound was prepared following the
procedure described above (82% yield). 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.3 Hz, 1H),
7.41 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 12.8 Hz, 1H), 7.15 (dd, J = 8.3, 2.0 Hz, 1H), 6.06 (d, J = 12.8
Hz, 1H), 3.99 (q, J = 7.0 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 152.69,
142.47, 139.38, 134.17, 125.97, 124.04, 117.83, 107.98, 101.40, 66.32, 14.74. HRMS (ESI); m/z
[M+H]+: Calculated for C11H11ClNO, 208.0529. Found 208.0534.

213

(E)-2-(2-Ethoxyvinyl)-4-(pyrrolidin-1-yl)benzonitrile (2d). This compound was prepared
following the procedure described above (64% yield). 1H NMR (500 MHz, DMSO-d6) δ 7.42 (d,
J = 12.7 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 8.8, 2.6 Hz, 1H),
5.89 (d, J = 12.7 Hz, 1H), 3.94 (q, J = 7.0 Hz, 2H), 3.42 – 3.00 (m, 4H), 2.08 – 1.66 (m, 4H), 1.27
(t, J = 7.0 Hz, 3H).

13

C NMR (126 MHz, DMSO-d6) δ 152.10, 150.38, 141.07, 134.16, 120.54,

110.32, 106.21, 102.83, 94.18, 66.22, 47.69, 25.33, 15.18. HRMS (ESI); m/z [M+H]+: Calculated
for C15H19N2O, 243.1497. Found 243.1504.
4-(Dimethylamino)-2-[(E)-2-ethoxyvinyl]benzonitrile (2e). This compound was prepared
following the procedure described above (87% yield). 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J =
8.8 Hz, 1H), 7.14 (d, J = 12.9 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H), 6.47 (dd, J = 8.8, 2.5 Hz, 1H),
6.05 (d, J = 12.9 Hz, 1H), 3.95 (q, J = 7.0 Hz, 2H), 3.02 (s, 6H), 1.36 (t, J = 7.0 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ 152.62, 150.80, 141.46, 134.21, 120.35, 111.52, 109.70, 106.44, 103.21,
65.69, 40.15, 14.77. HRMS (ESI); m/z [M+H]+: Calculated for C13H17N2O 217.1340. Found
217.1355.
2-[(E)-2-Ethoxyvinyl]-4-methoxy-benzonitrile (2f). This compound was prepared following the
procedure described above (88% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.68 – 7.44 (m, 2H),
7.17 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.7, 2.5 Hz, 1H), 5.90 (d, J = 12.7 Hz, 1H), 3.94 (q, J = 7.0
Hz, 2H), 3.80 (s, 3H), 1.25 (t, J = 7.0 Hz, 4H). 13C NMR (101 MHz, DMSO-d6) δ 163.09, 153.59,
142.56, 134.95, 118.98, 113.26, 108.94, 101.96, 100.79, 66.54, 56.11, 15.15. LRMS(ESI); m/z
[M+H]+: Calculated for C12H14NO2, 204.1024. Found 204.12.
2-[(E)-2-Ethoxyvinyl]-4-formyl-benzonitrile (2g). This compound was prepared following the
procedure described above, characterized as a mixture of isomers (E:Z ratio ≈ 3:1) (66% yield). Eisomer: 1H NMR (600 MHz, DMSO-d6) δ 10.15 (s, 1H), 8.09 (dd, J = 7.7, 1.4 Hz, 1H), 8.05 (dd,
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J = 7.8, 1.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 12.8 Hz, 1H), 6.36 (d, J = 12.8 Hz, 1H),
4.04 (q, J = 7.0 Hz, 2H), 1.31 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 190.47, 156.38,
143.00, 137.86, 134.16, 133.33, 126.26, 117.67, 113.03, 97.99, 66.61, 14.61. Z-isomer: 1H NMR
(600 MHz, DMSO-d6) δ 9.96 (s, 1H), 8.08 (dd, J = 7.7, 1.5 Hz, 1H), 7.99 (dd, J = 7.8, 1.4 Hz,
1H), 7.56 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 6.9 Hz, 1H), 5.72 (d, J = 6.8 Hz, 1H), 3.96 (q, J = 7.1 Hz,
2H), 1.14 (t, J = 7.1 Hz, 3H).

13

C NMR (151 MHz, CDCl3) δ 190.89, 150.68, 141.36, 137.09,

134.02, 131.51, 126.95, 117.35, 113.40, 97.85, 69.50, 15.02. HRMS (ESI); m/z [M+H]+:
Calculated for C12H12NO2, 202.0868. Found 202.0878.
2-[(E)-2-Ethoxyvinyl]-4-(hydroxymethyl)benzonitrile (2h). This compound was prepared
following the procedure described above (71% yield). 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J =
8.0 Hz, 1H), 7.45 – 7.42 (m, 1H), 7.21 (d, J = 12.8 Hz, 1H), 7.15 (dt, J = 8.0, 1.0 Hz, 1H), 6.11 (d,
J = 12.8 Hz, 1H), 4.72 (s, 2H), 3.97 (q, J = 7.0 Hz, 2H), 1.91 (s, 1H), 1.37 (t, J = 7.0 Hz, 3H). 13C
NMR (101 MHz, CDCl3) δ 151.84, 146.02, 140.96, 133.28, 123.77, 121.74, 118.58, 108.53,
102.25, 66.09, 64.55, 14.78. HRMS (ESI); m/z [M+H]+: Calculated for C12H14NO2, 204.1024.
Found 204.1023.
2-[(E)-2-Ethoxyvinyl]-4-(trifluoromethyl)benzonitrile (2i). This compound was prepared
following the procedure described above (73% yield). 1H NMR (600 MHz, DMSO-d6) δ 8.10 (s,
1H), 7.95 (d, J = 8.1 Hz, 1H), 7.79 (d, J = 12.5 Hz, 1H), 7.58 (dd, J = 8.2, 1.7 Hz, 1H), 6.02 (d, J
= 12.6 Hz, 1H), 4.03 (q, J = 7.0 Hz, 2H), 1.29 (t, J = 7.0 Hz, 3H). 19F NMR (376 MHz, DMSOd6) δ -62.05. 13C NMR (151 MHz, DMSO-d6) δ 155.55, 141.88, 134.58, 133.43 (q, J = 32.2 Hz),
123.83 (q, J = 273.4 Hz), 122.26 (q, J = 3.8 Hz), 121.03 (q, J = 3.8 Hz), 117.51, 111.97, 101.19,
67.15, 15.17.
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4-Fluoro-2-[(E)-2-ethoxyvinyl]benzonitrile (2j). This compound was prepared following the
procedure described above (77% yield). 1H NMR (400 MHz, CDCl3) δ 7.55 (dd, J = 8.6, 5.7 Hz,
1H), 7.19 (d, J = 12.9 Hz, 1H), 7.10 (dd, J = 10.2, 2.5 Hz, 1H), 6.88 (ddd, J = 8.7, 7.8, 2.5 Hz, 1H),
6.09 (dd, J = 12.8, 1.4 Hz, 1H), 3.99 (q, J = 7.0 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H). 13C NMR (101
MHz, CDCl3) δ 165.07 (d, J = 254.4 Hz), 152.55, 143.74 (d, J = 9.9 Hz), 135.24 (d, J = 10.0 Hz),
117.72, 113.35 (d, J = 23.4 Hz), 110.58 (d, J = 23.4 Hz), 105.67 (d, J = 3.0 Hz), 101.53 (d, J = 2.6
Hz), 66.11, 14.56. HRMS (ESI); m/z [M+H]+: Calculated for C11H11FNO 192.0824. Found
192.0825.
(E)-2-(2-Ethoxyvinyl)-5-fluorobenzonitrile (2k). This compound was prepared following the
procedure described above (61% yield). 1H NMR (400 MHz, CDCl3) δ 7.39 (dd, J = 8.9, 5.1 Hz,
1H), 7.29 – 7.22 (m, 1H), 7.18 (ddd, J = 9.0, 7.9, 2.8 Hz, 1H), 7.10 (d, J = 12.9 Hz, 1H), 6.07 (d, J
= 12.9 Hz, 1H), 3.97 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ
159.96 (d, J = 247.7 Hz), 151.52 (d, J = 1.8 Hz), 137.24 (d, J = 3.6 Hz), 126.03 (d, J = 7.9 Hz),
120.85 (d, J = 21.6 Hz), 119.28 (d, J = 24.3 Hz), 117.36 (d, J = 2.9 Hz), 110.55 (d, J = 9.0 Hz),
101.38, 66.02, 14.77. 19F NMR (471 MHz, DMSO-d6) δ -115.94. HRMS (ESI); m/z: [M+H]+:
Calculated for C11H11FNO, 192.0824. Found 192.0829.
(E)-2-(2-Ethoxyvinyl)-5-nitrobenzonitrile (2l). This compound was prepared following the
procedure described above (64% yield). 1H NMR (600 MHz, DMSO-d6) δ 8.60 (d, J = 2.5 Hz,
1H), 8.32 (dd, J = 9.0, 2.5 Hz, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.89 (d, J = 12.5 Hz, 1H), 6.06 (d, J
= 12.5 Hz, 1H), 4.09 (q, J = 7.0 Hz, 2H), 1.31 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, DMSOd6) δ 157.66, 146.91, 144.13, 128.72, 127.58, 124.36, 116.39, 108.34, 100.89, 67.30, 14.70.
HRMS (ESI); m/z [M+Na]+: Calculated for C11H10N2O3Na, 241.0589. Found 241.0557.
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(E)-5-Chloro-2-(2-ethoxyvinyl)benzonitrile (2m). This compound was prepared following the
procedure described above (51% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.86 (d, J = 2.3 Hz,
1H), 7.73 (d, J = 8.7 Hz, 1H), 7.62 (dd, J = 8.7, 2.4 Hz, 1H), 7.56 (d, J = 12.7 Hz, 1H), 5.94 (d, J
= 12.7 Hz, 1H), 3.98 (q, J = 7.0 Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSOd6) δ 154.12, 139.63, 133.70, 132.43, 130.10, 126.09, 117.31, 109.95, 101.09, 66.74, 15.09.
2-[(E)-2-Ethoxyvinyl]-6-methoxy-benzonitrile (2n). This compound was prepared following the
procedure described above (64% yield). 1H NMR (600 MHz, DMSO-d6) δ 7.53 – 7.36 (m, 2H),
7.22 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 5.90 (d, J = 12.7 Hz, 1H), 3.94 (q, J = 7.0 Hz,
2H), 3.84 (s, 3H), 1.25 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 161.38, 153.20,
141.67, 134.13, 115.77, 115.63, 108.03, 101.51, 97.69, 66.11, 56.19, 14.68. HRMS(ESI): m/z
[M+H]+: Calculated for C12H13NO2: 204.1024. Found 204.1035.
tert-Butyl (E)-((1-(4-cyano-5-(2-ethoxyvinyl)-2-fluorophenyl)pyrrolidin-3-yl)methyl)carbamate
(2o). This compound was prepared following the procedure described above (85% yield). 1H NMR
(400 MHz, DMSO-d6) δ 7.41 – 7.24 (m, 2H), 6.97 (t, J = 5.8 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H),
5.82 (d, J = 12.7 Hz, 1H), 3.91 (q, J = 7.0 Hz, 1H), 3.54 – 3.35 (m, 3H), 3.22 – 3.15 (m, 1H), 2.99
– 2.90 (m, 2H), 2.32 (p, J = 6.9 Hz, 1H), 1.95 (h, J = 6.6 Hz, 1H), 1.69 – 1.56 (m, 1H), 1.34 (s,
9H), 1.24 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 155.80, 151.81, 147.87 (d, J =
240.1 Hz), 140.29 (d, J = 9.2 Hz), 137.55 (d, J = 1.9 Hz), 119.27 (d, J = 24.5 Hz), 118.62 (d, J =
2.0 Hz), 109.24 (d, J = 5.6 Hz), 101.54, 93.67 (d, J = 8.9 Hz), 77.61, 65.87, 52.80 (d, J = 5.9 Hz),
48.76 (d, J = 5.0 Hz), 42.25, 38.45, 28.22, 14.73.

19

F NMR (376 MHz, DMSO-d6) δ -131.37.

HRMS (ESI); m/z [M+H]+: Calculated for C21H29FN3O3, 390.2192. Found 390.2218.
(E)-1-(2-Ethoxyvinyl)-2-naphthonitrile (6a). This compound was prepared following the
procedure described above (80% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.70 (dd, J = 7.9, 1.4
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Hz, 2H), 7.62 – 7.40 (m, 2H), 7.27 (t, J = 7.6 Hz, 1H), 5.99 (d, J = 12.7 Hz, 1H), 3.98 (q, J = 7.0
Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H).

13

C NMR (151 MHz, DMSO-d6) δ 152.86, 140.03, 133.15,

132.87, 125.86, 124.01, 118.15, 108.17, 101.48, 66.08, 14.68. HRMS (ESI); m/z [M+H]+:
Calculated for C15H14NO, 224.1075. Found 224.1089.
3-[(E)-2-Ethoxyvinyl]pyridine-2-carbonitrile (6b). This compound was prepared following the
procedure described above (68% yield). 1H NMR (600 MHz, DMSO-d6) δ 8.42 (dd, J = 4.5, 1.5
Hz, 1H), 8.14 (dd, J = 8.3, 1.5 Hz, 1H), 7.60 (d, J = 12.7 Hz, 1H), 7.56 (ddd, J = 8.4, 4.5, 0.6 Hz,
1H), 5.91 (d, J = 12.7 Hz, 1H), 3.99 (q, J = 7.0 Hz, 3H), 1.26 (t, J = 7.0 Hz, 3H). 13C NMR (151
MHz, DMSO-d6) δ 154.79, 147.87, 137.36, 131.87, 128.64, 127.41, 116.75, 98.63, 66.44, 14.64.
HRMS (ESI); m/z: [M+H]+: Calculated for C10H11N2O, 175.0871. Found, 175.0878.
3-[(E)-2-Ethoxyvinyl]pyrazine-2-carbonitrile (6c). This compound was prepared following the
procedure described above (83% yield). 1H NMR (600 MHz, DMSO-d6) δ 8.69 (d, J = 2.3 Hz,
1H), 8.47 (d, J = 2.3 Hz, 1H), 7.93 (d, J = 12.1 Hz, 1H), 6.03 (d, J = 12.1 Hz, 1H), 4.09 (q, J = 7.0
Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H).

13

C NMR (151 MHz, DMSO-d6) δ 159.04, 154.65, 147.94,

142.48, 124.66, 116.32, 99.20, 67.81, 15.03. HRMS (ESI); m/z [M+H]+: Calculated for C9H10N3O,
176.0823. Found, 176.0835.
5-[(E)-2-Ethoxyvinyl]pyrimidine-4-carbonitrile (6d). This compound was prepared following the
procedure described above (72%). 1H NMR (400 MHz, CDCl3) δ 9.01 (s, 1H), 8.92 (s, 1H), 7.35
(d, J = 13.0 Hz, 1H), 5.93 (d, J = 13.0 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H).
13

C NMR (101 MHz, CDCl3) δ 155.6126, 154.2384, 154.0070, 136.2051, 134.1332, 114.9959,

96.5042, 66.9160, 14.7028. HRMS (ESI); m/z: [M+H]+: Calculated for C9H9N3O, 176.0823.
Found 176.0833.
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General procedure for the synthesis of isoquinolin-1(2H)-ones (3) and (7). To a solution of 2[(E)-3-ethoxyallyl]benzonitrile (2) or (6) (0.74 mmol) in a mixture of EtOH:water (3:2 mL) was
added Parkins catalyst (0.02 mmol) and the solution was heated at reflux temperature until full
consumption of the starting material (12 to 48 h). Reaction mixture was concentrated in vacuo and
crude product was purified by flash column chromatography or PTLC to give the product (3) or
(7).
Isoquinolin-1(2H)-one (3a). This compound was prepared following the procedure described
above (87% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.22 (bs, 1H), 8.18 (d, J = 8.0 Hz, 1H),
7.67 (dt, J = 15.1, 7.6 Hz, 2H), 7.47 (t, J = 8.0 Hz, 1H), 7.16 (t, 1H), 6.54 (d, J = 7.1 Hz, 1H). 13C
NMR (101 MHz, DMSO-d6) δ 161.80, 137.87, 132.27, 128.93, 126.63, 126.28, 126.17, 126.06,
104.60. HRMS (ESI); m/z [M+H]+: Calculated for C9H8NO, 146.0605. Found 146.0606.
5-Methyl-2H-isoquinolin-1-one (3b). This compound was prepared following the procedure
descried above (81% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.28 (s, 1H), 8.05 (d, J = 8.0 Hz,
1H), 7.52 (d, J = 7.2 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.20 (d, J = 7.4 Hz, 1H), 6.57 (d, J = 7.4 Hz,
1H), 2.47 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 162.4845, 137.0985, 133.6040, 133.3190,
129.1464, 126.6912, 126.2658, 125.0587, 101.7141, 19.1346. HRMS (ESI); m/z [M+H]+:
Calculated for C10H10NO, 160.0762. Found 160.0765.
6-Chloroisoquinolin-1(2H)-one (3c). This compound was prepared following the procedure
descried above (91% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 8.12 (d, J = 8.6 Hz,
1H), 7.74 (d, J = 2.1 Hz, 1H), 7.44 (dd, J = 8.6, 2.1 Hz, 1H), 7.20 (d, J = 7.1 Hz, 1H), 6.49 (d, J =
7.1 Hz, 1H).

13

C NMR (101 MHz, DMSO-d6) δ 161.3227, 139.4688, 137.3056, 130.6532,

129.0399, 126.4926, 125.3264, 124.6429, 103.7976. HRMS(ESI); m/z[M+H]+: Calculated for
C9H7ClNO, 180.0216. Found 180.0219.
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6-(Pyrrolidin-1-yl)isoquinolin-1(2H)-one (3d). This compound was prepared following the
procedure described above (88% yield). 1H NMR (600 MHz, DMSO-d6) δ 10.63 (s, 1H), 7.94 (d,
J = 8.9 Hz, 1H), 6.97 (t, J = 6.4 Hz, 1H), 6.73 (d, J = 8.9 Hz, 1H), 6.49 (s, 1H), 6.30 (d, J = 7.1 Hz,
1H), 3.57 – 2.93 (m, 4H), 2.17 – 1.67 (m, 4H). 13C NMR (151 MHz, DMSO-d6) δ 161.81, 149.93,
139.56, 128.76, 128.10, 115.18, 112.51, 104.52, 104.44, 47.26, 24.98. HRMS (ESI); m/z [M+H]+:
Calculated for C13H15N2O, 215.1184. Found 215.1173.
6-(Dimethylamino)-2H-isoquinolin-1-one (3e). This compound was prepared following the
procedure described above (82% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.68 (s, 1H), 7.94 (d,
J = 9.0 Hz, 1H), 6.99 (t, J = 6.3 Hz, 1H), 6.90 (dd, J = 9.0, 2.6 Hz, 1H), 6.66 (d, J = 2.5 Hz, 1H),
6.32 (d, J = 7.2 Hz, 1H), 3.01 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 161.75, 152.57, 139.48,
128.81, 127.97, 115.61, 112.43, 105.01, 104.58. HRMS (ESI); m/z [M+H]+: Calculated
for C11H12N2O, 189.1028. Found 189.1039.
6-Methoxy-2H-isoquinolin-1-one (3f). This compound was prepared following the procedure
described above (47% yield) also 35% starting material was recovered. 1H NMR (400 MHz,
DMSO-d6) δ 11.03 (s, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.13 – 7.06 (m, 2H), 7.00 (dd, J = 8.9, 2.6 Hz,
1H), 6.43 (d, J = 7.1 Hz, 1H), 3.82 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 162.63, 161.96,
140.49, 130.00, 129.08, 120.25, 116.19, 107.51, 104.94, 55.88. HRMS(ESI): m/z [M+H]+:
Calculated for C10H9NO2 176.0711. Found 176.0718.
1-Oxo-2H-isoquinoline-6-carbaldehyde (3g). This compound was prepared following the
procedure described above (52 % yield). 1H NMR (600 MHz, DMSO-d6) δ 11.60 (s, 1H), 10.33
(s, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.29 (dd, J = 7.5, 1.6 Hz, 1H), 7.70 (t, J = 7.7 Hz, 1H), 7.65 (d, J
= 7.3 Hz, 1H), 7.39 (dd, J = 7.5, 5.9 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 194.00, 161.66,
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139.78, 137.25, 133.45, 132.84, 130.33, 127.53, 126.40, 100.82. HRMS (ESI); m/z [M+H]+:
Calculated for C10H8NO2, 174.0555. Found 174.0557.
6-(Hydroxymethyl)-2H-isoquinolin-1-one (3h). This compound was prepared following the
procedure described above (82% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, 1H), 8.12 (d,
J = 8.2 Hz, 1H), 7.56 (d, J = 1.7 Hz, 1H), 7.41 (dd, J = 8.3, 1.6 Hz, 1H), 7.14 (dd, J = 7.1, 5.1 Hz,
1H), 6.52 (d, J = 7.1 Hz, 1H), 5.40 (t, J = 5.7 Hz, 1H), 4.63 (d, J = 5.2 Hz, 2H). 13C NMR (101
MHz, DMSO-d6) δ 161.80, 147.15, 137.89, 129.0110, 126.57, 124.65, 123.01, 104.76, 62.57.
HRMS (ESI); m/z [M+H]+: Calculated for C10H9NO2 176.0711; Found 176.0701.
6-(Trifluoromethyl)-2H-isoquinolin-1-one (3i). This compound was prepared following the
procedure described above (47% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.54 (s, 1H), 8.32 (dd,
J = 8.5, 1.2 Hz, 1H), 8.09 (s, 1H), 7.71 (dd, J = 8.4, 1.8 Hz, 1H), 7.28 (dd, J = 7.1, 4.8 Hz, 1H),
6.68 (d, J = 7.1 Hz, 1H). 19F NMR (376 MHz, DMSO-d6) δ -61.57. 13C NMR (101 MHz, DMSOd6) δ 161.12, 138.14, 132.12 (q, J = 32.0 Hz), 130.78, 128.43, 128.24, 123.93 (q, J = 273.1 Hz),
123.69 (q, J = 4.0 Hz), 121.94 (q, J = 3.4 Hz), 104.42. HRMS(ESI): m/z [M+H]+: Calculated for
C10H7F3NO, 214.0479. Found, 214.0487.
6-Fluoroisoquinolin-1(2H)-one (3j). This compound was prepared following the procedure
descried above (79% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.22 (dd, J = 8.9,
6.0 Hz, 1H), 7.47 (dd, J = 10.1, 2.6 Hz, 1H), 7.30 (td, J = 8.9, 2.6 Hz, 1H), 7.22 (d, J = 7.2 Hz,
1H), 6.53 (d, J = 7.2 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 164.38 (d, J = 249.1 Hz), 161.22,
140.34 (d, J = 10.7 Hz), 130.51, 130.19 (d, J = 10.3 Hz), 122.95 (d, J = 1.7 Hz), 114.75 (d, J = 23.7
Hz), 110.90 (d, J = 21.8 Hz), 104.15 (d, J = 3.3 Hz). 19F NMR (471 MHz, DMSO-d6) δ -107.46.
HRMS(ESI); m/z[M+H]+: Calculated for C9H7FNO, 164.0511. Found 164.0510.
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7-Fluoroisoquinolin-1(2H)-one (3k). This compound was prepared following the procedure
described above (83% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.37 (bs, 1H), 7.83 (dd, J = 9.6,
2.8 Hz, 1H), 7.76 (dd, J = 8.8, 5.4 Hz, 1H), 7.60 (td, J = 8.7, 2.8 Hz, 1H), 7.16 (dd, J = 6.2, 2.6 Hz,
2H), 6.59 (d, J = 7.1 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 160.44 (d, J = 244.3 Hz), 161.09
(d, J = 3.5 Hz), 134.76 (d, J = 1.8 Hz), 129.16 (d, J = 8.0 Hz), 128.27 (d, J = 2.3 Hz), 127.49 (d, J
= 7.5 Hz), 121.02 (d, J = 23.5 Hz), 111.27 (d, J = 22.2 Hz), 104.17.
d6) δ -113.97. HRMS(ESI); m/z[M+H]+: Calculated for

19

F NMR (376 MHz, DMSO-

C9H7FNO, 164.0511. Found

HRMS(ESI); m/z[M+H]+: Calculated for C9H7FNO, 164.0511. Found 164.0496.
7-Nitroisoquinolin-1(2H)-one (3l). This compound was prepared following the procedure
described above (80% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.76 (s, 1H), 8.88 (d, J = 2.5 Hz,
1H), 8.43 (dd, J = 8.8, 2.5 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.45 (dd, J = 7.2, 4.8 Hz, 1H), 6.72
(d, J = 7.1 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 161.18, 145.09, 142.84, 133.52, 128.13,
126.19, 125.68, 122.66, 104.10. HRMS(ESI); m/z[M+H]+: Calculated for C9H7N2O3, 191.0456.
Found 191.0452.
7-Chloroisoquinolin-1(2H)-one (3m). This compound was prepared following the procedure
described above (79% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 8.11 (s, 1H), 7.87
- 7.46 (m, 1H), 7.33 -7.01 (m, 1H), 6.58 (d, J = 6.9 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ
160.78, 136.60, 132.47, 130.82, 129.56, 128.58, 127.25, 125.66, 104.10. HRMS(ESI); m/z[M+1]+:
Calculated for C9H7ClNO, 180.0216. Found 180.0219.
8-Methoxy-2H-isoquinolin-1-one (3n). This compound was prepared following the procedure
described above (55% yield). 1H NMR (600 MHz, DMSO-d6) δ 10.84 (s, 1H), 7.52 (t, J = 8.1 Hz,
1H), 7.08 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.35 (d, J = 7.0
Hz, 1H), 3.79 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 160.79, 160.77, 141.40, 133.42, 129.94,
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118.59, 115.92, 108.63, 104.67, 56.10. HRMS(ESI); m/z[M+H]+: Calculated for C10H10NO2,
176.0711. Found, 176.0709.
tert-Butyl

((1-(7-fluoro-1-oxo-1,2-dihydroisoquinolin-6-yl)pyrrolidin-3-yl)methyl)carbamate

(3o). This compound was prepared following the procedure described above (78% yield). 1H NMR
(400 MHz, DMSO-d6) δ 10.87 (bs, 1H), 7.63 (dd, J = 14.9, 2.1 Hz, 1H), 7.20 – 6.87 (m, 2H), 6.70
(d, J = 8.5 Hz, 1H), 6.36 (d, J = 7.0 Hz, 1H), 3.60 – 3.38 (m, 3H), 3.27 – 3.15 (m, 1H), 3.13 – 2.84
(m, 2H), 2.44 – 2.31 (m, 1H), 2.10 – 1.91 (m, 1H), 1.75 – 1.61 (m, 1H), 1.38 (s, 9H). 13C NMR
(101 MHz, DMSO-d6) δ 160.96 (d, J = 3.3 Hz), 155.81, 150.55 (d, J = 242.8 Hz), 140.70 (d, J =
10.8 Hz), 136.21, 128.31, 115.85 (d, J = 6.8 Hz), 112.24 (d, J = 22.2 Hz), 109.11 (d, J = 5.1 Hz),
103.86, 77.58, 53.01 (d, J = 5.5 Hz), 48.91 (d, J = 5.4 Hz), 42.38, 38.41, 28.31, 28.23. 19F NMR
(376 MHz, DMSO-d6) δ -127.33. HRMS (ESI); m/z [M+H]+: Calculated for C19H25FN3O3,
362.1879. Found 362.1869.
Benzo[f]isoquinolin-4(3H)-one (7a). This compound was prepared following the procedure
described above (91% yield). 1H NMR (500 MHz, DMSO-d6) δ 11.64 (bs, 1H), 8.64 (d, J = 8.0
Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.79 – 7.58
(m, 2H), 7.43 (t, J = 6.2 Hz, 2H).

13

C NMR (126 MHz, DMSO-d6) δ 161.79, 136.47, 134.36,

130.54, 128.52, 128.48, 128.17, 126.94, 126.43, 124.49, 123.33, 122.85, 100.30. HRMS
(ESI); m/z [M+H]+: Calculated for C13H10NO, 196.0762. Found 196.0766.
7H-1,7-Naphthyridin-8-one (7b). This compound was prepared following the procedure described
above (69% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.55 (s, 1H), 8.72 (dd, J = 4.3, 1.7 Hz, 1H),
8.07 (dd, J = 8.1, 1.7 Hz, 1H), 7.63 (dd, J = 8.1, 4.3 Hz, 1H), 7.23 (d, J = 7.1 Hz, 1H), 6.50 (d, J =
7.0 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 161.17, 149.26, 142.40, 135.18, 134.82, 130.43,
127.22, 103.67. HRMS(ESI); m/z[M+H]+: Calculated for C8H7N2O, 147.0558. Found 147.0557.
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6H-Pyrido[3,4-b]pyrazin-5-one (7c). This compound was prepared following the procedure
described above (79% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.83 (s, 1H), 8.90 (d, J = 2.1 Hz,
1H), 8.76 (d, J = 2.1 Hz, 1H), 7.50 (d, J = 6.5 Hz, 1H), 6.59 (d, J = 7.3 Hz, 1H). 13C NMR (101
MHz, DMSO-d6) δ 161.44, 150.65, 149.64, 144.26, 137.80, 134.50, 105.21. HRMS(ESI): m/z
[M+H]+: Calculated for C7H5N3O, 148.0510. Found, 148.0512.
7H-Pyrido[3,4-d]pyrimidin-8-one (7d). This compound was prepared following the procedure
described above (60% yield). 1H NMR (400 MHz, DMSO-d6) δ 11.90 (s, 1H), 9.35 (d, J = 2.0 Hz,
1H), 9.26 (d, J = 2.0 Hz, 1H), 7.39 (t, J = 5.2 Hz, 1H), 6.61 (dd, J = 7.0, 2.2 Hz, 1H). 13C NMR
(101 MHz, DMSO-d6) δ 160.0109, 158.7306, 155.5713, 145.7405, 132.0552, 130.8335,
100.6459. HRMS(ESI): m/z [M+H]+: Calculated for C7H5N3O, 148.0510. Found 148.0514.
(E)-5-(2-Ethoxyvinyl)pyrimidine-4-carboxamide (7d’). Small amounts of this compound were
obtained from the uncomplete reaction to produce 7d. 1H NMR (400 MHz, CDCl3) δ 8.96 (s, 1H),
8.91 (s, 1H), 7.90 (bs, 1H), 7.08 (d, J = 13.3 Hz, 1H), 7.02 (d, J = 13.3 Hz, 1H), 5.66 (bs, 1H), 4.01
(q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). HRMS(ESI): m/z [M+H]+: Calculated for C9H12N3O2,
194.0929. Found 194.0933.
Alternative synthesis of 6-(Pyrrolidin-1-yl)isoquinolin-1(2H)-one (3d). This compound was
alternatively prepared by dissolving 4-fluoro-2-[(E)-2-ethoxyvinyl]benzonitrile (3j) (5.00 mg,
0.03 mmol) in pyrrolidine (1 mL). The reaction was heated at reflux for 48 hrs. and pyrrolidine
was then removed in vacuo. The crude product was purified by PTLC to yield 6.2 mg (94% yield)
of the desired product as a light-yellow solid. The 1H NMR matched that described for (3d) (fully
characterized above). 1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 7.94 (d, J = 8.9 Hz, 1H),
6.97 (t, 1H), 6.73 (d, J = 8.9 Hz, 2H), 6.49 (s, 1H), 6.30 (d, J = 7.2 Hz, 1H), 3.50 – 3.16 (m, 4H),
2.08 – 1.82 (m, 4H).
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